{"70172763c8f98901cd55f23df594a6610073c2a9": [["Sr. Editor:El mundo est\u00e1 inmerso en una pandemia por SARS-CoV-2 que Q2 est\u00e1 llevando a los sistemas sanitarios al borde del colapso y a las unidades de cuidados intensivos a trabajar por encima de su capacidad.", [["CoV", "TEST", 58, 61], ["a los sistemas sanitarios", "TREATMENT", 85, 110]]], ["En esta primera oleada de la pandemia la m\u00e1xima prioridad se centra en mantener la mortalidad lo m\u00e1s baja posible, objetivo para el cual los cuidados cr\u00edticos se han convertido en un pilar elemental.Sr.", [["pilar", "ANATOMY", 183, 188]]], ["Editor:Sin embargo, en el futuro de la pandemia por SARS-CoV-2 conviven diferentes horizontes: cabe esperar una segunda oleada debida a la restricci\u00f3n de recursos en situaciones de urgencia para las enfermedades no-SARS-CoV-2, donde las muertes aumenten por un sistema de salud saturado 1 .", [["a la restricci\u00f3n", "TREATMENT", 134, 150]]], ["Editor:Dentro de este panorama general, los servicios de cuidados intensivos deben de estar alertados para identificar \u00abla cola de la primera oleada\u00bb, que englobar\u00e1 un s\u00edndrome post-cuidados intensivos (SPCI) de una gran magnitud y con caracter\u00edsticas especiales.Sr.", [["que englobar\u00e1 un s\u00edndrome", "PROBLEM", 151, 176]]], ["En circunstancias normales el SPCI afecta al 30-50% de nuestros pacientes 3 y sus secuelas pueden persistir incluso m\u00e1s all\u00e1 de los 5 a\u00f1os tras el alta hospitalaria, especialmente en la recuperaci\u00f3n del s\u00edndrome respiratorio agudo 4 .Sr.", [["En circunstancias", "TEST", 0, 17], ["afecta", "TEST", 35, 41]]], ["Editor:Es razonable intuir que las caracter\u00edsticas del SPCIpost SARS-CoV-2 tendr\u00e1n un componente afectivo especial.", [["CoV", "TEST", 69, 72]]], ["Si otras condiciones nos mostraron que hasta el 16% de los familiares no hab\u00edan reducido el nivel de depresi\u00f3n al a\u00f1o del alta 5 \u00bfestaremos preparados para el SPCI-post", [["Si", "CHEMICAL", 0, 2]]]], "PMC7123442": [["IntroductionSuccessful cell division requires complete duplication of genetic material followed by equal segregation into two cell bodies, resulting in two identical daughter cells.", [["cell", "ANATOMY", 23, 27], ["cell bodies", "ANATOMY", 126, 137], ["cells", "ANATOMY", 175, 180], ["cell", "CELL", 23, 27], ["cell bodies", "CELLULAR_COMPONENT", 126, 137], ["cells", "CELL", 175, 180], ["daughter cells", "CELL_TYPE", 166, 180], ["complete duplication of genetic material", "PROBLEM", 46, 86], ["duplication", "OBSERVATION_MODIFIER", 55, 66], ["two cell bodies", "OBSERVATION", 122, 137], ["daughter cells", "OBSERVATION", 166, 180]]], ["Historically, the cell cycle has been divided into four phases\u2014Gap 1 (G1), Synthesis (S), Gap 2 (G2), and Mitosis (M)\u2014that describe the chronological order of different events observed in normally cycling cells.", [["cell", "ANATOMY", 18, 22], ["cells", "ANATOMY", 205, 210], ["cell", "CELL", 18, 22], ["Gap 1", "GENE_OR_GENE_PRODUCT", 63, 68], ["Gap 2", "GENE_OR_GENE_PRODUCT", 90, 95], ["cells", "CELL", 205, 210], ["normally cycling cells", "CELL_TYPE", 188, 210], ["the cell cycle", "TREATMENT", 14, 28], ["Gap", "TEST", 63, 66], ["Synthesis (S)", "TEST", 75, 88], ["Gap", "TEST", 90, 93], ["different events", "PROBLEM", 159, 175], ["cycling cells", "OBSERVATION", 197, 210]]], ["The bulk of duplication and segregation events occur in S and M phases.", [["duplication", "PROBLEM", 12, 23], ["segregation events", "PROBLEM", 28, 46], ["bulk", "OBSERVATION_MODIFIER", 4, 8], ["duplication", "OBSERVATION", 12, 23], ["segregation events", "OBSERVATION", 28, 46]]], ["During S phase, both DNA and centrosomes are duplicated (Fig. 1).", [["centrosomes", "ANATOMY", 29, 40], ["DNA", "CELLULAR_COMPONENT", 21, 24], ["centrosomes", "CELLULAR_COMPONENT", 29, 40]]], ["Duplicated centrosomes separate in order to form the poles of the mitotic spindle responsible for segregating sister chromatids (Fig. 1).", [["centrosomes", "ANATOMY", 11, 22], ["spindle", "ANATOMY", 74, 81], ["chromatids", "ANATOMY", 117, 127], ["centrosomes", "CELLULAR_COMPONENT", 11, 22], ["mitotic spindle", "CELLULAR_COMPONENT", 66, 81], ["sister chromatids", "CELLULAR_COMPONENT", 110, 127], ["centrosomes", "OBSERVATION_MODIFIER", 11, 22], ["poles", "ANATOMY_MODIFIER", 53, 58], ["mitotic spindle", "OBSERVATION", 66, 81], ["responsible for", "UNCERTAINTY", 82, 97], ["sister chromatids", "OBSERVATION", 110, 127]]], ["Sister chromatid segregation is initiated during M phase, or mitosis (Fig. 1).", [["chromatid", "ANATOMY", 7, 16], ["chromatid", "CELLULAR_COMPONENT", 7, 16], ["Sister chromatid segregation", "PROBLEM", 0, 28], ["chromatid segregation", "OBSERVATION", 7, 28]]]], "PMC7126838": [["IntroductionNo sooner had a new year begun in 2003 than citizens were seized with panic in Guangdong in south China.", [["panic", "DISEASE", 82, 87], ["panic", "PROBLEM", 82, 87]]], ["Hundreds suffered from a pneumonia-like strange disease, some of whom died.", [["pneumonia", "DISEASE", 25, 34], ["a pneumonia", "PROBLEM", 23, 34], ["strange disease", "PROBLEM", 40, 55], ["pneumonia", "OBSERVATION", 25, 34], ["strange disease", "OBSERVATION", 40, 55]]], ["Both the Chinese government and the Chinese media remained silent as to the risk of a possible epidemic.", [["epidemic", "PROBLEM", 95, 103], ["possible", "UNCERTAINTY", 86, 94], ["epidemic", "OBSERVATION", 95, 103]]], ["No one in the rest of the world knew there was any real cause for alarm.", [["one", "OBSERVATION_MODIFIER", 3, 6]]], ["But in March, local outbreaks of a mysterious disease were reported in Hong Kong and Southeast Asian countries.", [["a mysterious disease", "PROBLEM", 33, 53], ["local", "OBSERVATION_MODIFIER", 14, 19], ["outbreaks", "OBSERVATION_MODIFIER", 20, 29], ["mysterious disease", "OBSERVATION", 35, 53]]], ["Even then, health authorities could not reveal where the disease had come from.", [["the disease", "PROBLEM", 53, 64], ["disease", "OBSERVATION", 57, 64]]], ["This story at the onset of the Severe Acute Respiratory Syndrome (SARS) outbreak poses an interesting question.", [["Acute Respiratory Syndrome", "DISEASE", 38, 64], ["SARS", "DISEASE", 66, 70], ["the Severe Acute Respiratory Syndrome", "PROBLEM", 27, 64], ["Severe", "OBSERVATION_MODIFIER", 31, 37], ["Acute", "OBSERVATION_MODIFIER", 38, 43], ["Respiratory Syndrome", "OBSERVATION", 44, 64]]], ["Is it possible to discover the presence of a missing disease spreader from the surveillance records on the cases in other regions?", [["a missing disease spreader", "PROBLEM", 43, 69]]], ["This study addresses such a node discovery problem for the spread of an infectious disease.IntroductionThe spread of an infectious disease is a stochastic phenomenon in a spatially heterogeneous medium.", [["node", "ANATOMY", 28, 32], ["infectious disease", "DISEASE", 72, 90], ["infectious disease", "DISEASE", 120, 138], ["This study", "TEST", 0, 10], ["a node discovery problem", "PROBLEM", 26, 50], ["an infectious disease", "PROBLEM", 69, 90], ["an infectious disease", "PROBLEM", 117, 138], ["a stochastic phenomenon", "PROBLEM", 142, 165], ["node", "OBSERVATION", 28, 32], ["infectious", "OBSERVATION", 72, 82], ["spread", "OBSERVATION_MODIFIER", 107, 113], ["infectious", "OBSERVATION", 120, 130], ["stochastic phenomenon", "OBSERVATION", 144, 165], ["spatially", "OBSERVATION_MODIFIER", 171, 180], ["heterogeneous", "OBSERVATION_MODIFIER", 181, 194], ["medium", "OBSERVATION_MODIFIER", 195, 201]]], ["Many mathematical models of disease transmission [1] rely on an epidemiological compartment model and a meta-population network model in formulating stochasticity and spatial heterogeneity [2], [3].", [["disease transmission", "PROBLEM", 28, 48], ["an epidemiological compartment model", "TEST", 61, 97], ["a meta-population network model", "TREATMENT", 102, 133], ["spatial heterogeneity", "PROBLEM", 167, 188], ["disease", "OBSERVATION", 28, 35]]], ["The analysis of the spread includes many tasks from reproduction to prediction.", [["The analysis", "TEST", 0, 12], ["the spread", "PROBLEM", 16, 26]]], ["Reproduction of the actual spread [5], [6] is essential in understanding the role of a so-called super-spreader [7], [8] and epidemiological thresholds [9], [10].", [["a so-called super-spreader", "TREATMENT", 85, 111]]], ["This is a forward analysis.", [["a forward analysis", "TEST", 8, 26]]], ["An inverse analysis includes estimating the transmission parameters from observation [11], [12].", [["An inverse analysis", "TEST", 0, 19]]], ["Statistical learning and computational Monte Carlo simulation contribute to developing a reliable bio-surveillance system in a noisy environment [15], detecting abnormal events [16] as an omen of the outbreak [17], and predicting the spread to aid health authorities in containing the outbreak [18].", [["abnormal events", "PROBLEM", 161, 176]]], ["A node discovery problem for a social network [19] is discovering a person who does not appear in the logs on communication, but is actually influential to others in an organization.", [["node", "ANATOMY", 2, 6], ["node", "MULTI-TISSUE_STRUCTURE", 2, 6], ["person", "SPECIES", 68, 74], ["node", "OBSERVATION", 2, 6]]], ["The substantial nature of the problem is the same as this.", [["substantial", "OBSERVATION_MODIFIER", 4, 15]]], ["But the mathematical solution should be different entirely because of the difference in the mechanism of the spread.IntroductionIn this study, a perturbation theory quantifies how the perturbation which a missing spreader node exerts disturbs the growth of the number of cases.", [["node", "ANATOMY", 222, 226], ["the mathematical solution", "TREATMENT", 4, 29], ["this study", "TEST", 131, 141], ["the perturbation", "PROBLEM", 180, 196], ["a missing spreader node", "PROBLEM", 203, 226], ["node", "OBSERVATION", 222, 226], ["growth", "OBSERVATION_MODIFIER", 247, 253]]], ["The missing spreader may be the place where the first patient appears (an index node) or not (an intermediate node).", [["node", "ANATOMY", 80, 84], ["node", "ANATOMY", 110, 114], ["patient", "ORGANISM", 54, 61], ["node", "MULTI-TISSUE_STRUCTURE", 110, 114], ["patient", "SPECIES", 54, 61], ["The missing spreader", "PROBLEM", 0, 20], ["an index node", "PROBLEM", 71, 84], ["node", "OBSERVATION", 80, 84], ["intermediate", "OBSERVATION_MODIFIER", 97, 109], ["node", "OBSERVATION", 110, 114]]], ["Their role is discriminating between the nodes which are neighboring to the missing spreader node, and the rest (non-neighboring nodes), given a dataset.", [["nodes", "ANATOMY", 41, 46], ["node", "ANATOMY", 93, 97], ["nodes", "ANATOMY", 129, 134], ["spreader node", "MULTI-TISSUE_STRUCTURE", 84, 97], ["nodes", "MULTI-TISSUE_STRUCTURE", 129, 134], ["the nodes", "PROBLEM", 37, 46], ["the missing spreader node", "PROBLEM", 72, 97], ["nodes", "OBSERVATION", 41, 46], ["spreader", "OBSERVATION_MODIFIER", 84, 92], ["node", "OBSERVATION", 93, 97], ["nodes", "OBSERVATION", 129, 134]]], ["It is a collection of the time sequence data on the number of cases, or on the cumulative number of new cases, at the nodes within the scope of surveillance in the early growth phase of the spread.", [["the time sequence data", "TEST", 22, 44], ["new", "OBSERVATION_MODIFIER", 100, 103], ["nodes", "OBSERVATION", 118, 123], ["early", "OBSERVATION_MODIFIER", 164, 169], ["growth", "OBSERVATION_MODIFIER", 170, 176], ["phase", "OBSERVATION_MODIFIER", 177, 182]]], ["The discriminators examine the mid-body or the tail-ends of the probability density function of the number of cases, and search for disturbed time sequence data to which the perturbation gives rise.", [["disturbed time sequence data", "TEST", 132, 160], ["tail", "ANATOMY", 47, 51], ["probability density", "OBSERVATION", 64, 83]]], ["The mid-body discriminator is founded on the Kolmogorov\u2013Smirnov test.", [["the Kolmogorov\u2013Smirnov test", "TEST", 41, 68]]], ["The tail-end discriminator is founded on the Chauvenet rejection test.", [["tail", "ANATOMY", 4, 8], ["the Chauvenet rejection test", "TEST", 41, 69], ["tail", "OBSERVATION_MODIFIER", 4, 8]]], ["The discriminators are tested with a number of computationally synthesized datasets, and applied to the WHO datasets on the SARS outbreak and on the flu pandemic (H1N1 swine influenza A) in 2009.ProblemThe mathematical model of the spread in this study is a special case of a stochastic reaction\u2013diffusion process, the integration of a standard epidemiological SIR compartment model and a meta-population network model.", [["SARS", "DISEASE", 124, 128], ["flu pandemic", "DISEASE", 149, 161], ["H1N1 swine influenza A", "DISEASE", 163, 185], ["H1N1 swine influenza", "SPECIES", 163, 183], ["H1N1 swine influenza A", "SPECIES", 163, 185], ["the SARS outbreak", "PROBLEM", 120, 137], ["the flu pandemic", "PROBLEM", 145, 161], ["this study", "TEST", 242, 252], ["a stochastic reaction\u2013diffusion process", "PROBLEM", 274, 313], ["a meta-population network model", "TREATMENT", 387, 418]]], ["The meta-population network model [20] sub-divides the entire population into distinct sub-populations in many geographical regions.", [["The meta-population network model", "TREATMENT", 0, 33], ["distinct", "OBSERVATION_MODIFIER", 78, 86], ["sub", "OBSERVATION_MODIFIER", 87, 90], ["populations", "OBSERVATION_MODIFIER", 91, 102], ["geographical", "ANATOMY_MODIFIER", 111, 123], ["regions", "ANATOMY_MODIFIER", 124, 131]]], ["The geographical regions are the nodes ni(i=0,1,\u2026).", [["geographical", "OBSERVATION_MODIFIER", 4, 16], ["regions", "ANATOMY_MODIFIER", 17, 24], ["nodes", "OBSERVATION", 33, 38]]], ["The adjacency matrix l, whose i-th row and j-th column element is lij, determines the network topology.", [["i-th row and j-th column element", "DNA", 30, 62], ["lij", "DNA", 66, 69], ["The adjacency matrix l", "PROBLEM", 0, 22], ["whose i-th row and j-th column element", "TREATMENT", 24, 62], ["lij", "TREATMENT", 66, 69], ["adjacency", "OBSERVATION_MODIFIER", 4, 13], ["matrix", "OBSERVATION_MODIFIER", 14, 20], ["l", "OBSERVATION_MODIFIER", 21, 22], ["column element", "OBSERVATION", 48, 62], ["lij", "OBSERVATION", 66, 69]]], ["If a link from ni to nj is present, lij is 1.", [["nj", "DNA", 21, 23], ["lij", "ANATOMY", 36, 39]]], ["If absent, lij is 0.", [["lij", "TEST", 11, 14], ["lij", "ANATOMY", 11, 14]]], ["The parameter \u03b3 is a matrix whose i-th row and j-th column element \u03b3ij is the probability at which a person moves from ni to nj per a unit time.", [["matrix", "CELLULAR_COMPONENT", 21, 27], ["\u03b3", "DNA", 14, 15], ["person", "SPECIES", 101, 107], ["a matrix whose i-th row and j-th column element", "TREATMENT", 19, 66]]], ["In many application areas, an empirical law \u03b3ij=\u0393ij(l) determines \u03b3 as a function of l.", [["\u03b3", "PROTEIN", 66, 67], ["an empirical law \u03b3ij", "TREATMENT", 27, 47]]], ["In the following, \u03b3 and l are interchangeable.ProblemIn the SIR compartment model [21] the state of a person changes from a susceptible state, through an infectious state, to a removed (recovered) state.", [["person", "SPECIES", 102, 108], ["a susceptible state", "PROBLEM", 122, 141], ["infectious", "OBSERVATION", 154, 164]]], ["The quantity Si(t) is the number of susceptible persons at a node ni at time t.", [["node", "ANATOMY", 61, 65], ["Si", "CHEMICAL", 13, 15], ["persons", "ORGANISM", 48, 55], ["persons", "SPECIES", 48, 55], ["quantity", "OBSERVATION_MODIFIER", 4, 12], ["Si", "OBSERVATION_MODIFIER", 13, 15], ["node", "ANATOMY", 61, 65]]], ["Ii(t) is the number of infectious persons.", [["Ii", "GENE_OR_GENE_PRODUCT", 0, 2], ["persons", "ORGANISM", 34, 41], ["persons", "SPECIES", 34, 41], ["infectious", "OBSERVATION", 23, 33]]], ["Ri(t) is the number of recovered persons.", [["persons", "ORGANISM", 33, 40], ["persons", "SPECIES", 33, 40]]], ["The parameter \u03b1 represents the probability at which an infectious person contacts a person and infect the person per a unit time.", [["person", "SPECIES", 66, 72], ["person", "SPECIES", 84, 90], ["person", "SPECIES", 106, 112], ["infectious", "OBSERVATION", 55, 65]]], ["The parameter \u03b2 represents the probability at which an infectious person recovers per unit time.", [["person", "SPECIES", 66, 72], ["infectious", "OBSERVATION", 55, 65]]], ["These transmission parameters do not depend on time and sub-populations.", [["These transmission parameters", "TEST", 0, 29]]], ["The reproductive ratio r is defined by r=\u03b1/\u03b2 [22].", [["The reproductive ratio", "TEST", 0, 22]]], ["Movement, infection and recovery are Markovian stochastic processes which are governed by \u03b8={\u03b1,\u03b2,l}.ProblemNode discovery is a problem to determine whether the nodes n0,n1,\u2026,nN\u22121 which appear in a given dataset are neighboring a missing spreader node nN or not.", [["node", "ANATOMY", 246, 250], ["infection", "DISEASE", 10, 19], ["\u03b8={\u03b1", "GENE_OR_GENE_PRODUCT", 90, 94], ["\u03b2", "GENE_OR_GENE_PRODUCT", 95, 96], ["n0", "GENE_OR_GENE_PRODUCT", 166, 168], ["\u03b8={\u03b1", "PROTEIN", 90, 94], ["\u03b2", "PROTEIN", 95, 96], ["l}", "PROTEIN", 97, 99], ["n0", "DNA", 166, 168], ["n1", "DNA", 169, 171], ["N\u22121", "DNA", 175, 178], ["infection", "PROBLEM", 10, 19], ["Markovian stochastic processes", "PROBLEM", 37, 67], ["the nodes n0", "PROBLEM", 156, 168], ["a missing spreader node nN", "PROBLEM", 227, 253], ["infection", "OBSERVATION", 10, 19], ["nodes", "OBSERVATION", 160, 165]]], ["The neighboring nodes are those having links to nN.", [["nodes", "ANATOMY", 16, 21], ["nodes", "MULTI-TISSUE_STRUCTURE", 16, 21], ["neighboring", "OBSERVATION_MODIFIER", 4, 15], ["nodes", "OBSERVATION", 16, 21]]], ["The dataset is either Ii(td), or \u0394Ji(td)=Ji(td+1)\u2212Ji(td), where i=0,1,\u2026,N\u22121 denotes the nodes, and d=0,1,\u2026,D\u22121 denotes observations.", [["D\u22121", "SIMPLE_CHEMICAL", 107, 110], ["\u0394Ji", "TEST", 33, 36], ["\u2026", "TEST", 70, 71], ["N\u2212", "TEST", 72, 74], ["the nodes", "TEST", 84, 93], ["d", "TEST", 99, 100], ["nodes", "ANATOMY", 88, 93]]], ["The network topology and the transmission parameters \u03b8={\u03b1,\u03b2,lij} for i,j=0,1,\u2026,N\u22121 are given under some conditions, and unknown under other conditions.", [["N\u22121", "SIMPLE_CHEMICAL", 79, 82], ["the transmission parameters", "TEST", 25, 52]]], ["The node nN is either present or absent.", [["node", "ANATOMY", 4, 8], ["node nN", "MULTI-TISSUE_STRUCTURE", 4, 11], ["node", "OBSERVATION", 4, 8], ["absent", "OBSERVATION", 33, 39]]], ["If present, it is either an index node or an intermediate node.", [["node", "ANATOMY", 34, 38], ["node", "ANATOMY", 58, 62], ["node", "MULTI-TISSUE_STRUCTURE", 58, 62], ["an index node", "PROBLEM", 25, 38], ["an intermediate node", "PROBLEM", 42, 62], ["index", "OBSERVATION_MODIFIER", 28, 33], ["node", "OBSERVATION", 34, 38], ["intermediate", "OBSERVATION_MODIFIER", 45, 57], ["node", "OBSERVATION", 58, 62]]], ["The parameters liN and lNj are unknown under any conditions.", [["liN", "GENE_OR_GENE_PRODUCT", 15, 18], ["lNj", "GENE_OR_GENE_PRODUCT", 23, 26], ["liN", "PROTEIN", 15, 18], ["lNj", "DNA", 23, 26], ["lNj", "TREATMENT", 23, 26]]], ["An empirical law \u03b3ij=\u0393ij(l) is postulated in this study.", [["An empirical law \u03b3ij=\u0393ij(l)", "TREATMENT", 0, 27], ["this study", "TEST", 45, 55]]], ["Without the law, when \u03b8 were unknown, the continuous parameter \u03b3 would be estimated, rather than the binary parameter l.Probability density function ::: MethodThe time evolution of Ii(t), or Ji(t) is given by Langevin equations [4].", [["Ii(t)", "PROTEIN", 181, 186], ["density", "OBSERVATION", 132, 139]]], ["The ensemble of an infinite number of sample trajectories Ii(t) is equivalent to the time dependent joint probability density function P(I,t) of the probability variables I=(I0,I1,\u2026).", [["Ii", "GENE_OR_GENE_PRODUCT", 58, 60], ["Ii", "PROTEIN", 58, 60], ["joint", "ANATOMY", 100, 105]]], ["Stochastic differential equations for Ii(t) are converted to a partial differential equation for P(I,t).", [["Ii(t)", "PROTEIN", 38, 43]]], ["This Fokker\u2013Planck equation [23] is converted to ordinary differential equations to calculate the moments of Ii one order after another.", [["Ii", "PROTEIN", 109, 111], ["Planck equation", "TEST", 12, 27]]], ["The first order moments mi(t|\u03b8)=\u222bIiP(I,t)dI are the mean of Ii at t.", [["Ii", "PROTEIN", 60, 62], ["the mean", "TEST", 48, 56]]], ["The second order moments vij(t|\u03b8) are the covariance about the mean between Ii and Ij.", [["Ii", "GENE_OR_GENE_PRODUCT", 76, 78], ["Ii", "PROTEIN", 76, 78], ["Ij", "PROTEIN", 83, 85], ["Ij", "TREATMENT", 83, 85], ["Ij", "ANATOMY", 83, 85]]], ["The third order moments sijk(t|\u03b8) are the skewness about the mean among Ii, Ij, and Ik.", [["Ii", "GENE_OR_GENE_PRODUCT", 72, 74], ["Ij", "GENE_OR_GENE_PRODUCT", 76, 78], ["Ii", "PROTEIN", 72, 74], ["Ij", "PROTEIN", 76, 78], ["Ik", "PROTEIN", 84, 86], ["Ij", "TREATMENT", 76, 78], ["Ij", "ANATOMY", 76, 78]]], ["The fourth order moments \u03baijkl(t|\u03b8) are the kurtosis about the mean among Ii, Ij, Ik, and Il.", [["Ii", "GENE_OR_GENE_PRODUCT", 74, 76], ["Ij", "GENE_OR_GENE_PRODUCT", 78, 80], ["Ik", "GENE_OR_GENE_PRODUCT", 82, 84], ["Ii", "PROTEIN", 74, 76], ["Ij", "PROTEIN", 78, 80], ["Ik", "PROTEIN", 82, 84], ["Il", "PROTEIN", 90, 92], ["the kurtosis", "PROBLEM", 40, 52], ["Ij", "TREATMENT", 78, 80], ["Ij", "ANATOMY", 78, 80]]], ["The formulae for the moments are listed in Appendix A. The observations Ii(td) at td are the initial condition to obtain the moments at td+1.", [["Ii", "GENE_OR_GENE_PRODUCT", 72, 74], ["Appendix", "ANATOMY", 43, 51]]], ["For small \u0394t, sijk(td+1|\u03b8),\u03baijkl(td+1|\u03b8)\u226ami(td+1|\u03b8),vij(td+1|\u03b8).", [["\u03baijkl", "PROTEIN", 27, 32], ["small \u0394t", "TEST", 4, 12], ["mi", "TEST", 41, 43], ["vij", "TEST", 52, 55]]], ["The probability density function is a multi-variate normal distribution in Eq.", [["probability density", "OBSERVATION", 4, 23], ["normal", "OBSERVATION", 52, 58], ["distribution", "OBSERVATION_MODIFIER", 59, 71]]], ["The i-th element of the row vector m(td+1|\u03b8) is mi(td+1|\u03b8).", [["mi", "PROBLEM", 48, 50]]], ["The i-th row and j-th column element of the matrix v(td+1|\u03b8) is vij(td+1|\u03b8).", [["i-th row and j-th column element", "DNA", 4, 36], ["The i-th row and j-th column element", "TREATMENT", 0, 36], ["the matrix v", "TEST", 40, 52]]], ["(1)P(I,td+1)\u2248PN(I;m(td+1|\u03b8),v(td+1|\u03b8)).", [["PN", "TEST", 13, 15]]]], "9c38bb9f6927619c85323d9bc1b5fc31c2b256ba": [["a1111111111 a1111111111 a1111111111 a1111111111 a1111111111IntroductionCollege of Pharmacists of BC made it available as a Schedule II drug (behind the counter) [12] .", [["Pharmacists of BC", "TREATMENT", 82, 99], ["a Schedule II drug", "TREATMENT", 121, 139]]], ["In September 2016, the College of Pharmacists of BC changed the status of naloxone for emergency use to 'unscheduled', making it available outside of pharmacies [14] .", [["naloxone", "CHEMICAL", 74, 82], ["naloxone", "CHEMICAL", 74, 82], ["naloxone", "SIMPLE_CHEMICAL", 74, 82], ["naloxone", "TREATMENT", 74, 82]]], ["Furthermore, the BC THN program removed the requirement to report individual naloxone kit IDs and/or patient names in October 2016 [15] .IntroductionIn December 2017, the BC THN program officially expanded to select community pharmacies to improve BC THN access across the province.", [["naloxone", "CHEMICAL", 77, 85], ["naloxone", "CHEMICAL", 77, 85], ["patient", "ORGANISM", 101, 108], ["patient", "SPECIES", 101, 108]]], ["The program partnered with pharmacy wholesalers, banners and chains to onboard pharmacies through centralized distribution models initially, later reaching stand-alone pharmacies in remote areas with limited access to harm reduction supply distribution sites.", [["harm reduction supply distribution sites", "TREATMENT", 218, 258]]], ["By the end of 2018, there were 1,448 active take-home naloxone distribution sites across BC [17] , including 562 community pharmacy sites [18] -representing 40.5% of all pharmacies [19] .IntroductionUnderstanding correlates of take-home naloxone distribution and access is crucial for planning and targeting services aimed at curbing opioid overdoses.", [["naloxone", "CHEMICAL", 54, 62], ["naloxone", "CHEMICAL", 237, 245], ["overdoses", "DISEASE", 341, 350], ["naloxone", "CHEMICAL", 54, 62], ["naloxone", "CHEMICAL", 237, 245], ["naloxone", "SIMPLE_CHEMICAL", 54, 62], ["naloxone", "SIMPLE_CHEMICAL", 237, 245], ["home naloxone distribution", "TREATMENT", 49, 75], ["home naloxone distribution", "TREATMENT", 232, 258], ["opioid overdoses", "PROBLEM", 334, 350]]], ["While analyses from the BCCDC shows that the BC THN program, combined with other harm reduction interventions, has averted thousands of opioid overdose deaths [20, 21] , there is still relatively little data in the published literature examining community reach and barriers to access of naloxone distribution programs in Canada.", [["overdose", "DISEASE", 143, 151], ["deaths", "DISEASE", 152, 158], ["naloxone", "CHEMICAL", 288, 296], ["naloxone", "CHEMICAL", 288, 296], ["naloxone", "SIMPLE_CHEMICAL", 288, 296], ["the BCCDC", "TEST", 20, 29], ["other harm reduction interventions", "TREATMENT", 75, 109], ["opioid overdose deaths", "PROBLEM", 136, 158], ["naloxone distribution programs", "TREATMENT", 288, 318]]], ["Furthermore, preliminary evidence from the BC Coroners Service suggests a spike in drug toxicity deaths corresponding with COVID-19 physical distancing measures and changes to the illicit drug supply; the Coroners Service reported a 130% increase in drug toxicity deaths in June 2020 compared to June 2019 [22] .", [["toxicity", "DISEASE", 88, 96], ["deaths", "DISEASE", 97, 103], ["toxicity", "DISEASE", 255, 263], ["deaths", "DISEASE", 264, 270], ["a spike in drug toxicity deaths", "PROBLEM", 72, 103], ["COVID", "TREATMENT", 123, 128], ["physical distancing measures", "TREATMENT", 132, 160]]], ["As overdose deaths continue to rise and organizations critical in the training and distribution of naloxone face reduced hours and temporary closures due to COVID-19 [23] , there is a need to understand barriers and access associated with different avenues of distribution.IntroductionThe current paper seeks to first provide an overview of uptake of the BC THN program since inception in August 2012 to the end of 2018, as well as correlates of naloxone distribution through pharmacy sites after the BC THN's pharmacy expansion in late 2017.", [["overdose", "DISEASE", 3, 11], ["deaths", "DISEASE", 12, 18], ["naloxone", "CHEMICAL", 99, 107], ["naloxone", "CHEMICAL", 446, 454], ["naloxone", "CHEMICAL", 99, 107], ["naloxone", "CHEMICAL", 446, 454], ["naloxone", "SIMPLE_CHEMICAL", 99, 107], ["naloxone", "SIMPLE_CHEMICAL", 446, 454], ["overdose deaths", "PROBLEM", 3, 18], ["naloxone face", "TREATMENT", 99, 112], ["temporary closures", "TREATMENT", 131, 149], ["COVID", "TEST", 157, 162], ["naloxone distribution", "TREATMENT", 446, 467], ["the BC", "TEST", 497, 503]]], ["Findings may help inform optimization of take-home naloxone programs across jurisdictions.EthicsThis study analysed anonymous administrative data.", [["naloxone", "CHEMICAL", 51, 59], ["naloxone", "CHEMICAL", 51, 59], ["naloxone", "SIMPLE_CHEMICAL", 51, 59], ["home naloxone programs", "TREATMENT", 46, 68]]], ["Ethics approval was obtained from the University of British Columbia Behavioural Ethics Board (H12-02557).Data sourcesThe BC THN program draws on two key sources of data to monitor and evaluate naloxone distribution and use across BC.", [["naloxone", "CHEMICAL", 194, 202], ["naloxone", "CHEMICAL", 194, 202], ["naloxone", "SIMPLE_CHEMICAL", 194, 202], ["BC", "CANCER", 231, 233], ["The BC", "TEST", 118, 124], ["naloxone distribution", "TREATMENT", 194, 215]]], ["Firstly, 'supply order forms' were used internally at the BCCDC to track the number of kits shipped, to participating distribution sites [9] .Data sourcesSecond, 'distribution records' were used by naloxone distribution sites to track characteristics of individuals who receive a naloxone kit [10] .", [["naloxone", "CHEMICAL", 198, 206], ["naloxone", "CHEMICAL", 280, 288], ["naloxone", "CHEMICAL", 198, 206], ["naloxone", "CHEMICAL", 280, 288], ["naloxone", "SIMPLE_CHEMICAL", 198, 206], ["naloxone distribution sites", "TREATMENT", 198, 225], ["a naloxone kit", "TREATMENT", 278, 292]]], ["No personal identifiers were collected, and sites were asked to return completed distribution records to the BCCDC on a monthly basis.", [["BCCDC", "CANCER", 109, 114]]], ["Since program inception, distribution records have included site-specific information (site's unique ID, city, and the date the kit was distributed to an individual) completed by on-site staff, as well as a 'site type' identifier (corrections facilities, pharmacy, post-secondary, and other (housing sites, treatment centres, non-governmental and peer-led organizations).Data sourcesIndividuals collecting a kit were asked to self-report their gender, their age range, and whether they are collecting a first or replacement kit (due to the previous kit being used, lost, stolen, expired or confiscated).Data sourcesFollowing the unscheduling of naloxone and THN program expansion in 2017 to individuals not personally at risk of an overdose, distribution record forms were amended to include self-reported risk of overdose i.e. personally at risk of overdose or at risk of witnessing an overdose (i.e. friends and family of someone at risk of overdose).", [["naloxone", "CHEMICAL", 645, 653], ["THN", "CHEMICAL", 658, 661], ["overdose", "DISEASE", 732, 740], ["overdose", "DISEASE", 814, 822], ["overdose", "DISEASE", 850, 858], ["overdose", "DISEASE", 887, 895], ["overdose", "DISEASE", 943, 951], ["naloxone", "CHEMICAL", 645, 653], ["THN", "CHEMICAL", 658, 661], ["naloxone", "SIMPLE_CHEMICAL", 645, 653], ["treatment centres", "TREATMENT", 307, 324], ["replacement kit", "TREATMENT", 512, 527], ["naloxone", "TREATMENT", 645, 653], ["THN program expansion", "TREATMENT", 658, 679], ["an overdose", "PROBLEM", 729, 740], ["overdose", "PROBLEM", 814, 822], ["overdose", "PROBLEM", 850, 858], ["overdose", "PROBLEM", 943, 951]]], ["Before this date, all kit recipients were assumed to be personally at risk of overdose.Data sourcesDistribution records often experience a delay in return and entry due to two reasons: 1) a delay and general decrease in submission of records from distribution sites and, 2) a lag in manual entry of records at the BCCDC.", [["overdose", "DISEASE", 78, 86], ["kit", "ORGANISM", 22, 25], ["recipients", "ORGANISM", 26, 36], ["all kit recipients", "TREATMENT", 18, 36], ["overdose", "PROBLEM", 78, 86], ["a delay", "PROBLEM", 137, 144], ["a delay", "PROBLEM", 188, 195], ["decrease", "OBSERVATION_MODIFIER", 208, 216]]], ["Together, we estimate the return window to be on average between three to six months.Study variablesSupply order forms were geographically coded by health authority (Vancouver Coastal Health, Fraser Health, Island Health, Interior Health, and Northern Health) and used to provide the number of naloxone kits shipped to distribution sites over time.Study variablesDistribution records were the primary data source used in this study.", [["naloxone", "CHEMICAL", 294, 302], ["naloxone", "CHEMICAL", 294, 302], ["naloxone", "SIMPLE_CHEMICAL", 294, 302], ["Study variables", "TEST", 85, 100], ["naloxone kits", "TREATMENT", 294, 307], ["Study variables", "TEST", 348, 363], ["this study", "TEST", 421, 431]]], ["Records were also used to classify records by age group (<19, 19-30, 31-60, >60, Unknown), gender (Male, Female, Other (Trans, gender non-conforming), Unknown), reason for collecting a kit (1 st kit, replacement kit-used, replacement kit-other (previous kit lost, stolen, confiscated or expired), site type (corrections facility, pharmacy, post-secondary institution, other (housing sites, treatment centres, non-governmental and peer-led organization), and 'eligibility for collecting a naloxone kit (not personally at risk of overdose, peronlly at risk of overdose, unknown).Analysis planThis study includes findings from distribution records and supply order forms across BC from program inception on August 31 st , 2012 to December 31 st , 2018.", [["naloxone", "CHEMICAL", 488, 496], ["overdose", "DISEASE", 528, 536], ["overdose", "DISEASE", 558, 566], ["naloxone", "CHEMICAL", 488, 496], ["replacement kit", "TREATMENT", 200, 215], ["replacement kit-other", "TREATMENT", 222, 243], ["treatment centres", "TREATMENT", 390, 407], ["a naloxone kit", "TREATMENT", 486, 500], ["overdose", "PROBLEM", 528, 536], ["overdose", "PROBLEM", 558, 566], ["This study", "TEST", 590, 600]]], ["To evaluate the effect of the THN program's expansion into community pharmacies, a separate analytic sample was created which limits distribution records to those returned between January 1 st , 2018 and December 31 st , 2018.", [["the THN program", "TREATMENT", 26, 41], ["a separate analytic sample", "TEST", 81, 107]]], ["Data for this study were retrieved and analyses conducted in January 2020.", [["this study", "TEST", 9, 19]]], ["All analyses were conducted using R version 3.5.3 [24] .Analysis planFrequency distributions were used to describe characteristics of individuals accessing the BC THN program from 2012 to the end of 2018, as well as to compare shipment and distribution data.", [["All analyses", "TEST", 0, 12], ["R version", "TEST", 34, 43]]], ["A chi-squared test for trend (Cochran-Armitage test) was used to evaluate differences in the proportion of naloxone kits used to respond to an opioid overdose over time.", [["naloxone", "CHEMICAL", 107, 115], ["overdose", "DISEASE", 150, 158], ["naloxone", "CHEMICAL", 107, 115], ["naloxone", "SIMPLE_CHEMICAL", 107, 115], ["opioid", "SIMPLE_CHEMICAL", 143, 149], ["A chi-squared test", "TEST", 0, 18], ["Cochran-Armitage test", "TEST", 30, 51], ["naloxone kits", "TREATMENT", 107, 120], ["an opioid overdose", "PROBLEM", 140, 158]]], ["In this sample, all non-pharmacy sites were grouped as 'other' sites to compare with pharmacy distribution.", [["non-pharmacy sites", "DNA", 20, 38], ["all non-pharmacy sites", "PROBLEM", 16, 38]]], ["Multivariate logistic regression was used to examine factors associated with distribution site type.Analysis planThe model building strategy described by Hosmer and Lemeshow [25] , and further operationalized by Zhang [26] , was employed.", [["Multivariate logistic regression", "PROBLEM", 0, 32]]], ["All available covariates were included for bivariable analysis to explore trends and examine distributions by the outcome variable.", [["bivariable analysis", "TEST", 43, 62]]], ["Covariates were cross-tabulated with the outcome variable and those with a p-value < 0.25 and were deemed to be conceptually relevant as indicated in the literature, were included for further multivariate analysis.", [["a p-value", "TEST", 73, 82], ["further multivariate analysis", "TEST", 184, 213]]], ["As per the purposeful selection model building strategy, variables which did not meet the p-value cut-off but were known to be conceptually relevant were included in further analyses.", [["further analyses", "TEST", 166, 182]]], ["Adjusted odds ratios (AOR), 95% confidence intervals (CI), and p-values are reported.", [["CI", "TEST", 54, 56], ["p-values", "TEST", 63, 71]]], ["Pvalues less than 0.05 were considered statistically significant.", [["Pvalues", "TEST", 0, 7]]], ["Table 1 provide a summary of naloxone kits shipped, reported distributed, and reported used to reverse an overdose from the BC THN program, from August 31 st , 2012 to December 31 st , 2018.", [["naloxone", "CHEMICAL", 29, 37], ["overdose", "DISEASE", 106, 114], ["naloxone", "CHEMICAL", 29, 37], ["naloxone", "SIMPLE_CHEMICAL", 29, 37], ["naloxone kits", "TREATMENT", 29, 42]]], ["During this time period, a total of 398,167 kits were shipped and 149,999 naloxone kits were reported distributed, according to records returned.", [["naloxone", "CHEMICAL", 74, 82], ["naloxone", "CHEMICAL", 74, 82], ["naloxone", "SIMPLE_CHEMICAL", 74, 82], ["naloxone kits", "TREATMENT", 74, 87]]], ["Data show a consistent increase in kits shipped, however the number of kits reported distributed increased through 2017 but dropped in 2018 (Fig 1) .PLOS ONEA total of 41,197 kits (27.5% of those distributed) were reported to have been obtained to replace a kit used to respond to an opioid overdose.", [["overdose", "DISEASE", 291, 299], ["a consistent increase in kits", "PROBLEM", 10, 39], ["kits", "TEST", 175, 179], ["a kit", "TREATMENT", 256, 261], ["an opioid overdose", "PROBLEM", 281, 299], ["consistent", "OBSERVATION_MODIFIER", 12, 22], ["increase", "OBSERVATION_MODIFIER", 23, 31]]], ["As a proportion of naloxone kits reported distributed, naloxone kits reported used to reverse an overdose increased steadily over time, from 8.7% in the pre-2015 period (168/1921), to 12 Table 2 presents summary characteristics of BC THN distribution records, from program inception to the end of 2018.", [["naloxone", "CHEMICAL", 19, 27], ["naloxone", "CHEMICAL", 55, 63], ["overdose", "DISEASE", 97, 105], ["naloxone", "CHEMICAL", 19, 27], ["naloxone", "CHEMICAL", 55, 63], ["naloxone", "SIMPLE_CHEMICAL", 19, 27], ["naloxone", "SIMPLE_CHEMICAL", 55, 63], ["naloxone kits", "TREATMENT", 19, 32], ["naloxone kits", "TREATMENT", 55, 68], ["an overdose", "PROBLEM", 94, 105]]], ["The majority of THN distribution records were received in 2017 (42.2%) and 2018 (40.1%).", [["THN", "CANCER", 16, 19], ["majority", "OBSERVATION_MODIFIER", 4, 12]]], ["The large majority (94.2%) of THN kits were distributed at 'Other' sites (including housing sites, health and treatment centres, non-governmental and peer-led organizations).", [["THN kits", "PROBLEM", 30, 38], ["treatment centres", "TREATMENT", 110, 127], ["large", "OBSERVATION_MODIFIER", 4, 9], ["majority", "OBSERVATION_MODIFIER", 10, 18]]], ["The overall kit distribution rate 2012-2018 was 31.4 kits per 1000 BC population but varied between health authorities (based on average population estimates 2012-2018).", [["The overall kit distribution rate", "TEST", 0, 33], ["BC population", "PROBLEM", 67, 80]]], ["The rate of kit distribution varied between health regions, from 22.4 to 50.4 kits/1,000 population, while the proportions distributed were similar between the four most populous health regions (20.8% -26.7%), with 5.2% of kits distributed in the least populous region-see the table in S1 Appendix for details.PLOS ONEOverall, most THN kits were distributed to individuals who identified as male (43.4%) compared to female (36.2%), other genders (1.2%), and unknown (19.3%), and to those between the ages of 19-30 (27.9%) or 31-60 (45.4%).", [["kits", "TEST", 223, 227], ["other genders", "TEST", 432, 445], ["kit distribution", "OBSERVATION", 12, 28], ["four", "OBSERVATION_MODIFIER", 160, 164], ["most", "OBSERVATION_MODIFIER", 165, 169], ["populous", "OBSERVATION_MODIFIER", 170, 178], ["least", "OBSERVATION_MODIFIER", 247, 252], ["populous", "OBSERVATION_MODIFIER", 253, 261]]], ["Eligibility criteria was introduced in 2017, when the THN program was expanded to individuals not personally at risk of overdose.", [["overdose", "DISEASE", 120, 128], ["overdose", "PROBLEM", 120, 128]]], ["All individuals who received a kit before 2017 were considered personally at risk of overdose, and account for the majority of the 'unknown' category.", [["overdose", "DISEASE", 85, 93], ["overdose", "PROBLEM", 85, 93], ["overdose", "OBSERVATION", 85, 93]]], ["For the age and gender variables, a high proportion of 'unknown' is likely due to the nature of ensuring a low-barrier THN program-some information is not always reported by THN distribution sites or by recipients.", [["a low-barrier THN program", "TREATMENT", 105, 130]]], ["Table 3 presents the analytic sample characteristics after limiting naloxone distribution records to 2018, stratified by eligibility.", [["naloxone", "CHEMICAL", 68, 76], ["naloxone", "CHEMICAL", 68, 76], ["naloxone", "SIMPLE_CHEMICAL", 68, 76]]], ["A breakdown of THN distributing pharmacy sites by Health Authority is provided in the table of S2 Appendix.", [["THN", "SIMPLE_CHEMICAL", 15, 18], ["THN", "PROTEIN", 15, 18], ["A breakdown of THN distributing pharmacy sites", "PROBLEM", 0, 46], ["breakdown", "OBSERVATION_MODIFIER", 2, 11], ["S2 Appendix", "ANATOMY", 95, 106]]], ["A total of 57,524 records were included, of which 39,208 (68.2%) self-reported being personally at risk of overdose, compared to 18,316 (31.8%) of individuals who reported not being personally at risk of overdose.", [["overdose", "DISEASE", 107, 115], ["overdose", "DISEASE", 204, 212], ["individuals", "ORGANISM", 147, 158], ["overdose", "PROBLEM", 107, 115], ["overdose", "PROBLEM", 204, 212]]], ["Of naloxone kits reported used to respond to an opioid overdose in 2018, 90.2% were kits obtained by individuals who were personally at risk of overdose.", [["naloxone", "CHEMICAL", 3, 11], ["overdose", "DISEASE", 55, 63], ["overdose", "DISEASE", 144, 152], ["naloxone", "CHEMICAL", 3, 11], ["naloxone", "SIMPLE_CHEMICAL", 3, 11], ["naloxone kits", "TREATMENT", 3, 16], ["an opioid overdose", "PROBLEM", 45, 63], ["overdose", "PROBLEM", 144, 152]]], ["Even after the introduction of pharmacy sites across BC, a large majority (93.2%) of individuals continued to access naloxone at 'other' community site types, compared to pharmacy sites (6.8%).", [["naloxone", "CHEMICAL", 117, 125], ["naloxone", "CHEMICAL", 117, 125], ["individuals", "ORGANISM", 85, 96], ["naloxone", "SIMPLE_CHEMICAL", 117, 125], ["BC", "TEST", 53, 55], ["naloxone", "TREATMENT", 117, 125], ["large", "OBSERVATION_MODIFIER", 59, 64]]], ["Furthermore, the majority of those who self-reported not being personally at risk of overdose accessed naloxone at a pharmacy (60.1%), while the majority of individuals personally at risk of overdose accessed naloxone at other sites (70.2%).", [["overdose", "DISEASE", 85, 93], ["naloxone", "CHEMICAL", 103, 111], ["overdose", "DISEASE", 191, 199], ["naloxone", "CHEMICAL", 209, 217], ["naloxone", "CHEMICAL", 103, 111], ["naloxone", "CHEMICAL", 209, 217], ["naloxone", "SIMPLE_CHEMICAL", 103, 111], ["naloxone", "SIMPLE_CHEMICAL", 209, 217], ["naloxone", "TREATMENT", 103, 111], ["overdose", "PROBLEM", 191, 199], ["naloxone", "TREATMENT", 209, 217]]], ["Table 4 presents the analytic sample characteristics after limiting naloxone distribution records to 2018, as well as multivariate logistic regression results (adjusted odds ratios and 95% confidence intervals) for correlates of THN kit collection at a pharmacy site, compared to other sites.", [["naloxone", "CHEMICAL", 68, 76], ["naloxone", "CHEMICAL", 68, 76], ["naloxone", "SIMPLE_CHEMICAL", 68, 76], ["ratios", "TEST", 174, 180], ["THN kit collection", "PROBLEM", 229, 247]]], ["In bivariate analyses, all covariates were statistically significant and conceptually relevant, and were included in the analysis.Correlates of collecting a THN kit through a pharmacy siteAfter adjustment, and consistent with descriptive statistics, individuals who were not personally at risk of overdose had more than twice the odds of collecting a THN kit at a pharmacy site, compared to other sites (AOR = 2.69 [95% CI 2.50-2.90]).", [["overdose", "DISEASE", 297, 305], ["bivariate analyses", "TEST", 3, 21], ["the analysis", "TEST", 117, 129], ["overdose", "PROBLEM", 297, 305], ["AOR", "TEST", 404, 407], ["CI", "TEST", 420, 422]]], ["Individuals collecting a replacement kit were less likely to collect those kits at a pharmacy site compared to first time kitDiscussionThe current study provides an overview of uptake of the BC THN program.", [["a replacement kit", "TREATMENT", 23, 40], ["The current study", "TEST", 135, 152], ["replacement", "OBSERVATION", 25, 36]]], ["While all Canadian provinces and territories have publicly funded THN programs, research and evaluation of these programs in the scholarly literature is limited.", [["evaluation", "TEST", 93, 103]]], ["A recent study from Ontario describes uptake of the province's pharmacy-dispensed naloxone kits in Ontario [27] , and preliminary analyses of provincial THN programs in Ontario [28] , Alberta [29] , Manitoba [30] , and British Columbia [15] have been published.", [["naloxone", "CHEMICAL", 82, 90], ["naloxone", "CHEMICAL", 82, 90], ["naloxone", "SIMPLE_CHEMICAL", 82, 90], ["A recent study", "TEST", 0, 14], ["naloxone kits", "TREATMENT", 82, 95]]], ["An environmental scan of provincial programs and distribution has also been conducted [9] , and our group is involved in efforts to combine aggregate jurisdictional level data nationally.", [["An environmental scan", "TEST", 0, 21]]], ["The current study finds that the BC THN program expanded to a total of approximately 1,500 sites across BC by the end of December 2018, including 562 pharmacy sites (40.5% of all community pharmacies in BC) since December 2017.", [["The current study", "TEST", 0, 17]]], ["Overall, almost 400,000 naloxone kits were shipped and 150,000 reported distributed since the program was launched in 2012.DiscussionOur findings show that there is a significant increasing trend in the proportion of kits reported used to reverse an overdose over time.", [["naloxone", "CHEMICAL", 24, 32], ["overdose", "DISEASE", 250, 258], ["naloxone", "CHEMICAL", 24, 32], ["naloxone kits", "TREATMENT", 24, 37], ["a significant increasing trend", "PROBLEM", 165, 195], ["an overdose", "PROBLEM", 247, 258], ["significant", "OBSERVATION_MODIFIER", 167, 178], ["increasing", "OBSERVATION_MODIFIER", 179, 189], ["trend", "OBSERVATION_MODIFIER", 190, 195]]], ["Most individuals collecting a naloxone kit selfreported being male and between the ages of 31-60.", [["naloxone", "CHEMICAL", 30, 38], ["naloxone", "CHEMICAL", 30, 38], ["individuals", "ORGANISM", 5, 16], ["a naloxone kit", "TREATMENT", 28, 42]]], ["This corresponds with data from the BCPLOS ONECoroners Service, which has found that the group at highest risk of overdose death in BC are men between the ages of 40-59 years old, as well as those 19-39 years [31] .", [["overdose", "DISEASE", 114, 122], ["death", "DISEASE", 123, 128], ["BC", "DISEASE", 132, 134], ["BC", "CANCER", 132, 134], ["men", "ORGANISM", 139, 142], ["men", "SPECIES", 139, 142], ["overdose death", "PROBLEM", 114, 128]]], ["Importantly, our findings also indicate that the vast majority of kits reported used to reverse an overdose were distributed to persons themselves at risk of an overdose.", [["overdose", "DISEASE", 99, 107], ["overdose", "DISEASE", 161, 169], ["persons", "ORGANISM", 128, 135], ["persons", "SPECIES", 128, 135], ["an overdose", "PROBLEM", 96, 107], ["an overdose", "PROBLEM", 158, 169], ["overdose", "OBSERVATION", 161, 169]]], ["While it is possible that individuals collect naloxone kits for others to use on them in the event they overdose, most individuals who use drugs do so around other people who use drugs.", [["naloxone", "CHEMICAL", 46, 54], ["overdose", "DISEASE", 104, 112], ["naloxone", "CHEMICAL", 46, 54], ["naloxone", "SIMPLE_CHEMICAL", 46, 54], ["people", "ORGANISM", 164, 170], ["people", "SPECIES", 164, 170], ["naloxone kits", "TREATMENT", 46, 59], ["drugs", "TREATMENT", 139, 144]]], ["We believe our findings suggest then that people who use drugs are most likely to respond to overdoses in their communities, though further research to help elucidate this question is warranted.", [["people", "ORGANISM", 42, 48], ["people", "SPECIES", 42, 48], ["drugs", "TREATMENT", 57, 62], ["most likely", "UNCERTAINTY", 67, 78]]], ["After evaluating data from 2018, our analysis also finds that individuals at risk of opioid overdose were significantly less likely to collect a naloxone kit at a pharmacy site compared to community-based sites.", [["overdose", "DISEASE", 92, 100], ["naloxone", "CHEMICAL", 145, 153], ["naloxone", "CHEMICAL", 145, 153], ["our analysis", "TEST", 33, 45], ["opioid overdose", "PROBLEM", 85, 100], ["a naloxone kit", "TREATMENT", 143, 157], ["opioid overdose", "OBSERVATION", 85, 100]]], ["In developing the BC THN program, the priority was to ensure a low barrier environment for individuals receiving overdose response training, collecting naloxone kits, and seeking other supports.", [["overdose", "DISEASE", 113, 121], ["naloxone", "CHEMICAL", 152, 160], ["naloxone", "CHEMICAL", 152, 160], ["a low barrier environment", "TREATMENT", 61, 86], ["overdose response training", "TREATMENT", 113, 139], ["collecting naloxone kits", "TREATMENT", 141, 165]]], ["Consistent with our findings, evidence from the literature suggests that people with lived and/or living experience of substance use may be reluctant to access pharmacies and other medical services due to past experiences of stigma or discrimination [32, 33] .", [["people", "ORGANISM", 73, 79], ["people", "SPECIES", 73, 79], ["stigma", "PROBLEM", 225, 231]]], ["Nevertheless, data from this study suggests that first time naloxone kit recipients may be more likely to collect kits from pharmacy sites, suggesting that these sites are important in reaching different cohort of clients who may not access traditional distribution sites aimed at higher-risk communities.PLOS ONEThe authors believe that these findings offer support for increased access to naloxone through pharmacy sites in BC, and highlights the importance of having a variety of distribution site types.", [["naloxone", "CHEMICAL", 60, 68], ["naloxone", "CHEMICAL", 391, 399], ["naloxone", "CHEMICAL", 60, 68], ["naloxone", "CHEMICAL", 391, 399], ["naloxone", "SIMPLE_CHEMICAL", 60, 68], ["naloxone", "SIMPLE_CHEMICAL", 391, 399], ["this study", "TEST", 24, 34], ["naloxone kit recipients", "TREATMENT", 60, 83], ["naloxone", "TREATMENT", 391, 399]]], ["A previous evaluation from our group suggests pharmacists are willing to be involved in the BC THN initiative, despite some initial concerns about lack of remuneration for training and dispensing.", [["A previous evaluation", "TEST", 0, 21], ["training", "TREATMENT", 172, 180]]], ["There are mixed views regarding further program growth; some pharmacy managers feel that naloxone is now fairly accessible and that there is no need for further expansion, while others feel that expansion to more pharmacy banners and chains would be beneficial [16] .PLOS ONEDue to the COVID-19 crisis, some harm reduction services and supply distribution sites have temporarily closed or have reduced hours [23] , while pharmacies remain an essential service that continue to be widely available, open, and hence accessible to distribute THN.", [["naloxone", "CHEMICAL", 89, 97], ["THN", "DISEASE", 539, 542], ["naloxone", "CHEMICAL", 89, 97], ["naloxone", "SIMPLE_CHEMICAL", 89, 97], ["THN", "CANCER", 539, 542], ["naloxone", "TREATMENT", 89, 97], ["the COVID", "TEST", 282, 291], ["crisis", "PROBLEM", 295, 301], ["some harm reduction services", "TREATMENT", 303, 331], ["no need for", "UNCERTAINTY", 141, 152]]], ["Online training is available for those who need refresher training or to be newly trained, allowing for physical distancing during the training process.", [["refresher training", "TREATMENT", 48, 66], ["the training process", "TREATMENT", 131, 151]]], ["The THN kits contain non-latex gloves which responders are advised to put on before responding to an overdose and to remove carefully after responding, as well as to practice hand hygiene.PLOS ONEWith recent changes of temporary exemptions [34] and clinical opioid prescribing guidelines [35] in relation to COVID-19, individuals may be receiving new opioid agonist therapy (OAT) prescriptions, longer prescriptions, and/or delivery of medications by pharmacies.", [["hand", "ANATOMY", 175, 179], ["overdose", "DISEASE", 101, 109], ["hand", "ORGANISM_SUBDIVISION", 175, 179], ["individuals", "ORGANISM", 318, 329], ["The THN kits", "TREATMENT", 0, 12], ["non-latex gloves", "TREATMENT", 21, 37], ["an overdose", "PROBLEM", 98, 109], ["temporary exemptions", "TREATMENT", 219, 239], ["clinical opioid prescribing guidelines", "TREATMENT", 249, 287], ["new opioid agonist therapy", "TREATMENT", 347, 373], ["medications", "TREATMENT", 436, 447]]], ["In many cases, pharmacists have been advised to co-dispense naloxone.", [["naloxone", "CHEMICAL", 60, 68], ["naloxone", "CHEMICAL", 60, 68], ["naloxone", "SIMPLE_CHEMICAL", 60, 68], ["naloxone", "TREATMENT", 60, 68]]], ["Future research is needed to explore changes in distribution and the role of pharmacies in providing naloxone to individuals at risk of overdose during the dual public health emergency period.PLOS ONEWhile data suggests a decline in naloxone kits reported distributed compared to kits shipped in 2018, it is important to note that distribution numbers may not accurately reflect naloxone kits in public circulation.", [["naloxone", "CHEMICAL", 101, 109], ["overdose", "DISEASE", 136, 144], ["naloxone", "CHEMICAL", 233, 241], ["naloxone", "CHEMICAL", 379, 387], ["naloxone", "CHEMICAL", 101, 109], ["naloxone", "CHEMICAL", 233, 241], ["naloxone", "CHEMICAL", 379, 387], ["naloxone", "SIMPLE_CHEMICAL", 101, 109], ["naloxone", "SIMPLE_CHEMICAL", 233, 241], ["naloxone", "SIMPLE_CHEMICAL", 379, 387], ["naloxone", "TREATMENT", 101, 109], ["overdose", "PROBLEM", 136, 144], ["a decline", "PROBLEM", 220, 229], ["naloxone kits", "TREATMENT", 233, 246], ["naloxone kits", "TREATMENT", 379, 392]]], ["Uneven response rates across sites, delays in returning distribution forms, and delays in entering data means that the true count of naloxone kits distributed to the public likely exceeds the reported kits distributed.", [["naloxone", "CHEMICAL", 133, 141], ["naloxone", "CHEMICAL", 133, 141], ["naloxone", "SIMPLE_CHEMICAL", 133, 141], ["Uneven response rates across sites", "PROBLEM", 0, 34], ["naloxone kits", "TREATMENT", 133, 146], ["rates", "OBSERVATION_MODIFIER", 16, 21]]], ["The authors note that the observed drop in reported kit distribution in 2018 is likely due to a lower return rate, and does not represent a true decrease in naloxone kits distributed to the public.", [["naloxone", "CHEMICAL", 157, 165], ["naloxone", "CHEMICAL", 157, 165], ["naloxone", "SIMPLE_CHEMICAL", 157, 165], ["a lower return rate", "PROBLEM", 94, 113], ["naloxone kits", "TREATMENT", 157, 170], ["likely due to", "UNCERTAINTY", 80, 93], ["does not represent", "UNCERTAINTY", 119, 137], ["true", "OBSERVATION_MODIFIER", 140, 144], ["decrease", "OBSERVATION_MODIFIER", 145, 153], ["naloxone kits", "OBSERVATION", 157, 170]]], ["Relatedly, the higher proportion of pharmacy naloxone kit distribution in the Vancouver Coastal Region in the 2018 analytic sample is likely due to low reporting in high volume, low-capacity community sites in the Vancouver region compared to other regions.", [["naloxone", "CHEMICAL", 45, 53], ["naloxone", "CHEMICAL", 45, 53], ["pharmacy naloxone", "TREATMENT", 36, 53], ["low reporting in high volume", "PROBLEM", 148, 176], ["low-capacity community sites", "PROBLEM", 178, 206], ["higher", "OBSERVATION_MODIFIER", 15, 21], ["likely due to", "UNCERTAINTY", 134, 147], ["low", "OBSERVATION_MODIFIER", 148, 151], ["high volume", "OBSERVATION_MODIFIER", 165, 176], ["low-capacity", "OBSERVATION_MODIFIER", 178, 190], ["Vancouver", "ANATOMY_MODIFIER", 214, 223], ["region", "ANATOMY_MODIFIER", 224, 230]]], ["Operationally, the program has confirmed with high volume sites, which have low reported distribution forms, that kits ordered are being distributed and not held in inventory or being thrown away due to naloxone expiry.", [["naloxone", "CHEMICAL", 203, 211], ["naloxone", "CHEMICAL", 203, 211], ["naloxone", "SIMPLE_CHEMICAL", 203, 211], ["high volume sites", "PROBLEM", 46, 63], ["naloxone expiry", "TREATMENT", 203, 218], ["high volume", "OBSERVATION_MODIFIER", 46, 57], ["low reported", "OBSERVATION_MODIFIER", 76, 88], ["distribution", "OBSERVATION_MODIFIER", 89, 101]]], ["The large majority of sites reorder kits as needed on a weekly or monthly basis.", [["large", "OBSERVATION_MODIFIER", 4, 9], ["majority", "OBSERVATION_MODIFIER", 10, 18]]], ["Thus, we believe that true distribution is likely much higher than the number of distribution records returned to the BCCDC.PLOS ONEAs previously mentioned, careful interpretation of this data is required; the program is low barrier and to ensure anonymity identifiers are not collected from naloxone kit recipients.", [["naloxone", "CHEMICAL", 292, 300], ["naloxone", "CHEMICAL", 292, 300], ["this data", "TEST", 183, 192], ["low barrier", "TREATMENT", 221, 232], ["naloxone kit recipients", "TREATMENT", 292, 315]]], ["Therefore, we cannot identify how many unique individuals are accessing or using naloxone kits, or how many kits are distributed and used per individual in BC.", [["naloxone", "CHEMICAL", 81, 89], ["naloxone", "CHEMICAL", 81, 89], ["individuals", "ORGANISM", 46, 57], ["naloxone", "SIMPLE_CHEMICAL", 81, 89], ["BC", "CANCER", 156, 158], ["naloxone kits", "TREATMENT", 81, 94]]], ["Stigma around drug use may discourage high-risk individuals from providing information or self-identifying as being at risk of experiencing an overdose, which may in turn bias results.ConclusionBetween 2012 and 2018, more than 40,000 take-home naloxone kits have been reported used to reverse an opioid overdose in BC.", [["overdose", "DISEASE", 143, 151], ["naloxone", "CHEMICAL", 244, 252], ["overdose", "DISEASE", 303, 311], ["BC", "DISEASE", 315, 317], ["naloxone", "CHEMICAL", 244, 252], ["naloxone", "SIMPLE_CHEMICAL", 244, 252], ["opioid", "SIMPLE_CHEMICAL", 296, 302], ["BC", "CANCER", 315, 317], ["an overdose", "PROBLEM", 140, 151], ["home naloxone kits", "TREATMENT", 239, 257], ["an opioid overdose", "PROBLEM", 293, 311]]], ["Community distribution sites are crucial for providing naloxone to people at high risk of overdose, who may be most likely to respond to overdoses in their communities.", [["naloxone", "CHEMICAL", 55, 63], ["overdose", "DISEASE", 90, 98], ["naloxone", "CHEMICAL", 55, 63], ["naloxone", "SIMPLE_CHEMICAL", 55, 63], ["people", "ORGANISM", 67, 73], ["people", "SPECIES", 67, 73], ["Community distribution sites", "PROBLEM", 0, 28], ["naloxone", "TREATMENT", 55, 63], ["overdose", "PROBLEM", 90, 98]]], ["Pharmacy sites appear to reach a cohort of first-time kit recipients, sustain longer opening and weekend hours, and support access in rural and hard-to-reach areas.", [["kit", "ORGANISM", 54, 57], ["recipients", "ORGANISM", 58, 68]]], ["Findings from this study highlight the importance of making naloxone available through a variety of distribution sites that are both widely accessible and responsive to the needs of people who require naloxone.", [["naloxone", "CHEMICAL", 60, 68], ["naloxone", "CHEMICAL", 201, 209], ["naloxone", "CHEMICAL", 60, 68], ["naloxone", "CHEMICAL", 201, 209], ["naloxone", "SIMPLE_CHEMICAL", 60, 68], ["people", "ORGANISM", 182, 188], ["naloxone", "SIMPLE_CHEMICAL", 201, 209], ["people", "SPECIES", 182, 188], ["this study", "TEST", 14, 24], ["naloxone", "TREATMENT", 60, 68], ["naloxone", "TREATMENT", 201, 209]]]], "PMC6630264": [], "c6093d3df122f7efa83e520b1b5549954c8ff9b5": [["IMPACT ON ENDOSCOPIC PROCEDURESAbout 350,000 endoscopic retrograde cholangiopancreatographies (ERCPs) and 200,000 endoscopic ultrasounds (EUS) are performed annually in the United States for a variety of pancreatobiliary indications.", [["pancreatobiliary", "ANATOMY", 204, 220], ["pancreatobiliary", "CANCER", 204, 220], ["endoscopic retrograde cholangiopancreatographies", "TEST", 45, 93], ["ERCPs", "TEST", 95, 100], ["endoscopic ultrasounds", "TEST", 114, 136], ["EUS", "TEST", 138, 141], ["pancreatobiliary", "ANATOMY", 204, 220]]], ["7, 8 Both procedures can lead to human-to-human airborne transmission by the generation of small droplet nuclei in high concentrations and are considered high-risk aerosol-generating procedures (AGPs).", [["nuclei", "ANATOMY", 105, 111], ["human", "ORGANISM", 33, 38], ["human", "ORGANISM", 42, 47], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 42, 47], ["human airborne transmission", "TREATMENT", 42, 69], ["small droplet nuclei", "PROBLEM", 91, 111], ["small", "OBSERVATION_MODIFIER", 91, 96], ["droplet nuclei", "OBSERVATION", 97, 111], ["high concentrations", "OBSERVATION_MODIFIER", 115, 134]]], ["6 Aerosolization may occur at the time of endoscope insertion into the pharynx, during removal of instruments through the endoscope channel, from airway stimulation and unexpected coughing during the procedure, and by insertion or removal of the endotracheal tube when ventilatory support is used.", [["pharynx", "ANATOMY", 71, 78], ["airway", "ANATOMY", 146, 152], ["endotracheal tube", "ANATOMY", 246, 263], ["coughing", "DISEASE", 180, 188], ["pharynx", "ORGAN", 71, 78], ["airway", "MULTI-TISSUE_STRUCTURE", 146, 152], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 246, 263], ["Aerosolization", "TREATMENT", 2, 16], ["endoscope insertion", "TREATMENT", 42, 61], ["removal of instruments", "TREATMENT", 87, 109], ["the endoscope channel", "TREATMENT", 118, 139], ["airway stimulation", "TREATMENT", 146, 164], ["unexpected coughing", "PROBLEM", 169, 188], ["the procedure", "TREATMENT", 196, 209], ["removal", "TREATMENT", 231, 238], ["the endotracheal tube", "TREATMENT", 242, 263], ["ventilatory support", "TREATMENT", 269, 288], ["pharynx", "ANATOMY", 71, 78], ["airway", "ANATOMY", 146, 152], ["coughing", "OBSERVATION", 180, 188], ["endotracheal tube", "OBSERVATION", 246, 263], ["ventilatory support", "OBSERVATION", 269, 288]]], ["9-12 Although all types of upper endoscopic procedures are currently considered in the same category of AGPs, it is possible that EUS and ERCP generate more respiratory droplets given the larger diameter of the endoscopes with a higher probability of cough, increased use of devices for interventions, longer procedural duration, and more leakage of body fluids through the working channel (eg, gastrointestinal secretion, bile) compared with other endoscopic procedures.", [["respiratory droplets", "ANATOMY", 157, 177], ["body", "ANATOMY", 350, 354], ["gastrointestinal", "ANATOMY", 395, 411], ["bile", "ANATOMY", 423, 427], ["9-12", "CHEMICAL", 0, 4], ["cough", "DISEASE", 251, 256], ["AGPs", "GENE_OR_GENE_PRODUCT", 104, 108], ["body", "ORGANISM_SUBDIVISION", 350, 354], ["gastrointestinal", "ORGAN", 395, 411], ["bile", "MULTI-TISSUE_STRUCTURE", 423, 427], ["AGPs", "PROTEIN", 104, 108], ["upper endoscopic procedures", "TREATMENT", 27, 54], ["EUS", "TEST", 130, 133], ["ERCP", "TEST", 138, 142], ["more respiratory droplets", "PROBLEM", 152, 177], ["the endoscopes", "TREATMENT", 207, 221], ["cough", "PROBLEM", 251, 256], ["devices", "TREATMENT", 275, 282], ["interventions", "TREATMENT", 287, 300], ["more leakage of body fluids", "PROBLEM", 334, 361], ["other endoscopic procedures", "TREATMENT", 443, 470], ["upper", "ANATOMY_MODIFIER", 27, 32], ["endoscopic", "OBSERVATION", 33, 43], ["respiratory droplets", "OBSERVATION", 157, 177], ["larger", "OBSERVATION_MODIFIER", 188, 194], ["diameter", "OBSERVATION_MODIFIER", 195, 203], ["cough", "OBSERVATION", 251, 256], ["leakage", "OBSERVATION_MODIFIER", 339, 346], ["gastrointestinal", "ANATOMY", 395, 411], ["bile", "ANATOMY", 423, 427]]], ["Therefore, it is crucial for HCPs involved in pancreatobiliary procedures to implement all approaches that may reduce the risk of COVID-19 transmission.TRIAGE OF PANCREATOBILIARY ENDOSCOPIC PROCEDURESPreprocedure questionnaire-based screening to detect infected individuals has limited value as viral transmission has been documented from mildly symptomatic and asymptomatic persons, especially when community spread has been established.", [["pancreatobiliary", "ANATOMY", 46, 62], ["pancreatobiliary", "ORGAN", 46, 62], ["COVID-19", "GENE_OR_GENE_PRODUCT", 130, 138], ["individuals", "ORGANISM", 262, 273], ["persons", "ORGANISM", 375, 382], ["persons", "SPECIES", 375, 382], ["pancreatobiliary procedures", "TREATMENT", 46, 73], ["all approaches", "TREATMENT", 87, 101], ["COVID", "TEST", 130, 135], ["PANCREATOBILIARY ENDOSCOPIC PROCEDURESPreprocedure questionnaire", "TEST", 162, 226], ["based screening", "TEST", 227, 242], ["infected individuals", "PROBLEM", 253, 273], ["viral transmission", "TEST", 295, 313], ["mildly symptomatic and asymptomatic persons", "PROBLEM", 339, 382], ["pancreatobiliary", "ANATOMY", 46, 62], ["PANCREATOBILIARY", "ANATOMY", 162, 178], ["mildly", "OBSERVATION_MODIFIER", 339, 345], ["symptomatic", "OBSERVATION_MODIFIER", 346, 357]]], ["13 When widely available, universal viral testing should be performed to detect infected individuals before they show up for outpatient endoscopic procedures and thus reduce transmissibility in endoscopy units.", [["universal viral testing", "TEST", 26, 49], ["infected individuals", "PROBLEM", 80, 100], ["outpatient endoscopic procedures", "TEST", 125, 157], ["endoscopy units", "TREATMENT", 194, 209]]], ["14, 15 Serological assays to identify those already immunized may be a valuable option, but further data that correlate antibody titers with COVID-19 immunity are still needed.", [["Serological assays", "TEST", 7, 25], ["further data", "TEST", 92, 104], ["antibody titers", "TEST", 120, 135], ["COVID", "TEST", 141, 146]]], ["16 Until these strategies are implemented in clinical practice, a critical step in limiting viral propagation is proper procedural triage and postponement of elective procedures.TRIAGE OF PANCREATOBILIARY ENDOSCOPIC PROCEDURESFor this purpose, the endoscopist needs to answer the following questions in a stepwise manner: (a) is the procedure indicated?, (b) is the procedure time sensitive?, (c) if time sensitive, is the procedure urgent (within 2 weeks) or semiurgent (within 8 weeks)?, and (d) if not time sensitive, then the procedure can be delayed for more than 8 weeks.", [["elective procedures", "TREATMENT", 158, 177], ["the procedure", "TREATMENT", 329, 342], ["the procedure", "TREATMENT", 419, 432], ["the procedure", "TREATMENT", 526, 539], ["PANCREATOBILIARY", "ANATOMY", 188, 204]]], ["6 These steps require thoughtful review of medical records, laboratory data, cross-sectional images, and prior endoscopic reports.", [["laboratory data", "TEST", 60, 75], ["cross-sectional images", "TEST", 77, 99]]], ["Virtual discussion with the patient, referring provider, subspecialty experts (eg, medical pancreatologist, radiologist, oncologist, surgeon), and multidisciplinary teams (eg, tumor boards, liver transplant committee) might further facilitate the decision about performing a procedure.", [["tumor", "ANATOMY", 176, 181], ["liver", "ANATOMY", 190, 195], ["tumor", "DISEASE", 176, 181], ["patient", "ORGANISM", 28, 35], ["tumor", "CANCER", 176, 181], ["liver", "ORGAN", 190, 195], ["patient", "SPECIES", 28, 35], ["a procedure", "TREATMENT", 273, 284], ["liver", "ANATOMY", 190, 195]]], ["If there is an alternative approach with less aerosol generation and similar efficacy or safety, then EUS or ERCP could be avoided.", [["less aerosol generation", "TREATMENT", 41, 64], ["EUS", "TEST", 102, 105], ["ERCP", "TEST", 109, 113]]], ["For example, in patients with a low or intermediate risk of choledocholithiasis, both magnetic resonance imaging/magnetic resonance cholangiopancreatography and EUS are accurate tests, but in the COVID-19 era, an magnetic resonance imaging/magnetic resonance cholangiopancreatography is the preferred first step in management.", [["choledocholithiasis", "DISEASE", 60, 79], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["choledocholithiasis", "PROBLEM", 60, 79], ["magnetic resonance imaging", "TEST", 86, 112], ["magnetic resonance cholangiopancreatography", "TEST", 113, 156], ["EUS", "TEST", 161, 164], ["accurate tests", "TEST", 169, 183], ["an magnetic resonance imaging", "TEST", 210, 239], ["magnetic resonance cholangiopancreatography", "TEST", 240, 283], ["choledocholithiasis", "OBSERVATION", 60, 79]]], ["17 When the facility does not have the capability to provide highly effective and safe endoscopic care, referral to a tertiary care hospital should be considered (eg, hospital reaching full capacity, lack of adequate personal protective equipment [PPE] , and limited experience of the endoscopist with the type of required procedure).TRIAGE OF PANCREATOBILIARY ENDOSCOPIC PROCEDURESCriteria that can be applied in deciding the time-sensitive nature of a pancreaticobiliary endoscopy include (a) threat to the patient's life if the procedure is not performed, (b) threat of permanent dysfunction of an organ system; (c) risk of metastasis or disease progression, and (d ) risk of rapid disease worsening.", [["pancreaticobiliary", "ANATOMY", 454, 472], ["organ system", "ANATOMY", 601, 613], ["metastasis", "DISEASE", 627, 637], ["patient", "ORGANISM", 509, 516], ["organ", "ORGAN", 601, 606], ["patient", "SPECIES", 509, 516], ["safe endoscopic care", "TREATMENT", 82, 102], ["procedure", "TREATMENT", 323, 332], ["PANCREATOBILIARY ENDOSCOPIC PROCEDURESCriteria", "TREATMENT", 344, 390], ["a pancreaticobiliary endoscopy", "TEST", 452, 482], ["the procedure", "TREATMENT", 527, 540], ["permanent dysfunction of an organ system", "PROBLEM", 573, 613], ["metastasis", "PROBLEM", 627, 637], ["disease progression", "PROBLEM", 641, 660], ["rapid disease worsening", "PROBLEM", 679, 702], ["PANCREATOBILIARY", "ANATOMY", 344, 360], ["pancreaticobiliary", "ANATOMY", 454, 472], ["metastasis", "OBSERVATION", 627, 637], ["rapid", "OBSERVATION_MODIFIER", 679, 684], ["disease", "OBSERVATION", 685, 692]]], ["6 Procedures identified as time sensitive can be further stratified based on the potential harms of delaying the intervention-\"urgent\" when there is an immediate necessity for the procedure to reduce harm, and \"semiurgent\" if the procedure can be delayed but no more than 8 weeks.", [["the intervention", "TREATMENT", 109, 125], ["the procedure", "TREATMENT", 176, 189], ["the procedure", "TREATMENT", 226, 239]]], ["18 If none of these criteria is met, the procedure is deemed elective and can be delayed until all procedures are being locally ramped up.", [["the procedure", "TREATMENT", 37, 50], ["all procedures", "TREATMENT", 95, 109]]], ["A nonexhaustive list of potential indications for pancreatobiliary procedures and proposed urgency of the intervention is presented in Table 1 .TRIAGE OF PANCREATOBILIARY ENDOSCOPIC PROCEDURESIn addition to the indication, careful assessment of individual variables (age, comorbidities [diabetes, cardiovascular or lung disease], immunosuppression, COVID-19 symptoms, or exposure) and environmental factors (availability of PPE, hospital beds, ventilators, staff health, and local situation of the pandemic) should be used to determine the timing of each patient's procedure.", [["pancreatobiliary", "ANATOMY", 50, 66], ["cardiovascular", "ANATOMY", 297, 311], ["lung", "ANATOMY", 315, 319], ["diabetes", "DISEASE", 287, 295], ["cardiovascular or lung disease", "DISEASE", 297, 327], ["pancreatobiliary", "MULTI-TISSUE_STRUCTURE", 50, 66], ["lung", "ORGAN", 315, 319], ["patient", "ORGANISM", 555, 562], ["patient", "SPECIES", 555, 562], ["pancreatobiliary procedures", "TREATMENT", 50, 77], ["the intervention", "TREATMENT", 102, 118], ["careful assessment", "TEST", 223, 241], ["individual variables", "PROBLEM", 245, 265], ["comorbidities", "PROBLEM", 272, 285], ["diabetes", "PROBLEM", 287, 295], ["cardiovascular or lung disease", "PROBLEM", 297, 327], ["immunosuppression", "TREATMENT", 330, 347], ["COVID", "TEST", 349, 354], ["symptoms", "PROBLEM", 358, 366], ["ventilators", "TREATMENT", 444, 455], ["each patient's procedure", "TREATMENT", 550, 574], ["PANCREATOBILIARY", "ANATOMY", 154, 170], ["lung", "ANATOMY", 315, 319], ["disease", "OBSERVATION", 320, 327]]], ["19 In patients with COVID-19 infection and nonurgent indications, the procedure may need deferral until resolution of symptoms and negative viral testing.", [["infection", "DISEASE", 29, 38], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["COVID-19 infection", "PROBLEM", 20, 38], ["nonurgent indications", "TREATMENT", 43, 64], ["the procedure", "TREATMENT", 66, 79], ["deferral", "TREATMENT", 89, 97], ["symptoms", "PROBLEM", 118, 126], ["viral testing", "TEST", 140, 153], ["infection", "OBSERVATION", 29, 38]]], ["For elective procedures, adopting a tiered allocation approach might facilitate prioritization and triage of patients during the ramp-up period ( Table 2) .", [["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["elective procedures", "TREATMENT", 4, 23], ["a tiered allocation approach", "TREATMENT", 34, 62]]], ["All suggested algorithms for prioritization might change when point-of-care testing is widely available.INFORMED CONSENTSpecifically, endoscopists must include a disclosure of possible nosocomial infection of COVID-19 within the facility and the careful consideration given to the urgency of the intervention.", [["infection", "DISEASE", 196, 205], ["prioritization", "TREATMENT", 29, 43], ["care testing", "TEST", 71, 83], ["nosocomial infection of COVID", "PROBLEM", 185, 214], ["the intervention", "TREATMENT", 292, 308], ["possible", "UNCERTAINTY", 176, 184], ["nosocomial", "OBSERVATION_MODIFIER", 185, 195], ["infection", "OBSERVATION", 196, 205]]], ["This could be obtained through telemedicine to ensure that the patient agrees with the risks of coming to the facility and is documented in the chart.", [["patient", "ORGANISM", 63, 70], ["patient", "SPECIES", 63, 70]]], ["The consent should also include all potential interventions that would be beneficial to maximize efficacy and reduce future procedures.", [["all potential interventions", "TREATMENT", 32, 59], ["future procedures", "TREATMENT", 117, 134]]], ["For example, patients undergoing ERCP for any biliary indication should also consent for EUS-guided biliary drainage in case conventional ERCP fails.INTRAPROCEDURAL CONSIDERATIONSIn patients with known or presumptive COVID-19, negative pressure operating rooms are preferred, whereas advanced endoscopy suites may be sufficient for those without suspected infection.", [["biliary", "ANATOMY", 46, 53], ["biliary", "ANATOMY", 100, 107], ["infection", "DISEASE", 356, 365], ["patients", "ORGANISM", 13, 21], ["biliary", "ORGAN", 46, 53], ["biliary", "MULTI-TISSUE_STRUCTURE", 100, 107], ["patients", "ORGANISM", 182, 190], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 182, 190], ["ERCP", "TEST", 33, 37], ["EUS", "TEST", 89, 92], ["biliary drainage", "TREATMENT", 100, 116], ["conventional ERCP", "TEST", 125, 142], ["COVID", "TEST", 217, 222], ["suspected infection", "PROBLEM", 346, 365], ["biliary", "ANATOMY", 46, 53], ["biliary", "ANATOMY", 100, 107], ["drainage", "OBSERVATION", 108, 116], ["infection", "OBSERVATION", 356, 365]]], ["The decision to pursue pancreaticobiliary endoscopy under monitored anesthesia care or general endotracheal anesthesia has been traditionally based on institutional protocols.", [["pancreaticobiliary", "ANATOMY", 23, 41], ["endotracheal", "ANATOMY", 95, 107], ["pancreaticobiliary", "MULTI-TISSUE_STRUCTURE", 23, 41], ["pancreaticobiliary endoscopy", "TEST", 23, 51], ["monitored anesthesia care", "TREATMENT", 58, 83], ["general endotracheal anesthesia", "TREATMENT", 87, 118], ["institutional protocols", "TREATMENT", 151, 174], ["pancreaticobiliary", "ANATOMY", 23, 41]]], ["20 Anesthesia -Acute cholangitis -Symptomatic choledocholithiasis -Obstructive jaundice (malignant and benign strictures) -Bile leak -Sphincterotomy bleeding -Infected or symptomatic pancreatic necrosis or pseudocyst -Suspected pancreatic cancer without known metastatic lesions -Pancreatic cyst with any high-risk feature -Asymptomatic Choledocholithiasis -Indeterminate biliary stricture without jaundice -Dilated bile duct with abnormal liver function tests -Ampullary adenoma without symptoms -Pancreatic mass with evidence of probable metastasis -Suspected metastatic lesion from other primary cancers -Scheduled plastic stent change or removal -Scheduled lumen apposing stent removal from peripancreatic fluid collections -Symptomatic obstructive chronic pancreatitis (eg, main pancreatic duct stone or stricture) -Celiac plexus block -Suspected biliary or pancreatic type pain without laboratory abnormalities -Evaluation and therapy of idiopathic or recurrent acute pancreatitis -Nonspecific radiologic findings (eg, dilated bile duct, pancreatic fullness) without laboratory abnormalities -Pancreatic cyst without high-risk features -Pancreatic cancer screening in high-risk individuals -Surveillance after prior ampullectomy -Metal stent change or removal for benign biliary disease *Suggested period at which the procedure should be performed, or patient's chart should be reviewed for recurrent triage.", [["benign strictures", "ANATOMY", 103, 120], ["Bile", "ANATOMY", 123, 127], ["pancreatic", "ANATOMY", 183, 193], ["pseudocyst", "ANATOMY", 206, 216], ["pancreatic cancer", "ANATOMY", 228, 245], ["metastatic lesions", "ANATOMY", 260, 278], ["Pancreatic cyst", "ANATOMY", 280, 295], ["biliary", "ANATOMY", 372, 379], ["bile duct", "ANATOMY", 416, 425], ["liver", "ANATOMY", 440, 445], ["Ampullary adenoma", "ANATOMY", 462, 479], ["Pancreatic mass", "ANATOMY", 498, 513], ["metastatic lesion", "ANATOMY", 562, 579], ["primary cancers", "ANATOMY", 591, 606], ["lumen", "ANATOMY", 661, 666], ["peripancreatic fluid", "ANATOMY", 695, 715], ["pancreatic duct stone", "ANATOMY", 784, 805], ["stricture", "ANATOMY", 809, 818], ["Celiac plexus", "ANATOMY", 821, 834], ["biliary", "ANATOMY", 852, 859], ["pancreatic", "ANATOMY", 863, 873], ["bile duct", "ANATOMY", 1033, 1042], ["pancreatic", "ANATOMY", 1044, 1054], ["Pancreatic cyst", "ANATOMY", 1099, 1114], ["Pancreatic cancer", "ANATOMY", 1143, 1160], ["benign biliary", "ANATOMY", 1270, 1284], ["cholangitis", "DISEASE", 21, 32], ["choledocholithiasis", "DISEASE", 46, 65], ["Obstructive jaundice", "DISEASE", 67, 87], ["strictures", "DISEASE", 110, 120], ["bleeding", "DISEASE", 149, 157], ["pancreatic necrosis", "DISEASE", 183, 202], ["pseudocyst", "DISEASE", 206, 216], ["pancreatic cancer", "DISEASE", 228, 245], ["Pancreatic cyst", "DISEASE", 280, 295], ["Choledocholithiasis", "DISEASE", 337, 356], ["biliary stricture", "DISEASE", 372, 389], ["jaundice", "DISEASE", 398, 406], ["Dilated bile duct", "DISEASE", 408, 425], ["abnormal liver function", "DISEASE", 431, 454], ["Ampullary adenoma", "DISEASE", 462, 479], ["Pancreatic mass", "DISEASE", 498, 513], ["primary cancers", "DISEASE", 591, 606], ["obstructive chronic pancreatitis", "DISEASE", 741, 773], ["pancreatic duct stone", "DISEASE", 784, 805], ["stricture", "DISEASE", 809, 818], ["Celiac plexus block", "DISEASE", 821, 840], ["biliary or pancreatic type pain", "DISEASE", 852, 883], ["pancreatitis", "DISEASE", 974, 986], ["dilated bile duct, pancreatic fullness", "DISEASE", 1025, 1063], ["Pancreatic cyst", "DISEASE", 1099, 1114], ["Pancreatic cancer", "DISEASE", 1143, 1160], ["biliary disease", "DISEASE", 1277, 1292], ["pancreatic necrosis", "CANCER", 183, 202], ["pseudocyst -Suspected pancreatic cancer", "CANCER", 206, 245], ["metastatic lesions", "CANCER", 260, 278], ["Pancreatic cyst", "CANCER", 280, 295], ["biliary stricture", "PATHOLOGICAL_FORMATION", 372, 389], ["bile duct", "MULTI-TISSUE_STRUCTURE", 416, 425], ["liver", "ORGAN", 440, 445], ["Ampullary adenoma", "CANCER", 462, 479], ["Pancreatic", "ORGAN", 498, 508], ["metastatic lesion", "CANCER", 562, 579], ["cancers", "CANCER", 599, 606], ["pancreatic duct", "MULTI-TISSUE_STRUCTURE", 784, 799], ["stricture", "PATHOLOGICAL_FORMATION", 809, 818], ["biliary", "MULTI-TISSUE_STRUCTURE", 852, 859], ["pancreatic", "ORGAN", 863, 873], ["bile duct", "MULTI-TISSUE_STRUCTURE", 1033, 1042], ["pancreatic", "ORGAN", 1044, 1054], ["Pancreatic cyst", "CANCER", 1099, 1114], ["Pancreatic cancer", "CANCER", 1143, 1160], ["biliary", "ORGAN", 1277, 1284], ["patient", "ORGANISM", 1358, 1365], ["patient", "SPECIES", 1358, 1365], ["Acute cholangitis", "PROBLEM", 15, 32], ["Symptomatic choledocholithiasis", "PROBLEM", 34, 65], ["Obstructive jaundice", "PROBLEM", 67, 87], ["malignant and benign strictures", "PROBLEM", 89, 120], ["Bile leak", "PROBLEM", 123, 132], ["Sphincterotomy bleeding", "PROBLEM", 134, 157], ["Infected or symptomatic pancreatic necrosis", "PROBLEM", 159, 202], ["pseudocyst", "PROBLEM", 206, 216], ["pancreatic cancer", "PROBLEM", 228, 245], ["known metastatic lesions", "PROBLEM", 254, 278], ["Pancreatic cyst", "PROBLEM", 280, 295], ["any high-risk feature", "PROBLEM", 301, 322], ["Asymptomatic Choledocholithiasis", "PROBLEM", 324, 356], ["Indeterminate biliary stricture", "PROBLEM", 358, 389], ["jaundice", "PROBLEM", 398, 406], ["Dilated bile duct", "PROBLEM", 408, 425], ["abnormal liver function tests", "PROBLEM", 431, 460], ["Ampullary adenoma", "PROBLEM", 462, 479], ["symptoms", "PROBLEM", 488, 496], ["Pancreatic mass", "PROBLEM", 498, 513], ["metastasis", "PROBLEM", 540, 550], ["metastatic lesion", "PROBLEM", 562, 579], ["other primary cancers", "PROBLEM", 585, 606], ["plastic stent change", "TREATMENT", 618, 638], ["removal", "TREATMENT", 642, 649], ["Scheduled lumen apposing stent removal", "TREATMENT", 651, 689], ["peripancreatic fluid collections", "PROBLEM", 695, 727], ["Symptomatic obstructive chronic pancreatitis", "PROBLEM", 729, 773], ["main pancreatic duct stone", "PROBLEM", 779, 805], ["stricture", "PROBLEM", 809, 818], ["Celiac plexus block", "PROBLEM", 821, 840], ["pancreatic type pain", "PROBLEM", 863, 883], ["laboratory abnormalities", "PROBLEM", 892, 916], ["Evaluation", "TEST", 918, 928], ["therapy", "TREATMENT", 933, 940], ["idiopathic or recurrent acute pancreatitis", "PROBLEM", 944, 986], ["Nonspecific radiologic findings (eg, dilated bile duct", "PROBLEM", 988, 1042], ["pancreatic fullness", "PROBLEM", 1044, 1063], ["laboratory abnormalities", "PROBLEM", 1073, 1097], ["Pancreatic cyst", "PROBLEM", 1099, 1114], ["high-risk features", "PROBLEM", 1123, 1141], ["Pancreatic cancer", "PROBLEM", 1143, 1160], ["screening", "TEST", 1161, 1170], ["prior ampullectomy", "TREATMENT", 1216, 1234], ["Metal stent change", "TREATMENT", 1236, 1254], ["removal", "TREATMENT", 1258, 1265], ["benign biliary disease", "PROBLEM", 1270, 1292], ["the procedure", "TREATMENT", 1320, 1333], ["Acute", "OBSERVATION_MODIFIER", 15, 20], ["cholangitis", "OBSERVATION", 21, 32], ["Symptomatic", "OBSERVATION_MODIFIER", 34, 45], ["choledocholithiasis", "OBSERVATION", 46, 65], ["Obstructive", "OBSERVATION_MODIFIER", 67, 78], ["jaundice", "OBSERVATION", 79, 87], ["malignant", "OBSERVATION_MODIFIER", 89, 98], ["benign", "OBSERVATION_MODIFIER", 103, 109], ["strictures", "OBSERVATION", 110, 120], ["Bile", "ANATOMY", 123, 127], ["leak", "OBSERVATION", 128, 132], ["Sphincterotomy bleeding", "OBSERVATION", 134, 157], ["Infected", "OBSERVATION_MODIFIER", 159, 167], ["symptomatic", "OBSERVATION_MODIFIER", 171, 182], ["pancreatic", "ANATOMY", 183, 193], ["necrosis", "OBSERVATION", 194, 202], ["pseudocyst", "OBSERVATION", 206, 216], ["pancreatic", "ANATOMY", 228, 238], ["cancer", "OBSERVATION", 239, 245], ["metastatic", "OBSERVATION_MODIFIER", 260, 270], ["Pancreatic", "ANATOMY", 280, 290], ["cyst", "OBSERVATION", 291, 295], ["Asymptomatic", "OBSERVATION_MODIFIER", 324, 336], ["Choledocholithiasis", "OBSERVATION", 337, 356], ["Indeterminate", "OBSERVATION_MODIFIER", 358, 371], ["biliary", "ANATOMY", 372, 379], ["stricture", "OBSERVATION", 380, 389], ["without", "UNCERTAINTY", 390, 397], ["jaundice", "OBSERVATION", 398, 406], ["Dilated", "OBSERVATION", 408, 415], ["bile duct", "ANATOMY", 416, 425], ["liver", "ANATOMY", 440, 445], ["Ampullary", "ANATOMY", 462, 471], ["adenoma", "OBSERVATION", 472, 479], ["Pancreatic", "ANATOMY", 498, 508], ["mass", "OBSERVATION", 509, 513], ["probable", "UNCERTAINTY", 531, 539], ["metastasis", "OBSERVATION", 540, 550], ["metastatic", "OBSERVATION_MODIFIER", 562, 572], ["lesion", "OBSERVATION", 573, 579], ["primary", "OBSERVATION_MODIFIER", 591, 598], ["cancers", "OBSERVATION", 599, 606], ["stent", "OBSERVATION", 626, 631], ["stent", "OBSERVATION", 676, 681], ["peripancreatic", "ANATOMY", 695, 709], ["fluid collections", "OBSERVATION", 710, 727], ["Symptomatic", "OBSERVATION_MODIFIER", 729, 740], ["obstructive", "OBSERVATION_MODIFIER", 741, 752], ["chronic", "OBSERVATION_MODIFIER", 753, 760], ["pancreatitis", "OBSERVATION", 761, 773], ["pancreatic duct", "ANATOMY", 784, 799], ["stone", "OBSERVATION", 800, 805], ["stricture", "OBSERVATION", 809, 818], ["Celiac plexus", "ANATOMY", 821, 834], ["biliary", "ANATOMY", 852, 859], ["pancreatic", "ANATOMY", 863, 873], ["idiopathic", "OBSERVATION_MODIFIER", 944, 954], ["recurrent", "OBSERVATION_MODIFIER", 958, 967], ["acute", "OBSERVATION_MODIFIER", 968, 973], ["pancreatitis", "OBSERVATION", 974, 986], ["dilated", "OBSERVATION", 1025, 1032], ["bile duct", "ANATOMY", 1033, 1042], ["pancreatic", "ANATOMY", 1044, 1054], ["fullness", "OBSERVATION", 1055, 1063], ["Pancreatic", "ANATOMY", 1099, 1109], ["cyst", "OBSERVATION", 1110, 1114], ["Pancreatic", "ANATOMY", 1143, 1153], ["cancer", "OBSERVATION", 1154, 1160], ["stent", "OBSERVATION", 1242, 1247], ["benign", "OBSERVATION_MODIFIER", 1270, 1276], ["biliary", "ANATOMY", 1277, 1284], ["disease", "OBSERVATION", 1285, 1292]]], ["This time is dependent on patient's factors, facility capacity, and local COVID-19 prevalence. societies currently recommend the use of general endotracheal anesthesia to reduce aerosolization in patients with suspected or confirmed COVID-19 and in asymptomatic patients undergoing AGPs at areas of high-community transmission.", [["endotracheal", "ANATOMY", 144, 156], ["patient", "ORGANISM", 26, 33], ["patients", "ORGANISM", 196, 204], ["patients", "ORGANISM", 262, 270], ["patient", "SPECIES", 26, 33], ["patients", "SPECIES", 196, 204], ["patients", "SPECIES", 262, 270], ["local COVID", "TEST", 68, 79], ["general endotracheal anesthesia", "TREATMENT", 136, 167], ["aerosolization", "TREATMENT", 178, 192], ["COVID", "TEST", 233, 238], ["AGPs", "PROBLEM", 282, 286], ["high", "OBSERVATION_MODIFIER", 299, 303]]], ["12 Institutional protocols specifying the type and number of HCP present in the endoscopy room during a procedure need to be reviewed with the goal of minimizing exposure to personnel, reduce nosocomial viral transmission, and preserve PPE.", [["Institutional protocols", "TREATMENT", 3, 26], ["a procedure", "TREATMENT", 102, 113], ["nosocomial viral transmission", "TREATMENT", 192, 221]]], ["A recent guideline of the American Society of Gastrointestinal Endoscopy recommended that for ERCP or EUS assisted by an anesthesia provider, the minimum number of HCP should be one nurse or technician, in addition to the endoscopist.", [["Gastrointestinal Endoscopy", "TEST", 46, 72], ["ERCP", "TEST", 94, 98], ["Gastrointestinal", "ANATOMY", 46, 62]]], ["21 To prevent leakage of aerosol production outside the room, transition of nursing and anesthesia staff during the procedure should be eliminated if possible.", [["leakage of aerosol production", "PROBLEM", 14, 43], ["the procedure", "TREATMENT", 112, 125], ["leakage", "OBSERVATION_MODIFIER", 14, 21], ["aerosol production", "OBSERVATION", 25, 43]]], ["Additional considerations to limit HCP in the endoscopy suite include the operation of fluoroscopy units by the endoscopist rather than a radiology technician, as well as onsite cytopathology evaluation and processing outside the procedure room.INTRAPROCEDURAL CONSIDERATIONSAppropriate use of PPE as detailed by society guidelines is essential for pancreatobiliary endoscopic procedures during the COVID-19 pandemic.", [["pancreatobiliary", "ANATOMY", 349, 365], ["pancreatobiliary", "PATHOLOGICAL_FORMATION", 349, 365], ["onsite cytopathology evaluation", "TEST", 171, 202], ["PPE", "TREATMENT", 294, 297], ["pancreatobiliary endoscopic procedures", "TREATMENT", 349, 387], ["the COVID", "TEST", 395, 404], ["pandemic", "PROBLEM", 408, 416]]], ["This includes (a) adequate hand hygiene, (b) universal use of fit-tested respirators (N95 or N99 masks, or powered air-purifying respirators), (c) waterproof gowns, (d) double pair of gloves, with outer pair over the gown covering the writs, (e) hairnet, ( f ) goggles or face shield for eyes protection, and (g) long-sleeve shoe covers.", [["hand", "ANATOMY", 27, 31], ["writs", "ANATOMY", 235, 240], ["eyes", "ANATOMY", 288, 292], ["hand", "ORGANISM_SUBDIVISION", 27, 31], ["eyes", "ORGAN", 288, 292], ["fit-tested respirators", "TREATMENT", 62, 84], ["N99 masks", "TREATMENT", 93, 102], ["powered air-purifying respirators", "TREATMENT", 107, 140], ["waterproof gowns", "TREATMENT", 147, 163], ["double pair of gloves", "TREATMENT", 169, 190], ["outer pair", "PROBLEM", 197, 207], ["face shield", "TREATMENT", 272, 283], ["eyes protection", "TREATMENT", 288, 303], ["(g) long-sleeve shoe covers", "TREATMENT", 309, 336], ["sleeve shoe", "OBSERVATION", 318, 329]]], ["6, 22, 23 The generation of procedural aerosols can be reduced by applying air suctioning during the removal of instruments through the biopsy channel.", [["procedural aerosols", "TREATMENT", 28, 47], ["air suctioning", "TREATMENT", 75, 89], ["the removal of instruments", "TREATMENT", 97, 123], ["the biopsy channel", "TEST", 132, 150], ["air suctioning", "OBSERVATION", 75, 89]]], ["10 For ERCPs, the use of urine bags attached to the biopsy port can be considered to reduce external fluid spillage.INTRAPROCEDURAL CONSIDERATIONSThere is lack of evidence for changing pancreaticobiliary endoscopy procedural practices during the COVID-19 pandemic.", [["urine", "ANATOMY", 25, 30], ["biopsy port", "ANATOMY", 52, 63], ["fluid", "ANATOMY", 101, 106], ["pancreaticobiliary", "ANATOMY", 185, 203], ["urine", "ORGANISM_SUBSTANCE", 25, 30], ["biopsy port", "MULTI-TISSUE_STRUCTURE", 52, 63], ["pancreaticobiliary", "ORGAN", 185, 203], ["ERCPs", "TREATMENT", 7, 12], ["urine bags", "TREATMENT", 25, 35], ["the biopsy port", "TREATMENT", 48, 63], ["external fluid spillage", "PROBLEM", 92, 115], ["changing pancreaticobiliary endoscopy", "TREATMENT", 176, 213], ["the COVID", "TEST", 242, 251], ["pandemic", "PROBLEM", 255, 263], ["fluid spillage", "OBSERVATION", 101, 115], ["lack of evidence for", "UNCERTAINTY", 155, 175], ["pancreaticobiliary", "ANATOMY", 185, 203]]], ["Necessary interventions must continue to be guided by highquality data supporting efficacy and reduced harms.", [["Necessary interventions", "TREATMENT", 0, 23], ["reduced harms", "PROBLEM", 95, 108], ["reduced", "OBSERVATION_MODIFIER", 95, 102], ["harms", "OBSERVATION", 103, 108]]], ["Anecdotal evidence limited to case reports and mechanistic pharmacology has suggested a possible link between ibuprofen and severity of COVID-19 infection.", [["ibuprofen", "CHEMICAL", 110, 119], ["COVID-19", "CHEMICAL", 136, 144], ["infection", "DISEASE", 145, 154], ["ibuprofen", "CHEMICAL", 110, 119], ["ibuprofen", "SIMPLE_CHEMICAL", 110, 119], ["COVID-19", "GENE_OR_GENE_PRODUCT", 136, 144], ["ibuprofen", "TREATMENT", 110, 119], ["COVID-19 infection", "PROBLEM", 136, 154], ["infection", "OBSERVATION", 145, 154]]], ["24 This weak evidence should not preclude the use of rectal indomethacin for preventing post-ERCP pancreatitis, which has demonstrated high efficacy in randomized controlled trials.", [["rectal", "ANATOMY", 53, 59], ["indomethacin", "CHEMICAL", 60, 72], ["post-ERCP pancreatitis", "DISEASE", 88, 110], ["indomethacin", "CHEMICAL", 60, 72], ["rectal", "ORGAN", 53, 59], ["indomethacin", "SIMPLE_CHEMICAL", 60, 72], ["rectal indomethacin", "TREATMENT", 53, 72], ["post-ERCP pancreatitis", "PROBLEM", 88, 110], ["randomized controlled trials", "TREATMENT", 152, 180], ["pancreatitis", "OBSERVATION", 98, 110], ["high", "OBSERVATION_MODIFIER", 135, 139], ["efficacy", "OBSERVATION_MODIFIER", 140, 148]]], ["25 Staff administering the medication rectally should be cautious and be aware that COVID-19 particles can be found in feces, which is still of unknown significance for potential fecal-oral transmission.", [["feces", "ANATOMY", 119, 124], ["fecal", "ANATOMY", 179, 184], ["oral", "ANATOMY", 185, 189], ["COVID-19 particles", "CHEMICAL", 84, 102], ["fecal-oral transmission", "DISEASE", 179, 202], ["COVID-19", "CHEMICAL", 84, 92], ["COVID-19 particles", "SIMPLE_CHEMICAL", 84, 102], ["feces", "ORGANISM_SUBSTANCE", 119, 124], ["fecal", "ORGANISM_SUBDIVISION", 179, 184], ["oral", "ORGANISM_SUBDIVISION", 185, 189], ["the medication rectally", "TREATMENT", 23, 46], ["COVID-19 particles", "TREATMENT", 84, 102], ["feces", "OBSERVATION", 119, 124]]], ["26 Cleaning and disinfection of the room should be promptly performed after adequate time for air change has elapsed.", [["disinfection of the room", "TREATMENT", 16, 40], ["air change", "PROBLEM", 94, 104], ["air", "OBSERVATION", 94, 97]]], ["Decontamination of the lead apron, lead glasses, ultrasound processor, endoscopy boom, and C-arm should occur after every use.", [["the lead apron", "TREATMENT", 19, 33], ["lead glasses", "TREATMENT", 35, 47], ["ultrasound processor", "TEST", 49, 69], ["endoscopy boom", "TREATMENT", 71, 85], ["arm", "ANATOMY", 93, 96]]], ["The ingredients used in current disinfection and reprocessing protocols of duodenoscopes and echoendoscopes are effective in inactivating all viruses including the coronavirus; hence, endoscope-related COVID-19 infections should not occur when these methods are perhaps for appropriately implemented.", [["coronavirus", "DISEASE", 164, 175], ["infections", "DISEASE", 211, 221], ["coronavirus", "ORGANISM", 164, 175], ["COVID-19", "ORGANISM", 202, 210], ["The ingredients", "TREATMENT", 0, 15], ["current disinfection", "TREATMENT", 24, 44], ["reprocessing protocols of duodenoscopes", "TREATMENT", 49, 88], ["echoendoscopes", "TREATMENT", 93, 107], ["inactivating all viruses", "PROBLEM", 125, 149], ["the coronavirus", "PROBLEM", 160, 175], ["endoscope", "TEST", 184, 193], ["COVID-19 infections", "PROBLEM", 202, 221]]], ["6,23RAMP-UP STRATEGYAs COVID-19 rates are reaching plateau, the focus of endoscopy units should be toward implementing exit strategies for an expected large backlog of elective procedures.", [["6,23RAMP", "CHEMICAL", 0, 8], ["COVID", "TEST", 23, 28], ["endoscopy units", "TREATMENT", 73, 88], ["exit strategies", "TREATMENT", 119, 134], ["elective procedures", "TREATMENT", 168, 187], ["large", "OBSERVATION_MODIFIER", 151, 156]]], ["The decision for ramping up procedures should be informed by a sustained reduction in local COVID-19 cases for at least 14 days, adequate hospital capacity to safely treat all potential patients requiring hospitalization, wide availability of testing for subjects with COVID-19 symptoms, and regional ability to conduct active monitoring of confirmed cases and their contacts.", [["patients", "ORGANISM", 186, 194], ["patients", "SPECIES", 186, 194], ["ramping up procedures", "TREATMENT", 17, 38], ["local COVID", "TREATMENT", 86, 97], ["testing", "TEST", 243, 250], ["COVID", "TEST", 269, 274], ["symptoms", "PROBLEM", 278, 286], ["active monitoring", "TEST", 320, 337]]], ["27 Based on local diagnostic capabilities, universal testing policies need to be developed for patients undergoing planned endoscopic procedures and for HCP.", [["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["local diagnostic capabilities", "TEST", 12, 41], ["universal testing policies", "TREATMENT", 43, 69], ["endoscopic procedures", "TREATMENT", 123, 144]]], ["A pre-COVID era endoscopy case log can be envisioned if testing can be implemented for all patients and perhaps for HCPs (at each shift change).RAMP-UP STRATEGYA reliable supply chain of PPE, equipment, devices, anesthesia medications, and cleaning products must be in place before escalating endoscopic procedures.", [["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["A pre-COVID era endoscopy", "TREATMENT", 0, 25], ["devices", "TREATMENT", 203, 210], ["anesthesia medications", "TREATMENT", 212, 234], ["cleaning products", "TREATMENT", 240, 257], ["escalating endoscopic procedures", "TREATMENT", 282, 314]]], ["Potential adjustments to endoscopy unit schedules are anticipated, including assignment of longer blocks to ensure cleaning and adequate air circulation between procedures, and extension of hours of daily operation and weekend sessions to accommodate the high procedure demands.", [["endoscopy unit schedules", "TREATMENT", 25, 49], ["longer blocks", "PROBLEM", 91, 104], ["cleaning", "TREATMENT", 115, 123], ["procedures", "TREATMENT", 161, 171], ["daily operation", "TREATMENT", 199, 214], ["the high procedure demands", "TREATMENT", 251, 277]]], ["28 Preemptive discussion and coordination with anesthesia, nursing, housekeeping, and endoscopy supply team are necessary for expanded hours of operation.", [["anesthesia", "TREATMENT", 47, 57], ["operation", "TREATMENT", 144, 153]]], ["To avoid a rapid influx of procedures that can overwhelm the local facility, the endoscopy workforce should continue using a thoughtful prioritization approach with tiers for elective indications and should consider assigning a capacity goal for each tier before resuming elective procedures ( Table 2 ).FINAL REMARKSAlthough the medical community faces an unprecedented situation and as the pandemic progresses, additional challenges will arise that will require innovation and flexibility to overcome this global health crisis.", [["the endoscopy workforce", "TREATMENT", 77, 100], ["a thoughtful prioritization approach", "TREATMENT", 123, 159], ["elective indications", "TREATMENT", 175, 195], ["elective procedures", "TREATMENT", 272, 291], ["this global health crisis", "PROBLEM", 503, 528]]], ["Pancreaticobiliary endoscopists should follow local regulations, use clinical judgment to prioritize procedures, and perform interventions guided by high-quality data.", [["Pancreaticobiliary endoscopists", "TREATMENT", 0, 31], ["clinical judgment", "TREATMENT", 69, 86], ["procedures", "TEST", 101, 111], ["interventions", "TREATMENT", 125, 138]]], ["Moreover, we cannot be effective clinicians and endoscopists, unless we take care of our physical and mental well-being, care for our families, and coordinate effectively with colleagues at work.", [["endoscopists", "TREATMENT", 48, 60]]], ["Together, the pancreaticobiliary community will need to support each other, continue to adapt, and provide the best possible care to the patients.", [["pancreaticobiliary community", "ANATOMY", 14, 42], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145], ["pancreaticobiliary", "ANATOMY", 14, 32]]]], "f83eaa06108a3387433b69ff528e0ed986d77f5e": [["IntroductionOn December 2019, an outbreak of unexplained pneumonia occurred in Wuhan, China.", [["pneumonia", "DISEASE", 57, 66], ["unexplained pneumonia", "PROBLEM", 45, 66], ["unexplained", "OBSERVATION_MODIFIER", 45, 56], ["pneumonia", "OBSERVATION", 57, 66]]], ["On January 7, 2020, the causative pathogen was identified as a novel coronavirus, currently named SARS-CoV-2 [1] .", [["coronavirus", "DISEASE", 69, 80], ["coronavirus", "ORGANISM", 69, 80], ["SARS-CoV", "SPECIES", 98, 106], ["the causative pathogen", "PROBLEM", 20, 42], ["a novel coronavirus", "PROBLEM", 61, 80]]], ["The illness caused by this virus-COVID-19-spread swiftly around the globe, and on March 11, 2020, The World Health Organization (WHO) declared COVID-19 as a pandemic [2] .IntroductionIn most patients, the illness produce mild to moderate symptoms but approximately 15% progress to severe pneumonia, about 1% of patients experience progression that can quickly progress to profound hypoxemia and/or ARDS [3] .", [["illness", "DISEASE", 4, 11], ["illness", "DISEASE", 205, 212], ["pneumonia", "DISEASE", 288, 297], ["hypoxemia", "DISEASE", 381, 390], ["ARDS", "DISEASE", 398, 402], ["patients", "ORGANISM", 191, 199], ["patients", "ORGANISM", 311, 319], ["patients", "SPECIES", 191, 199], ["patients", "SPECIES", 311, 319], ["The illness", "PROBLEM", 0, 11], ["this virus", "PROBLEM", 22, 32], ["COVID", "TEST", 33, 38], ["mild to moderate symptoms", "PROBLEM", 221, 246], ["severe pneumonia", "PROBLEM", 281, 297], ["profound hypoxemia", "PROBLEM", 372, 390], ["ARDS", "PROBLEM", 398, 402], ["globe", "ANATOMY", 68, 73], ["moderate", "OBSERVATION_MODIFIER", 229, 237], ["severe", "OBSERVATION_MODIFIER", 281, 287], ["pneumonia", "OBSERVATION", 288, 297], ["profound", "OBSERVATION_MODIFIER", 372, 380], ["hypoxemia", "OBSERVATION", 381, 390], ["ARDS", "OBSERVATION", 398, 402]]], ["As of June 25, 2020, more than 16.1 million cases of COVID-19 have been confirmed, with 645,752 deaths.", [["deaths", "DISEASE", 96, 102], ["COVID", "TEST", 53, 58]]], ["Currently, there are no specific approved treatment, nor a vaccine is available, and supportive care remains the cornerstone of management.IntroductionECMO is currently a widely accepted support measure for selected patients with life-threatening respiratory failure that does not respond to maximal support care with mechanical ventilation [4] .", [["respiratory", "ANATOMY", 247, 258], ["respiratory failure", "DISEASE", 247, 266], ["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 216, 224], ["a vaccine", "TREATMENT", 57, 66], ["life-threatening respiratory failure", "PROBLEM", 230, 266], ["maximal support care", "TREATMENT", 292, 312], ["mechanical ventilation", "TREATMENT", 318, 340], ["no", "UNCERTAINTY", 21, 23], ["respiratory failure", "OBSERVATION", 247, 266]]], ["However, few centers have this technology available and some patients are too ill to be transferred under conventional transport (mechanical ventilation) to a facility that can provide it, meaning that they must be transferred on ECMO support to specialized centers [5] .", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["conventional transport (mechanical ventilation", "TREATMENT", 106, 152], ["ECMO support", "TREATMENT", 230, 242]]], ["Safety of healthcare workers is an important aspect of COVID-19 management.", [["COVID-19 management", "TREATMENT", 55, 74]]], ["Coronaviruses are believed to be transmitted from person to person via large respiratory droplets, either being inhaled or deposited on mucosal surfaces.", [["respiratory droplets", "ANATOMY", 77, 97], ["mucosal", "ANATOMY", 136, 143], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["mucosal surfaces", "TISSUE", 136, 152], ["person", "SPECIES", 50, 56], ["person", "SPECIES", 60, 66], ["Coronaviruses", "PROBLEM", 0, 13], ["large respiratory droplets", "PROBLEM", 71, 97], ["respiratory droplets", "OBSERVATION", 77, 97], ["mucosal surfaces", "ANATOMY", 136, 152]]], ["Other routes implicated in transmission of coronaviruses include contact with contaminated fomites and inhalation of aerosols produced during aerosol-generating procedures (AGPs).", [["coronaviruses", "DISEASE", 43, 56], ["coronaviruses", "ORGANISM", 43, 56], ["coronaviruses", "PROBLEM", 43, 56], ["inhalation of aerosols", "TREATMENT", 103, 125], ["aerosol-generating procedures", "TREATMENT", 142, 171]]], ["SARS-CoV-2 viral RNA has also been detected on rare occasions in blood specimens but there is no evidence of transmission through contact with blood [7] , for AGPs healthcare workers should use airborne-level personal protective equipment (PPE) [7] .IntroductionHere, we report the first interhospital extracorporeal membrane oxygenation transport of a COVID-19 patient in Chile.Case report51-year-old woman, with a history of hypothyroidism and mild asymptomatic asthma.", [["blood specimens", "ANATOMY", 65, 80], ["blood", "ANATOMY", 143, 148], ["interhospital extracorporeal membrane", "ANATOMY", 288, 325], ["SARS", "DISEASE", 0, 4], ["hypothyroidism", "DISEASE", 427, 441], ["asthma", "DISEASE", 464, 470], ["SARS-CoV-2", "ORGANISM", 0, 10], ["blood specimens", "ORGANISM_SUBSTANCE", 65, 80], ["blood", "ORGANISM_SUBSTANCE", 143, 148], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 302, 325], ["patient", "ORGANISM", 362, 369], ["woman", "ORGANISM", 402, 407], ["SARS-CoV-2 viral RNA", "RNA", 0, 20], ["patient", "SPECIES", 362, 369], ["woman", "SPECIES", 402, 407], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["2 viral RNA", "PROBLEM", 9, 20], ["blood specimens", "TEST", 65, 80], ["the first interhospital extracorporeal membrane oxygenation transport", "TREATMENT", 278, 347], ["a COVID", "TREATMENT", 351, 358], ["hypothyroidism", "PROBLEM", 427, 441], ["mild asymptomatic asthma", "PROBLEM", 446, 470], ["no evidence of", "UNCERTAINTY", 94, 108], ["hypothyroidism", "OBSERVATION", 427, 441], ["mild", "OBSERVATION_MODIFIER", 446, 450], ["asymptomatic", "OBSERVATION_MODIFIER", 451, 463], ["asthma", "OBSERVATION", 464, 470]]], ["Thirteen days prior to developing COVID-19 symptoms she arrived healthy from Dominican Republic, back to Punta Arenas, Chile.", [["developing COVID-19 symptoms", "PROBLEM", 23, 51]]], ["On March 29, 2020 she was admitted to the Regional Hospital after 2 days of progressive cough and malaise, associated with resting dyspnea.", [["cough", "DISEASE", 88, 93], ["resting dyspnea", "DISEASE", 123, 138], ["progressive cough", "PROBLEM", 76, 93], ["malaise", "PROBLEM", 98, 105], ["resting dyspnea", "PROBLEM", 123, 138], ["progressive", "OBSERVATION_MODIFIER", 76, 87], ["cough", "OBSERVATION", 88, 93], ["malaise", "OBSERVATION", 98, 105], ["dyspnea", "OBSERVATION", 131, 138]]], ["In the emergency department she had sinus tachycardia (heart rate (HR) 120 bpm), blood pressure 155/83 mmHg and polypnea [respiratory rate (RR) 40 bpm], 50% O 2 pulse oximetry on room air, with poor respiratory mechanics.", [["sinus", "ANATOMY", 36, 41], ["heart", "ANATOMY", 55, 60], ["blood", "ANATOMY", 81, 86], ["respiratory", "ANATOMY", 122, 133], ["respiratory", "ANATOMY", 199, 210], ["sinus tachycardia", "DISEASE", 36, 53], ["heart", "ORGAN", 55, 60], ["blood", "ORGANISM_SUBSTANCE", 81, 86], ["sinus tachycardia", "PROBLEM", 36, 53], ["heart rate", "TEST", 55, 65], ["HR", "TEST", 67, 69], ["blood pressure", "TEST", 81, 95], ["polypnea", "TEST", 112, 120], ["respiratory rate", "TEST", 122, 138], ["RR", "TEST", 140, 142], ["pulse oximetry", "TEST", 161, 175], ["poor respiratory mechanics", "PROBLEM", 194, 220], ["sinus", "ANATOMY", 36, 41], ["heart", "ANATOMY", 55, 60], ["respiratory mechanics", "OBSERVATION", 199, 220]]], ["Consequently, rapid sequence intubation was performed.", [["rapid sequence intubation", "TEST", 14, 39]]], ["Laboratory results showed 6.69 \u00d7 10 9 /L white blood cells, 1.17 \u00d7 10 9 /L lymphocyte, aspartate aminotransferase 19 U/L, alanine aminotransferase 12 U/L, lactate dehydrogenase 206 U/L; blood urea nitrogen 3.3 mmol/L, creatine kinase 76 mmol/L; procalcitonin 0.11 ng/mL, C-reactive protein 54.86 mg/L; blood gas analysis (ABGs): pH: 7.41, pO 2 91 mmHg, pCO 2 39 mmHg, fraction of inspired oxygen (F I O 2 ) 70%.", [["white blood cells", "ANATOMY", 41, 58], ["lymphocyte", "ANATOMY", 75, 85], ["blood", "ANATOMY", 186, 191], ["blood", "ANATOMY", 302, 307], ["aspartate", "CHEMICAL", 87, 96], ["alanine", "CHEMICAL", 122, 129], ["lactate", "CHEMICAL", 155, 162], ["blood urea nitrogen", "CHEMICAL", 186, 205], ["creatine", "CHEMICAL", 218, 226], ["oxygen", "CHEMICAL", 389, 395], ["aspartate", "CHEMICAL", 87, 96], ["alanine", "CHEMICAL", 122, 129], ["lactate", "CHEMICAL", 155, 162], ["urea", "CHEMICAL", 192, 196], ["nitrogen", "CHEMICAL", 197, 205], ["creatine", "CHEMICAL", 218, 226], ["oxygen", "CHEMICAL", 389, 395], ["blood cells", "CELL", 47, 58], ["lymphocyte", "CELL", 75, 85], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 87, 113], ["alanine aminotransferase", "GENE_OR_GENE_PRODUCT", 122, 146], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 155, 176], ["blood", "ORGANISM_SUBSTANCE", 186, 191], ["urea", "SIMPLE_CHEMICAL", 192, 196], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 218, 233], ["blood", "ORGANISM_SUBSTANCE", 302, 307], ["oxygen", "SIMPLE_CHEMICAL", 389, 395], ["aspartate aminotransferase", "PROTEIN", 87, 113], ["alanine aminotransferase", "PROTEIN", 122, 146], ["lactate dehydrogenase", "PROTEIN", 155, 176], ["creatine kinase", "PROTEIN", 218, 233], ["procalcitonin", "PROTEIN", 245, 258], ["C-reactive protein", "PROTEIN", 271, 289], ["white blood cells", "TEST", 41, 58], ["\u00d7", "TEST", 65, 66], ["lymphocyte", "TEST", 75, 85], ["aspartate aminotransferase", "TEST", 87, 113], ["U/L", "TEST", 117, 120], ["alanine aminotransferase", "TEST", 122, 146], ["U/L", "TEST", 150, 153], ["lactate dehydrogenase", "TEST", 155, 176], ["U", "TEST", 181, 182], ["blood urea nitrogen", "TEST", 186, 205], ["mmol", "TEST", 210, 214], ["creatine kinase", "TEST", 218, 233], ["mmol", "TEST", 237, 241], ["procalcitonin", "TEST", 245, 258], ["C-reactive protein", "TEST", 271, 289], ["blood gas analysis", "TEST", 302, 320], ["ABGs", "TEST", 322, 326], ["pH", "TEST", 329, 331], ["pO", "TEST", 339, 341], ["mmHg", "TEST", 347, 351], ["pCO", "TEST", 353, 356], ["mmHg", "TEST", 362, 366], ["fraction", "TEST", 368, 376], ["inspired oxygen (F I O", "TEST", 380, 402]]], ["Throat swabs of patients were harvested and tested positive for SARS-CoV-2 nucleic acid by the fluorescence quantitative RT-PCR.", [["Throat swabs", "ANATOMY", 0, 12], ["SARS-CoV-2 nucleic acid", "CHEMICAL", 64, 87], ["Throat swabs", "ORGANISM_SUBSTANCE", 0, 12], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["SARS-CoV", "SPECIES", 64, 72], ["Throat swabs", "TEST", 0, 12], ["SARS", "PROBLEM", 64, 68], ["CoV", "TEST", 69, 72], ["nucleic acid", "TEST", 75, 87], ["the fluorescence", "TEST", 91, 107], ["PCR", "TEST", 124, 127]]], ["PCR respiratory panel (FilmArray\u00ae), blood and deep airways cultures were negative for others infectious agents.Case reportChest CT scan showed severe bilateral alveolar condensation with isolated foci of normal parenchyma (Fig. 1) .", [["blood", "ANATOMY", 36, 41], ["airways cultures", "ANATOMY", 51, 67], ["alveolar", "ANATOMY", 160, 168], ["foci", "ANATOMY", 196, 200], ["parenchyma", "ANATOMY", 211, 221], ["blood", "ORGANISM_SUBSTANCE", 36, 41], ["airways cultures", "CELL", 51, 67], ["parenchyma", "TISSUE", 211, 221], ["PCR respiratory panel", "TEST", 0, 21], ["FilmArray\u00ae", "TEST", 23, 33], ["blood", "TEST", 36, 41], ["deep airways cultures", "TEST", 46, 67], ["Case reportChest CT scan", "TEST", 111, 135], ["severe bilateral alveolar condensation", "PROBLEM", 143, 181], ["blood", "ANATOMY", 36, 41], ["deep", "ANATOMY_MODIFIER", 46, 50], ["airways", "ANATOMY", 51, 58], ["severe", "OBSERVATION_MODIFIER", 143, 149], ["bilateral", "ANATOMY_MODIFIER", 150, 159], ["alveolar", "ANATOMY", 160, 168], ["condensation", "OBSERVATION", 169, 181], ["isolated", "OBSERVATION_MODIFIER", 187, 195], ["foci", "OBSERVATION", 196, 200], ["normal", "OBSERVATION", 204, 210], ["parenchyma", "ANATOMY_MODIFIER", 211, 221]]], ["She was managed with on deep sedation (RASS-5), neuromuscular blockade, and recruitment maneuver; hemodynamics was maintained with low dose norepinephrine.", [["neuromuscular", "ANATOMY", 48, 61], ["neuromuscular blockade", "DISEASE", 48, 70], ["norepinephrine", "CHEMICAL", 140, 154], ["norepinephrine", "CHEMICAL", 140, 154], ["norepinephrine", "SIMPLE_CHEMICAL", 140, 154], ["deep sedation (RASS", "TREATMENT", 24, 43], ["neuromuscular blockade", "TREATMENT", 48, 70], ["recruitment maneuver", "TREATMENT", 76, 96], ["low dose norepinephrine", "TREATMENT", 131, 154]]], ["Ventilator settings were adjusted to volume-controlled ventilation 6 , pCO 2 63 mmHg.", [["Ventilator settings", "TREATMENT", 0, 19], ["volume-controlled ventilation", "TREATMENT", 37, 66], ["pCO", "TEST", 71, 74]]], ["As per protocole, oseltamivir, ceftriaxone, azithromycin and hydroxicloroquine were empirically started.", [["oseltamivir", "CHEMICAL", 18, 29], ["ceftriaxone", "CHEMICAL", 31, 42], ["azithromycin", "CHEMICAL", 44, 56], ["hydroxicloroquine", "CHEMICAL", 61, 78], ["oseltamivir", "CHEMICAL", 18, 29], ["ceftriaxone", "CHEMICAL", 31, 42], ["azithromycin", "CHEMICAL", 44, 56], ["hydroxicloroquine", "CHEMICAL", 61, 78], ["oseltamivir", "SIMPLE_CHEMICAL", 18, 29], ["ceftriaxone", "SIMPLE_CHEMICAL", 31, 42], ["azithromycin", "SIMPLE_CHEMICAL", 44, 56], ["hydroxicloroquine", "SIMPLE_CHEMICAL", 61, 78], ["oseltamivir", "TREATMENT", 18, 29], ["ceftriaxone", "TREATMENT", 31, 42], ["azithromycin", "TREATMENT", 44, 56], ["hydroxicloroquine", "TREATMENT", 61, 78]]], ["In the next hours PaO 2 /F I O 2 ratio deteriorated to 108 mmHg, without improvement after recruitment maneuvers nor the implementation of prone position.", [["O 2", "CHEMICAL", 29, 32], ["PaO 2 /F I O 2 ratio", "TEST", 18, 38], ["recruitment maneuvers", "TREATMENT", 91, 112]]], ["Guided per Chilean ARDS's recommendations, transfer to an ECMO unit was requested.", [["ARDS", "DISEASE", 19, 23]]], ["Due to patient condition and given distance from the nearest hospital with mobile ECMO capacity (3019 km), she was deemed to need airborne mobile ECMO.Case reportMobile ECMO team at Cl\u00ednica Las Condes was deployed, which is composed of a cardiac surgeon, an anesthetist, a perfusionist and an ICU nurse.", [["cardiac", "ANATOMY", 238, 245], ["patient", "ORGANISM", 7, 14], ["patient", "SPECIES", 7, 14], ["patient condition", "PROBLEM", 7, 24], ["mobile ECMO capacity", "TREATMENT", 75, 95], ["airborne mobile ECMO", "TREATMENT", 130, 150]]], ["Since cardiac echoscopy showed no significant left ventricular disfunction, venovenous ECMO was installed.", [["cardiac", "ANATOMY", 6, 13], ["left ventricular", "ANATOMY", 46, 62], ["venovenous", "ANATOMY", 76, 86], ["cardiac", "ORGAN", 6, 13], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 46, 62], ["cardiac echoscopy", "TEST", 6, 23], ["significant left ventricular disfunction", "PROBLEM", 34, 74], ["venovenous ECMO", "TREATMENT", 76, 91], ["no", "UNCERTAINTY", 31, 33], ["significant", "OBSERVATION_MODIFIER", 34, 45], ["left ventricular", "ANATOMY", 46, 62], ["disfunction", "OBSERVATION", 63, 74], ["venovenous ECMO", "OBSERVATION", 76, 91]]], ["Cannulation was guided by ultrasonography extraction from right femoral vein (29 Fr) and return to patient through right jugular vein (19 Fr).", [["right femoral vein", "ANATOMY", 58, 76], ["right jugular vein", "ANATOMY", 115, 133], ["femoral vein", "MULTI-TISSUE_STRUCTURE", 64, 76], ["patient", "ORGANISM", 99, 106], ["right jugular vein", "MULTI-TISSUE_STRUCTURE", 115, 133], ["patient", "SPECIES", 99, 106], ["Cannulation", "TREATMENT", 0, 11], ["ultrasonography extraction", "TEST", 26, 52], ["right", "ANATOMY_MODIFIER", 58, 63], ["femoral vein", "ANATOMY", 64, 76], ["right", "ANATOMY_MODIFIER", 115, 120], ["jugular vein", "ANATOMY", 121, 133]]], ["Sweep gas flow 2 LPM; 3200 RPM, 3.4 ECMO flow, titrating parameters until 92% patient saturation.", [["patient", "ORGANISM", 78, 85], ["patient", "SPECIES", 78, 85], ["Sweep gas flow", "TEST", 0, 14], ["ECMO flow", "TEST", 36, 45], ["titrating parameters", "TEST", 47, 67], ["patient saturation", "TEST", 78, 96]]], ["Rotaflow\u00ae centrifugal pump and PLS-i oxygenators (Maquet Cardiopulmonary Hirrlingen\u00ae, Germany) were used.", [["Rotaflow\u00ae centrifugal pump", "TREATMENT", 0, 26], ["PLS-i oxygenators", "TREATMENT", 31, 48], ["Cardiopulmonary Hirrlingen\u00ae, Germany)", "TREATMENT", 57, 94]]], ["No complications where reported during cannulation.", [["complications", "PROBLEM", 3, 16], ["cannulation", "TEST", 39, 50], ["complications", "OBSERVATION", 3, 16]]], ["Ventilatory settings where modified to pressure control 5 cm H 2 O, PEEP 5 cm H 2 O, RR 5 bpm, once leaving the hospital, the patient was left in inspiratory apnea at 8 cm H 2 O, and endotracheal tube was clamped to reduce the aerosolization risk.", [["endotracheal tube", "ANATOMY", 183, 200], ["apnea", "DISEASE", 158, 163], ["patient", "ORGANISM", 126, 133], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 183, 200], ["patient", "SPECIES", 126, 133], ["Ventilatory settings", "TREATMENT", 0, 20], ["pressure control", "TREATMENT", 39, 55], ["PEEP", "TEST", 68, 72], ["RR", "TEST", 85, 87], ["inspiratory apnea", "PROBLEM", 146, 163], ["endotracheal tube", "TREATMENT", 183, 200], ["the aerosolization risk", "PROBLEM", 223, 246], ["left", "ANATOMY_MODIFIER", 138, 142], ["inspiratory apnea", "OBSERVATION", 146, 163], ["endotracheal", "ANATOMY", 183, 195], ["tube", "OBSERVATION", 196, 200], ["aerosolization risk", "OBSERVATION", 227, 246]]], ["During all these maneuvers the whole team members used PPE according to air transmission; well-fitted N95 respirators, eye protection with visor or goggles, gloves, and long-sleeved impermeable protective gown.", [["eye", "ANATOMY", 119, 122], ["eye", "ORGAN", 119, 122], ["PPE", "TREATMENT", 55, 58], ["N95 respirators", "TREATMENT", 102, 117], ["eye protection", "TREATMENT", 119, 133], ["visor", "TREATMENT", 139, 144], ["gloves", "TREATMENT", 157, 163], ["eye", "ANATOMY", 119, 122]]], ["No complication occurred during the flight (Fig. 2) .", [["complication", "PROBLEM", 3, 15], ["complication", "OBSERVATION", 3, 15]]], ["To minimize the aerolization risk of SARS-CoV-2 through the gas-exit port of the membrane lung we kept a strict control for the detection of plasma leakage signs in the exhaust port of the oxygenator [8] .", [["membrane lung", "ANATOMY", 81, 94], ["plasma", "ANATOMY", 141, 147], ["SARS", "DISEASE", 37, 41], ["membrane", "CELLULAR_COMPONENT", 81, 89], ["lung", "ORGAN", 90, 94], ["plasma", "ORGANISM_SUBSTANCE", 141, 147], ["SARS-CoV", "SPECIES", 37, 45], ["SARS", "PROBLEM", 37, 41], ["CoV", "TEST", 42, 45], ["a strict control", "TREATMENT", 103, 119], ["plasma leakage signs", "PROBLEM", 141, 161], ["the oxygenator", "TREATMENT", 185, 199], ["gas", "OBSERVATION", 60, 63], ["membrane lung", "ANATOMY", 81, 94]]], ["According to the Chilean Ministry of Health's guidelines for the transportation of COVID-19 patient, the crew (pilot and copilot) used droplets and contact sufficient PPE, embarked and disembarked at different time than healthcare personnel and patient; cabin was isolated from the rest of the aircraft and HEPA filters were used in ventilation circuits.", [["patient", "ORGANISM", 92, 99], ["patient", "ORGANISM", 245, 252], ["patient", "SPECIES", 92, 99], ["patient", "SPECIES", 245, 252], ["the crew (pilot and copilot)", "TREATMENT", 101, 129], ["droplets", "TREATMENT", 135, 143], ["HEPA filters", "TREATMENT", 307, 319], ["ventilation circuits", "TREATMENT", 333, 353], ["HEPA filters", "OBSERVATION", 307, 319], ["ventilation circuits", "OBSERVATION", 333, 353]]], ["After arrival, the cabin was disinfected with isopropyl alcohol and the rest of the aircraft with quaternary ammonium, and disinfection of the room-air was carried out by the filter using an ozone generating device.Case reportOn arrival at the referral center (Cl\u00ednica Las Condes, Santiago, Chile), endotracheal tube clamp was removed, and mechanical ventilation was set to pressure control, support pressure 10 cm H 2 O, RR 10 bpm, PEEP 10 cm H 2 O, F I O 2 30%.", [["endotracheal tube", "ANATOMY", 299, 316], ["isopropyl alcohol", "CHEMICAL", 46, 63], ["quaternary ammonium", "CHEMICAL", 98, 117], ["ozone", "CHEMICAL", 191, 196], ["isopropyl alcohol", "CHEMICAL", 46, 63], ["quaternary ammonium", "CHEMICAL", 98, 117], ["ozone", "CHEMICAL", 191, 196], ["isopropyl alcohol", "SIMPLE_CHEMICAL", 46, 63], ["ammonium", "SIMPLE_CHEMICAL", 109, 117], ["ozone", "SIMPLE_CHEMICAL", 191, 196], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 299, 316], ["isopropyl alcohol", "TREATMENT", 46, 63], ["quaternary ammonium", "TREATMENT", 98, 117], ["disinfection", "TREATMENT", 123, 135], ["an ozone generating device", "TREATMENT", 188, 214], ["endotracheal tube clamp", "TREATMENT", 299, 322], ["mechanical ventilation", "TREATMENT", 340, 362], ["support pressure", "TREATMENT", 392, 408], ["RR", "TEST", 422, 424], ["PEEP", "TEST", 433, 437], ["quaternary ammonium", "OBSERVATION", 98, 117], ["air", "OBSERVATION", 148, 151], ["endotracheal", "ANATOMY", 299, 311], ["tube clamp", "OBSERVATION", 312, 322], ["mechanical ventilation", "OBSERVATION", 340, 362]]], ["ABGs showed pH 7.38 pO 2 92.8 mmHg, pCO 2 32 mmHg.", [["ABGs", "SIMPLE_CHEMICAL", 0, 4], ["ABGs", "TEST", 0, 4], ["pH", "TEST", 12, 14], ["pO", "TEST", 20, 22], ["mmHg", "TEST", 30, 34], ["pCO", "TEST", 36, 39]]], ["Physical examination suggested deep vein thrombosis of right inferior limb, which was confirmed with echography, patient was transferred to the operating room, where vascular access was reconfigured to left axillar vein drainage, no significant recirculation nor other complication occurred.", [["deep vein", "ANATOMY", 31, 40], ["right inferior limb", "ANATOMY", 55, 74], ["vascular", "ANATOMY", 166, 174], ["left axillar vein", "ANATOMY", 202, 219], ["vein thrombosis", "DISEASE", 36, 51], ["deep vein", "MULTI-TISSUE_STRUCTURE", 31, 40], ["right", "ORGANISM_SUBDIVISION", 55, 60], ["inferior limb", "ORGANISM_SUBDIVISION", 61, 74], ["patient", "ORGANISM", 113, 120], ["vascular", "MULTI-TISSUE_STRUCTURE", 166, 174], ["axillar vein", "MULTI-TISSUE_STRUCTURE", 207, 219], ["patient", "SPECIES", 113, 120], ["Physical examination", "TEST", 0, 20], ["deep vein thrombosis of right inferior limb", "PROBLEM", 31, 74], ["echography", "TEST", 101, 111], ["left axillar vein drainage", "TREATMENT", 202, 228], ["significant recirculation", "PROBLEM", 233, 258], ["other complication", "PROBLEM", 263, 281], ["deep", "ANATOMY_MODIFIER", 31, 35], ["vein", "ANATOMY", 36, 40], ["thrombosis", "OBSERVATION", 41, 51], ["right", "ANATOMY_MODIFIER", 55, 60], ["inferior limb", "ANATOMY", 61, 74], ["vascular", "ANATOMY", 166, 174], ["left", "ANATOMY_MODIFIER", 202, 206], ["axillar vein", "ANATOMY", 207, 219], ["drainage", "OBSERVATION", 220, 228], ["no", "UNCERTAINTY", 230, 232], ["significant", "OBSERVATION_MODIFIER", 233, 244], ["recirculation", "OBSERVATION", 245, 258], ["complication", "OBSERVATION", 269, 281]]], ["Parameters where readjusted to 4 l pm RPM 3700 and FGF 3 lpm until ABGs normalized.Case reportProne position ventilation for 48 h and ultrafiltration through the circuit to reach negative water balance were implemented.", [["FGF 3 lpm", "GENE_OR_GENE_PRODUCT", 51, 60], ["FGF", "PROTEIN", 51, 54], ["FGF", "TEST", 51, 54], ["ABGs", "TEST", 67, 71], ["Case reportProne position ventilation", "TREATMENT", 83, 120], ["ultrafiltration", "TREATMENT", 134, 149], ["the circuit", "TREATMENT", 158, 169]]], ["Native lung function progressively improved and decannulation was undertaken on day 6th after cannulation.", [["lung", "ANATOMY", 7, 11], ["lung", "ORGAN", 7, 11], ["decannulation", "TREATMENT", 48, 61], ["cannulation", "TREATMENT", 94, 105], ["lung", "ANATOMY", 7, 11], ["function", "OBSERVATION", 12, 20], ["progressively", "OBSERVATION_MODIFIER", 21, 34], ["improved", "OBSERVATION_MODIFIER", 35, 43], ["decannulation", "OBSERVATION", 48, 61]]], ["An inferior vena cava filter was installed given the high thrombotic load.", [["inferior vena cava", "ANATOMY", 3, 21], ["thrombotic", "DISEASE", 58, 68], ["inferior vena cava", "MULTI-TISSUE_STRUCTURE", 3, 21], ["An inferior vena cava filter", "TREATMENT", 0, 28], ["the high thrombotic load", "PROBLEM", 49, 73], ["inferior vena cava", "ANATOMY", 3, 21], ["filter", "OBSERVATION", 22, 28], ["high", "OBSERVATION_MODIFIER", 53, 57], ["thrombotic load", "OBSERVATION", 58, 73]]], ["Ten days of treatment with hydroxychloroquine were completed, azithromycin was stopped after 4 days due to QT prolongation.Case reportOn day 14th after admission, methicillin sensitive Staphylococcus aureus pneumonia was confirmed, cefazolin was started, and a second round of prone positioning was needed (48 h).", [["hydroxychloroquine", "CHEMICAL", 27, 45], ["azithromycin", "CHEMICAL", 62, 74], ["QT prolongation", "DISEASE", 107, 122], ["methicillin", "CHEMICAL", 163, 174], ["Staphylococcus aureus pneumonia", "DISEASE", 185, 216], ["cefazolin", "CHEMICAL", 232, 241], ["hydroxychloroquine", "CHEMICAL", 27, 45], ["azithromycin", "CHEMICAL", 62, 74], ["methicillin", "CHEMICAL", 163, 174], ["cefazolin", "CHEMICAL", 232, 241], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 27, 45], ["azithromycin", "SIMPLE_CHEMICAL", 62, 74], ["methicillin sensitive Staphylococcus aureus", "ORGANISM", 163, 206], ["cefazolin", "SIMPLE_CHEMICAL", 232, 241], ["Staphylococcus aureus", "SPECIES", 185, 206], ["Staphylococcus aureus", "SPECIES", 185, 206], ["treatment", "TREATMENT", 12, 21], ["hydroxychloroquine", "TREATMENT", 27, 45], ["azithromycin", "TREATMENT", 62, 74], ["QT prolongation", "PROBLEM", 107, 122], ["methicillin sensitive Staphylococcus aureus pneumonia", "PROBLEM", 163, 216], ["cefazolin", "TREATMENT", 232, 241], ["prone positioning", "TREATMENT", 277, 294], ["Staphylococcus aureus", "OBSERVATION", 185, 206], ["pneumonia", "OBSERVATION", 207, 216]]], ["Considering prolonged invasive mechanical ventilation, tracheostomy was performed on day 24 after admission, with appropriate air-transmission PPE, without incidents.", [["prolonged invasive mechanical ventilation", "TREATMENT", 12, 53], ["tracheostomy", "TREATMENT", 55, 67], ["invasive", "OBSERVATION_MODIFIER", 22, 30], ["mechanical ventilation", "OBSERVATION", 31, 53], ["tracheostomy", "OBSERVATION", 55, 67]]], ["Given adequate clinical and laboratory response, neuromuscular blockade and deep sedation where progressively retired.", [["neuromuscular", "ANATOMY", 49, 62], ["neuromuscular blockade", "TREATMENT", 49, 71], ["deep sedation", "TREATMENT", 76, 89]]], ["A multimodal rehabilitation process was implemented, with a good response.", [["A multimodal rehabilitation process", "TREATMENT", 0, 35]]], ["Tracheostomy was removed, and the patient was discharged to home in a good general condition.DiscussionHere we report the first documented interhospital ECMO transport of a COVID-19 patient showing that it is feasible and safe if a mobile ECMO program is correctly implemented and the particularities of protective measures are properly taken.", [["patient", "ORGANISM", 34, 41], ["patient", "ORGANISM", 182, 189], ["patient", "SPECIES", 34, 41], ["patient", "SPECIES", 182, 189], ["Tracheostomy", "TREATMENT", 0, 12], ["a COVID", "TEST", 171, 178], ["a mobile ECMO program", "TREATMENT", 230, 251], ["protective measures", "TREATMENT", 304, 323]]], ["ECMO was studied for ARDS treatment in patients with Middle East Respiratory Syndrome Coronavirus (MERS-CoV), a similar coronavirus disease that emerged in 2012, showing a significant decrease of in-hospital mortality in patients supported by ECMO compared to those managed with conventional therapy [9] .", [["ARDS", "DISEASE", 21, 25], ["Middle East Respiratory Syndrome Coronavirus", "DISEASE", 53, 97], ["coronavirus disease", "DISEASE", 120, 139], ["patients", "ORGANISM", 39, 47], ["Middle East Respiratory Syndrome Coronavirus", "ORGANISM", 53, 97], ["MERS-CoV", "ORGANISM", 99, 107], ["coronavirus", "ORGANISM", 120, 131], ["patients", "ORGANISM", 221, 229], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 221, 229], ["Middle East Respiratory Syndrome Coronavirus (MERS-CoV", "SPECIES", 53, 107], ["ECMO", "TREATMENT", 0, 4], ["ARDS treatment", "TREATMENT", 21, 35], ["Middle East Respiratory Syndrome Coronavirus", "PROBLEM", 53, 97], ["a similar coronavirus disease", "PROBLEM", 110, 139], ["ECMO", "TREATMENT", 243, 247], ["conventional therapy", "TREATMENT", 279, 299], ["Respiratory Syndrome", "OBSERVATION", 65, 85], ["coronavirus disease", "OBSERVATION", 120, 139], ["significant", "OBSERVATION_MODIFIER", 172, 183], ["decrease", "OBSERVATION_MODIFIER", 184, 192]]], ["At this time there is little worldwide reported experience regarding ECMO support on COVID-19 patients [10] [11] [12] , although the WHO's guidance document includes a statement to \"consider referral patients with refractory hypoxemia despite lung-protective ventilation in settings with access to expertise in ECMO [13] .", [["lung", "ANATOMY", 243, 247], ["hypoxemia", "DISEASE", 225, 234], ["patients", "ORGANISM", 94, 102], ["patients", "ORGANISM", 200, 208], ["lung", "ORGAN", 243, 247], ["patients", "SPECIES", 94, 102], ["patients", "SPECIES", 200, 208], ["ECMO support", "TREATMENT", 69, 81], ["COVID", "TEST", 85, 90], ["refractory hypoxemia", "PROBLEM", 214, 234], ["lung-protective ventilation", "TREATMENT", 243, 270], ["ECMO", "TREATMENT", 311, 315], ["lung", "ANATOMY", 243, 247]]], ["Considering that, if ECMO expertise is available, it should be considered into ARDS managing algorithms, including ARDS secondary to viral pneumonia.DiscussionThe Extracorporeal Life Support Organization (ELSO) reports at July 25, 2020, 1972 confirmed COVID-19 cases have been supported with ECMO, and 55% of discharged patients are alive (753 out 1365).", [["ARDS", "DISEASE", 79, 83], ["ARDS", "DISEASE", 115, 119], ["viral pneumonia", "DISEASE", 133, 148], ["patients", "ORGANISM", 320, 328], ["patients", "SPECIES", 320, 328], ["ARDS managing algorithms", "PROBLEM", 79, 103], ["ARDS", "PROBLEM", 115, 119], ["viral pneumonia", "PROBLEM", 133, 148], ["ECMO", "TREATMENT", 292, 296], ["ARDS", "OBSERVATION", 115, 119], ["viral", "OBSERVATION_MODIFIER", 133, 138], ["pneumonia", "OBSERVATION", 139, 148]]], ["As treatment for severe respiratory failure with ECMO requires specialized knowledge and training, the number of patients annually supported with ECMO is positively associated with the survival rate [5] .", [["respiratory", "ANATOMY", 24, 35], ["respiratory failure", "DISEASE", 24, 43], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["treatment", "TREATMENT", 3, 12], ["severe respiratory failure", "PROBLEM", 17, 43], ["ECMO", "TREATMENT", 49, 53], ["ECMO", "TREATMENT", 146, 150], ["severe", "OBSERVATION_MODIFIER", 17, 23], ["respiratory", "ANATOMY", 24, 35], ["failure", "OBSERVATION", 36, 43]]], ["It is also known that hospitalization at a center, where health care professionals are well-trained on respiratory care results in improved outcomes [14] .", [["respiratory care", "TREATMENT", 103, 119]]], ["Therefore, it is recommended that those patients who meet the criteria to be connected to ECMO should be transferred to centers with high experience in this technique [12] .DiscussionHowever, few centers have this technology available in situ and some patients are too ill to be transferred under conventional transport (mechanical ventilation) to a facility that can provide it, meaning that they must be transferred on ECMO support to specialized centers [5] .DiscussionOn March 3 2020, the first COVID-19 case was reported in Chile and as on July 25 the Ministry of Health has reported 343,592 COVID-19 confirmed cases nationwide, 1% of them are considered serious or critical, and by the time of this publication, 80 patients have been supported with ECMO.DiscussionChile is an upper middle income country with a population of 19.4 million people.", [["patients", "ORGANISM", 40, 48], ["patients", "ORGANISM", 252, 260], ["patients", "ORGANISM", 721, 729], ["people", "ORGANISM", 844, 850], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 252, 260], ["patients", "SPECIES", 721, 729], ["people", "SPECIES", 844, 850], ["ECMO", "TREATMENT", 90, 94], ["this technology", "TREATMENT", 209, 224], ["mechanical ventilation", "TREATMENT", 321, 343], ["ECMO support", "TREATMENT", 421, 433], ["COVID", "TEST", 597, 602], ["ECMO", "TREATMENT", 755, 759], ["upper", "ANATOMY_MODIFIER", 782, 787], ["middle", "ANATOMY_MODIFIER", 788, 794]]], ["Fifteen clinical centers can provide ECMO support distributed in only 6 cities; therefore, patients from remote regions requiring advanced support with ECMO, need to be transferred to these centers.", [["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["ECMO support", "TREATMENT", 37, 49], ["advanced support", "TREATMENT", 130, 146], ["ECMO", "TREATMENT", 152, 156]]], ["In Chile, there is a central coordination system that analyzes requests for ECMO support from all hospitals in the country.DiscussionWhen the need for ECMO is confirmed, each patient is referred to one of the 29 available beds in ECMO centers throughout the country [15] .", [["patient", "ORGANISM", 175, 182], ["patient", "SPECIES", 175, 182], ["ECMO support", "TREATMENT", 76, 88], ["ECMO", "TREATMENT", 151, 155]]], ["Currently only one center in Chile transport ECMO patients on a regular basis, although they have been done sporadically by others.", [["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58]]], ["Figure 3 shows map providing information on the location of ECMO centers in the country.", [["ECMO centers", "TREATMENT", 60, 72]]], ["Here we report the first interhospital ECMO transport of a COVID-19 patient in our country and, to our knowledge, the first case described.", [["patient", "ORGANISM", 68, 75], ["patient", "SPECIES", 68, 75]]], ["The patient was too ill to undergo conventional transport, so had to be moved under ECMO support to Santiago.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["ECMO support", "TREATMENT", 84, 96]]], ["Patient was cannulated by ECMO mobile team at the referral center in Punta Arenas and successfully transferred to Cl\u00ednica las Condes, in Santiago by airplane without any complication during transport.DiscussionAn important aspect to pay attention in patients with COVID-19 is the safety of health care workers.", [["patients", "ORGANISM", 250, 258], ["Patient", "SPECIES", 0, 7], ["patients", "SPECIES", 250, 258], ["any complication", "PROBLEM", 166, 182]]], ["In this case, all team members used personal protective equipment according to the procedure with generation of aerosols and the crew members used PPE to droplets and contact transmission.", [["personal protective equipment", "TREATMENT", 36, 65], ["the procedure", "TREATMENT", 79, 92], ["generation of aerosols", "TREATMENT", 98, 120]]], ["To minimize risk of air circuit disconnection and aerosolization during flight we decided to clamp endotracheal tube.", [["endotracheal tube", "ANATOMY", 99, 116], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 99, 116], ["air circuit disconnection", "TREATMENT", 20, 45], ["aerosolization", "TREATMENT", 50, 64], ["clamp endotracheal tube", "TREATMENT", 93, 116], ["air circuit", "OBSERVATION", 20, 31], ["endotracheal tube", "OBSERVATION", 99, 116]]], ["Other ECMO teams use a strong tape to secure the connection between endotracheal tube and mechanical ventilator, but we prefer endotracheal tube clamping to avoid the risk of endotracheal tube displacement/damage at time of taping remove minimizing the risk of tube replacement need in a COVID19 patient.DiscussionAll heath workers in Cl\u00ednica las Condes had receive previous training in the use of PPE and the air transport company (AeroTac) has also established protocols for the transportation of COVID-19 patient.", [["endotracheal tube", "ANATOMY", 68, 85], ["endotracheal tube", "ANATOMY", 127, 144], ["endotracheal tube", "ANATOMY", 175, 192], ["tube", "ANATOMY", 261, 265], ["endotracheal tube", "TISSUE", 68, 85], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 127, 144], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 175, 192], ["tube", "TISSUE", 261, 265], ["patient", "ORGANISM", 296, 303], ["patient", "ORGANISM", 508, 515], ["patient", "SPECIES", 296, 303], ["patient", "SPECIES", 508, 515], ["a strong tape", "TREATMENT", 21, 34], ["endotracheal tube", "TREATMENT", 68, 85], ["mechanical ventilator", "TREATMENT", 90, 111], ["endotracheal tube clamping", "TREATMENT", 127, 153], ["endotracheal tube displacement", "PROBLEM", 175, 205], ["damage", "PROBLEM", 206, 212], ["taping", "TREATMENT", 224, 230], ["tube replacement", "TREATMENT", 261, 277], ["previous training", "TREATMENT", 366, 383], ["PPE", "TREATMENT", 398, 401], ["endotracheal tube", "OBSERVATION", 68, 85], ["mechanical ventilator", "OBSERVATION", 90, 111], ["tube clamping", "OBSERVATION", 140, 153], ["endotracheal", "OBSERVATION", 175, 187], ["tube displacement", "OBSERVATION", 188, 205], ["tube replacement", "OBSERVATION", 261, 277]]], ["After 21 days, none of the members participating in the cannulation procedure nor in the transport was infected with SARS-Cov-2.DiscussionThe experience of the rescue team can also be an important factor in the final outcomes.", [["SARS", "DISEASE", 117, 121], ["the cannulation procedure", "TREATMENT", 52, 77]]], ["Cl\u00ednica las Condes began the mobile ECMO program in March 2007 and until now, more than 120 patients have been transported to specialized centers.", [["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100]]], ["Although there is still little evidence regarding the utility of ECMO in ARDS by COVID-19, the utility in other pathologies that occur with severe ARDS has been demonstrated; waiting to gain more knowledge about this disease, patients undergoing ECMO should be managed in experienced centers.", [["ARDS", "DISEASE", 73, 77], ["ARDS", "DISEASE", 147, 151], ["patients", "ORGANISM", 226, 234], ["patients", "SPECIES", 226, 234], ["ECMO", "TREATMENT", 65, 69], ["ARDS", "PROBLEM", 73, 77], ["COVID", "TEST", 81, 86], ["other pathologies", "PROBLEM", 106, 123], ["severe ARDS", "PROBLEM", 140, 151], ["this disease", "PROBLEM", 212, 224], ["ECMO", "TREATMENT", 246, 250], ["ECMO", "OBSERVATION", 65, 69], ["ARDS", "OBSERVATION", 73, 77], ["severe", "OBSERVATION_MODIFIER", 140, 146], ["ARDS", "OBSERVATION", 147, 151]]], ["The transfer of these patients by experienced and consolidated ECMO transport teams, in addition to protocols of infection prevention and control measures could significantly influence the outcome of both the patient's disease and the safety of the health workers.DiscussionFunding None.Compliance with ethical standardsConflict of interest Felipe Salech is currently receiving a Grant from \"FONDECYT\" (Chilean government research Grant) #11190882.", [["infection", "DISEASE", 113, 122], ["patients", "ORGANISM", 22, 30], ["patient", "ORGANISM", 209, 216], ["patients", "SPECIES", 22, 30], ["patient", "SPECIES", 209, 216], ["infection prevention", "TREATMENT", 113, 133], ["control measures", "TREATMENT", 138, 154], ["the patient's disease", "PROBLEM", 205, 226], ["ethical standards", "TREATMENT", 303, 320], ["infection", "OBSERVATION", 113, 122]]], ["The remaining authors have disclosed that they do not have any conflicts of interest.Compliance with ethical standardsEthics and institutional review board A document review approval of the above case report was performed by the Review Board, as well as by the Ethics Committee of Cl\u00ednica las Condes.", [["ethical standards", "TREATMENT", 101, 118]]], ["After a detailed descriptions of the case report, a relative of the patient signed a written informed consent for publication of results.", [["patient", "ORGANISM", 68, 75], ["patient", "SPECIES", 68, 75]]]], "5f22ebfb139529e6ce2104ca05de134e9be26e10": [["IntroductionSeveral studies were conducted regarding the inbreeding strategy of different animals.", [["IntroductionSeveral studies", "TEST", 0, 27]]], ["They have reported from inbreeding tolerance in for different species [2, 3] to inbreeding preference for some of them [4] .", [["inbreeding tolerance", "PROBLEM", 24, 44], ["different species", "PROBLEM", 52, 69]]], ["Recent studies have also found evidence of regular incest behavior in wild mammals [5] .", [["Recent studies", "TEST", 0, 14], ["regular incest behavior", "PROBLEM", 43, 66]]], ["Even more interesting is the fact that the existence of extreme inbreeding in humans was also detected when considering a European ancestry sample, taken from the contemporary UK population [1] .IntroductionMotivated by the new evidence, and based on the ideas and the model presented in previous works [6, 7, 8] , here we address the question of how animal species (including humans) may achieve diversity when having inbreeding at the same time.", [["humans", "ORGANISM", 78, 84], ["humans", "ORGANISM", 377, 383], ["humans", "SPECIES", 78, 84], ["humans", "SPECIES", 377, 383], ["humans", "SPECIES", 78, 84], ["humans", "SPECIES", 377, 383], ["extreme inbreeding in humans", "PROBLEM", 56, 84]]], ["In our previous studies, we simulated random trees of ancestors considering inbreeding along the tree.", [["inbreeding along the tree", "PROBLEM", 76, 101], ["tree", "ANATOMY_MODIFIER", 97, 101]]], ["[8] ), to build the tree, generations were added of it in a markovian way.", [["tree", "ANATOMY_MODIFIER", 20, 24]]], ["In that approach, the only constraint considered in the number of ancestors was random blood relationships between individuals of the same generation.", [["blood", "ANATOMY", 87, 92], ["blood", "ORGANISM_SUBSTANCE", 87, 92]]], ["Other restrictions in the number of ancestors related to culture, in the human case, ethological in the animal case, or regarding isolation of populations, were not taken into account.IntroductionFrom a mathematical point of view, it was possible to calculate the first two cumulants of the probability distribution of ancestor number at each generation.", [["human", "ORGANISM", 73, 78], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 73, 78], ["culture", "TEST", 57, 64]]], ["This was possible through the development of new methods to describe the underlying stochastic process.IntroductionIn the present work, we deepen our previous studies.", [["the underlying stochastic process", "PROBLEM", 69, 102], ["new", "OBSERVATION_MODIFIER", 45, 48], ["stochastic process", "OBSERVATION", 84, 102]]], ["We now address diversity in terms of all possible links between the ancestors in the tree.", [["tree", "ANATOMY_MODIFIER", 85, 89]]], ["First, we count how many different inbreeding cases are, in terms of tree connections, for a fixed number of available individuals at a given generation.", [["tree connections", "OBSERVATION", 69, 85]]], ["We find that even for a few generations, this number is quite large.", [["large", "OBSERVATION_MODIFIER", 62, 67]]], ["The number of individuals in each generation may also be previously fixed by the user.", [["number", "OBSERVATION_MODIFIER", 4, 10]]], ["We also present a mapping from the tree representation to an adjacency matrix.", [["matrix", "CELLULAR_COMPONENT", 71, 77], ["a mapping", "TEST", 16, 25], ["adjacency matrix", "OBSERVATION", 61, 77]]], ["The mathematical treatment of the number of possible tree representations is presented in Section 3.", [["The mathematical treatment", "TREATMENT", 0, 26], ["possible", "UNCERTAINTY", 44, 52], ["tree representations", "OBSERVATION", 53, 73]]], ["Section 4 shows the description of the algorithm and computational implementation.", [["the algorithm", "TEST", 35, 48]]], ["The adjacency matrix representation is discussed in Section 5.", [["matrix", "CELLULAR_COMPONENT", 14, 20], ["adjacency matrix", "OBSERVATION", 4, 20]]], ["In that section, we profit from the flexibility of the code presented in this work to generate different cases of trees and comment on their different characteristics in the adjacency matrix representation.", [["matrix", "CELLULAR_COMPONENT", 184, 190], ["adjacency matrix", "OBSERVATION", 174, 190]]], ["Finally, we close in Section 6 with conclusions and discuss future work.A possible tree representationIn this section, we will describe how we consider and build different representations of trees with inbreeding, and mention the notation we will use in the rest of this work.", [["possible", "UNCERTAINTY", 74, 82], ["tree representation", "OBSERVATION", 83, 102]]], ["We then proceed to remove in each generation as many nodes as indicated by the simulation presented in our previous work [8] .", [["nodes", "OBSERVATION", 53, 58]]], ["The labels to be removed, in each generation, are chosen at random.", [["removed", "OBSERVATION", 17, 24]]], ["The gender of the removed individuals is chosen in such a way that we keep close to 50% individuals of each gender (this may be changed in the code presented here if necessary).A possible tree representationRegarding notation used in present work: we call A n the totalnumber of ancestors at the n\u2212generation given by the simulation presented in [8] .", [["possible", "UNCERTAINTY", 179, 187], ["tree", "OBSERVATION_MODIFIER", 188, 192]]], ["The removed ancestors at n\u2212generation will be called A n [9] , in the way described by the following equationA possible tree representationwhere n = 1, \u00b7 \u00b7 \u00b7 , N , 2 n is the number of individuals at the n \u2212 th generation in a full binary tree, and A 1 = 2, or equivalently A 1 = 0.A possible tree representationIn Figure 2 , we show the resulting tree, obtained after subtracting the nodes from the binary graph.", [["individuals", "TEST", 185, 196], ["tree", "ANATOMY_MODIFIER", 239, 243], ["possible", "UNCERTAINTY", 284, 292], ["tree", "OBSERVATION_MODIFIER", 293, 297], ["tree", "OBSERVATION_MODIFIER", 348, 352], ["nodes", "OBSERVATION", 385, 390]]], ["Due to this process, some of the individuals will lose the links which represent the \"progenitor-offspring\" relationship between generations.", [["progenitor", "CELL", 86, 96], ["this process", "PROBLEM", 7, 19]]], ["In Figure 2 we indicate different types of missing links in the nodes.", [["nodes", "ANATOMY", 64, 69], ["nodes", "MULTI-TISSUE_STRUCTURE", 64, 69], ["missing links in the nodes", "PROBLEM", 43, 69], ["different types", "OBSERVATION_MODIFIER", 24, 39], ["nodes", "OBSERVATION", 64, 69]]], ["The goal now is to distribute all the missing links between generations among the current nodes.", [["nodes", "ANATOMY", 90, 95], ["nodes", "MULTI-TISSUE_STRUCTURE", 90, 95], ["nodes", "OBSERVATION", 90, 95]]], ["These nodes will be the progenitors of those members who lost a link in the tree when removing individuals.", [["nodes", "ANATOMY", 6, 11], ["nodes", "MULTI-TISSUE_STRUCTURE", 6, 11], ["nodes", "OBSERVATION", 6, 11], ["tree", "ANATOMY_MODIFIER", 76, 80]]], ["These new links represent inbreeding relationships, since they will not follow the full binary tree.", [["inbreeding", "OBSERVATION", 26, 36]]], ["Pink nodes labeled with even numbers represent females, green nodes with odd numbers represent males.", [["Pink nodes", "ANATOMY", 0, 10], ["nodes", "ANATOMY", 62, 67], ["Pink nodes", "MULTI-TISSUE_STRUCTURE", 0, 10], ["green nodes", "MULTI-TISSUE_STRUCTURE", 56, 67], ["nodes", "OBSERVATION", 5, 10], ["green nodes", "OBSERVATION", 56, 67], ["males", "OBSERVATION", 95, 100]]], ["Nodes missing different types of links are indicated.A possible tree representationTherefore, the next step to obtain one realization of the ancestor tree is to generate an algorithm that includes a criterion to distribute the nodes in such a way that each member of the tree has both a female and a male direct ancestor (since we consider only binary reproduction).", [["an algorithm", "TEST", 170, 182], ["the nodes", "PROBLEM", 223, 232], ["possible", "UNCERTAINTY", 55, 63], ["tree", "OBSERVATION_MODIFIER", 64, 68], ["nodes", "OBSERVATION", 227, 232]]], ["In this work, the criterion that we applied was to choose the remaining nodes (ancestors) at random to be linked to the nodes in the following generation.", [["nodes", "OBSERVATION", 72, 77], ["nodes", "OBSERVATION", 120, 125]]], ["We take into account the label of the ancestor to complete for each node one direct ancestor of each type, and in such a way that every node is connected to both the previous and the next generation (except of course those from the first and the last generations).", [["node", "ANATOMY", 68, 72], ["node", "ANATOMY", 136, 140], ["node", "OBSERVATION", 136, 140]]], ["As a result, we obtained a graph like the one shown in Figure 3 .", [["a graph", "TEST", 25, 32]]], ["Clearly, this is only one possible realization of a tree with seven generations, and the numbers of individuals per generation shown in the figure.", [["tree", "ANATOMY_MODIFIER", 52, 56]]], ["Figure 3 : Example of a tree where some ancestors (nodes) have been removed, and the links between the remaining ancestors were added.", [["nodes", "ANATOMY", 51, 56], ["nodes", "MULTI-TISSUE_STRUCTURE", 51, 56], ["tree", "ANATOMY_MODIFIER", 24, 28], ["nodes", "OBSERVATION", 51, 56]]], ["As before, pink nodes labeled with even numbers represent females, green nodes with odd numbers represent males.", [["pink nodes", "ANATOMY", 11, 21], ["nodes", "ANATOMY", 73, 78], ["pink nodes", "MULTI-TISSUE_STRUCTURE", 11, 21], ["green nodes", "MULTI-TISSUE_STRUCTURE", 67, 78], ["pink nodes", "PROBLEM", 11, 21], ["pink", "OBSERVATION_MODIFIER", 11, 15], ["nodes", "OBSERVATION", 16, 21], ["females", "OBSERVATION", 58, 65], ["green nodes", "OBSERVATION", 67, 78], ["males", "OBSERVATION", 106, 111]]], ["This graph is one possible representation of inbreeding between individuals.Diversity of trees with a fixed number of ancestorsIn section 2, we built one of the possible trees given the number of male and female ancestors in each generation.", [["inbreeding between individuals", "PROBLEM", 45, 75], ["one possible", "UNCERTAINTY", 14, 26], ["inbreeding", "OBSERVATION", 45, 55]]], ["Now we will count all possible and different trees, meaning all the different kin relations between the individuals of the tree.", [["tree", "ANATOMY_MODIFIER", 123, 127]]], ["In terms of Figure 2 , this means all the possible graphs (such as Figure 3 ) that we can obtain with labeled ancestors with all the different links distribution.Diversity of trees with a fixed number of ancestorsTo start the procedure let's suppose that this tree has N generations, we remove from the tree the value of A n ancestors in each generation n, including male M n and female F n , in a way that:Diversity of trees with a fixed number of ancestorsLet's also remember that A n = 2 n \u2212 A n , where this equation allows us to compare the value of removed ancestors with the binary tree.", [["the procedure", "TREATMENT", 222, 235], ["binary", "ANATOMY", 582, 588], ["tree", "ANATOMY_MODIFIER", 589, 593]]], ["Now we considered the n\u2212generation.", [["the n\u2212generation", "PROBLEM", 18, 34]]], ["Let's consider first Equation (3):Diversity of trees with a fixed number of ancestorsthis is because the number of individuals in the tree without a female direct ancestor, or lacking both direct ancestors must be equivalent to all the links that were lost when subtracting F n+1 female nodes in the previous generation.Diversity of trees with a fixed number of ancestorsIn other words, the number of individuals without mother in the n\u2212generation plus the number of individuals lacing of mother and father is equal to the number of females substracted in the (n+1)\u2212generation.", [["ancestorsthis", "DISEASE", 76, 89], ["female nodes", "MULTI-TISSUE_STRUCTURE", 280, 292], ["nodes", "OBSERVATION", 287, 292]]], ["Following the same reasoning for males, we obtain:Diversity of trees with a fixed number of ancestorsAlso equivalent to all the links that were lost, when subtracting M n+1 male nodes in the previous generation.Diversity of trees with a fixed number of ancestorsIf we want to compare with a binary tree, meaning one ancestors tree without inbreeding, we know that the number of female and male ancestors in a given n generation is half of each one, as shown in Equation (5).Diversity of trees with a fixed number of ancestorsNow we use Equation (1) with equation (2) to split and count how many available male (M n ) and female (F n ) we have, to distribute kinship represented by the links in the graph.Diversity of trees with a fixed number of ancestorswhereDiversity of trees with a fixed number of ancestorsWe now have all that we need to count how many different ways we have to distribute the link between the actual available males and females.Diversity of trees with a fixed number of ancestorsLet's consider first the case where we distribute all ancestors in the (n + 1)\u2212generation in a way that every ancestor in the n\u2212generation is linked to different nodes till the point that we have no more different nodes in the (n + 1)\u2212generation to assign.", [["\u2212generation", "PROBLEM", 1080, 1091], ["different nodes", "PROBLEM", 1154, 1169], ["nodes", "OBSERVATION", 178, 183], ["trees", "ANATOMY_MODIFIER", 487, 492], ["trees", "ANATOMY_MODIFIER", 717, 722], ["nodes", "OBSERVATION", 1164, 1169], ["no", "UNCERTAINTY", 1198, 1200], ["more different", "OBSERVATION_MODIFIER", 1201, 1215], ["nodes", "OBSERVATION", 1216, 1221]]], ["As a consequence, some individuals will be \"siblings\" or \"half-siblings\".Diversity of trees with a fixed number of ancestorsThe total number of different ways to distribute all the females at the (n + 1)-generation between the individuals without a female direct ancestor \u00b5 at the n\u2212generation, T \u00b5 (n), comes from Equation (8).Diversity of trees with a fixed number of ancestorswhere C(F n+1 , 1) denotes the combinatorial number of 1 element (one female progenitor) from a given set of F n+1 elements (potential female progenitors) and the index i corresponds to the individuals in n\u2212generation without a female direct ancestor.", [["progenitor", "ANATOMY", 456, 466], ["progenitors", "ANATOMY", 521, 532], ["female progenitors", "CELL", 514, 532], ["F n+1 elements", "DNA", 488, 502], ["female progenitors", "CELL_TYPE", 514, 532], ["total", "OBSERVATION_MODIFIER", 128, 133], ["trees", "ANATOMY_MODIFIER", 341, 346]]], ["Now, we proceed in the same way for the males: we count the ways to distribute all the males at the (n + 1)-generation between the individuals without a male direct ancestor \u03d5 at the n\u2212generation, T \u03d5 (n), given by equation (9) .Diversity of trees with a fixed number of ancestorswhere C(M n+1 , 1) denotes the number of the combination of one element (one male) from a given set of F n+1 elements (potential male progenitors) and the index j corresponds to the individuals in n\u2212generation without a male direct ancestor.", [["F n+1 elements", "DNA", 383, 397], ["male progenitors", "CELL_TYPE", 409, 425], ["trees", "ANATOMY_MODIFIER", 242, 247]]], ["Finally, we distribute the female and male potential direct ancestors between the individuals without any progenitor in equation (10):Diversity of trees with a fixed number of ancestorswhere the index k corresponds to the individuals in n\u2212generation without without any links to the previous generation \u03c0.", [["progenitor", "CELL", 106, 116]]], ["In this way, the full problem consists of counting with repetitions all the possible combinations to distribute the links between all the individuals without one or two progenitors, by the following simple multiplication:Diversity of trees with a fixed number of ancestorsIn this way, Equation (11) shows all the possible different combinations for inbreeding links between two generations (a sub-graph).", [["progenitors", "CELL", 169, 180]]], ["For a tree whose total number of generations equals to N , the different possible inbreeding trees, T N , is given by Equation (12):Diversity of trees with a fixed number of ancestorsWe know that for x \u2208 N : C(x, 1) is equal to x, thus we can replace in Equation (12) the combinatorial number in each term:Diversity of trees with a fixed number of ancestorsAnd also we know that L l=1 S = S L , if S and l are independent, thus the Equation (13) can be rewritten as:Diversity of trees with a fixed number of ancestorsRearranging we obtain:Diversity of trees with a fixed number of ancestorsIt is useful to write Equation (15) in terms of the number of subtracted males and females, and also in terms of the binary tree.", [["binary tree", "OBSERVATION", 707, 718]]], ["We can use use the relations given by Equations (6) and (7):Diversity of trees with a fixed number of ancestorsFinally if we use the constraint given by Equations (3) and (4) we obtain:Diversity of trees with a fixed number of ancestorsEquation (17) gives us the analytical way to count all possible inbreeding trees (graphs) for a fixed number of ancestors, given that we know how many males and females are not present in the ancestor's tree (compared to the full binary tree) for a tree with N generation.Diversity of trees with a fixed number of ancestorsIf we want to consider what happens when we change the rate of subtracted male and female, we have to add all possible combinations of M k+1 + F k+1 that gives the same value of subtracted ancestors.Diversity of trees with a fixed number of ancestorsAs we can see from Equation (17), this number could be very large.", [["tree", "ORGANISM_SUBDIVISION", 439, 443], ["very", "OBSERVATION_MODIFIER", 864, 868], ["large", "OBSERVATION", 869, 874]]], ["We can observe from the equation clearly that this number diverges when we increase the number of generations of the tree.Diversity of trees with a fixed number of ancestorsFor example for a tree of 7 generations, as the one that we considered in the previous section, we can obtain the order of 1.99 \u00d7 10 78 different representations.", [["tree", "ANATOMY_MODIFIER", 117, 121]]], ["Clearly, to generate and explore different representations a numerical method is needed.", [["a numerical method", "TREATMENT", 59, 77]]], ["In this direction, we introduce an algorithm described in the next section to randomly generate representations for a tree with N generations.", [["an algorithm", "TEST", 32, 44], ["a tree with N generations", "TREATMENT", 116, 141]]], ["As we will discuss later, this code is flexible and allows different possibilities: one can build possible representations for an N generation tree with a fixed number of trees per generation, or fix the number of individuals and distribute them among N generations, or among more (or less) generations, etc., depending on the interest of the user.Methods: Algorithm descriptionThe algorithm to construct one realization for the tree of ancestors with inbreeding starts with a full binary tree first (in terms of code, it is a list of nodes and links).", [["an N generation tree", "TREATMENT", 127, 147], ["nodes", "OBSERVATION", 535, 540]]], ["In this tree, each member has an associated tag (a number).Methods: Algorithm descriptionWe go over the description from Section 2 in detail, which we represent in Figure 4: 1.", [["tree", "ANATOMY_MODIFIER", 8, 12]]], ["We start from a full binary tree with a given number of generations 2.", [["a full binary tree", "TREATMENT", 14, 32]]], ["After choosing a criterion, as some nodes were extracted, the links involving them disappear.", [["nodes", "ANATOMY", 36, 41], ["nodes", "MULTI-TISSUE_STRUCTURE", 36, 41], ["some nodes", "PROBLEM", 31, 41], ["nodes", "OBSERVATION", 36, 41]]], ["The criteria used to ensure that each node has a direct ancestor of each gender is as follows: we go over each of the generations of the tree except the last one.", [["node", "ANATOMY", 38, 42], ["node", "MULTI-TISSUE_STRUCTURE", 38, 42], ["each node", "PROBLEM", 33, 42], ["node", "OBSERVATION", 38, 42], ["tree", "ANATOMY_MODIFIER", 137, 141]]], ["In each generation, we analyze one by one each node.", [["node", "ANATOMY", 47, 51], ["node", "OBSERVATION", 47, 51]]], ["In each node of the generation, we observe how many links arrive, and if these links came from a female or male gender label.", [["node", "ANATOMY", 8, 12], ["node", "OBSERVATION", 8, 12]]], ["With this information we decide what to do:Methods: Algorithm description(a) If there is no link arriving at the node from the previous generation we randomly choose a node of the previous one to be its ancestor. (b) If there is a link from the node of the previous generation, we check the label from this ancestor and randomly choose an individual from that generation among those with the opposite label. (c) If the node considered already has the 2 links, we do not add anything.Methods: Algorithm descriptionWhen we finish, we move to the next generation and repeat the process, thus going through the entire tree.Methods: Algorithm descriptionIn this way, we can obtain one representation, like the one shown at the left of Figure 4 .", [["node", "ANATOMY", 113, 117], ["node", "ANATOMY", 168, 172], ["node", "ANATOMY", 419, 423], ["node", "MULTI-TISSUE_STRUCTURE", 419, 423], ["the node", "PROBLEM", 415, 423], ["no link", "UNCERTAINTY", 89, 96], ["node", "OBSERVATION", 113, 117], ["node", "OBSERVATION", 168, 172], ["node", "OBSERVATION", 245, 249], ["node", "OBSERVATION", 419, 423], ["left", "ANATOMY_MODIFIER", 722, 726]]], ["As we have mentioned, there are multiple ways to distribute the links between generations among the existing nodes.", [["nodes", "ANATOMY", 109, 114], ["nodes", "MULTI-TISSUE_STRUCTURE", 109, 114], ["multiple", "OBSERVATION_MODIFIER", 32, 40], ["nodes", "OBSERVATION", 109, 114]]], ["The output of the program is: i) one of all possible graphs for the tree ii) its corresponding adjacency matrix, and node distributions [10] , which we present and discuss in the next section.", [["node", "ANATOMY", 117, 121], ["matrix", "CELLULAR_COMPONENT", 105, 111], ["output", "OBSERVATION_MODIFIER", 4, 10], ["adjacency matrix", "OBSERVATION", 95, 111], ["node", "OBSERVATION", 117, 121]]], ["Also, with the number of ancestors, the program estimates the number of possible trees configurations following the estimation explained in Section 3.Methods: Algorithm descriptionOur representation depends on the number of ancestors in each generation and gender labels, also depend on the seed we put in the random number generator.", [["possible", "UNCERTAINTY", 72, 80], ["trees configurations", "OBSERVATION", 81, 101]]], ["Different seed values give rise to different representations like those observed in Figure 5 .Methods: Algorithm descriptionCode to obtain the tree representation was developed using Python [11] and Networkx [12] .", [["Different seed values", "PROBLEM", 0, 21]]], ["It will be available at the Github repository to be used and modified freely.Graph properties of the TreeLet us consider the adjacency matrix for a simple graph with vertex set V. It is a square |V| \u00d7 |V| matrix M M M where the element M ij is 1 when there is a edge from the i\u2212vertex to the j\u2212vertex, and 0 when there is no edge [10] , where |V| is the number of elements of V. We use this definition with the matrix of each directed graph representing the tree in such a way that columns represent the relationships between generations.", [["matrix", "CELLULAR_COMPONENT", 135, 141], ["TreeLet", "DNA", 101, 108], ["V|", "PROTEIN", 344, 346], ["ij", "ANATOMY", 238, 240], ["j\u2212vertex", "ANATOMY", 292, 300], ["no", "UNCERTAINTY", 322, 324], ["tree", "ANATOMY_MODIFIER", 458, 462]]], ["Each column always has two non-null elements representing each progenitor.", [["progenitor", "ANATOMY", 63, 73], ["progenitor", "CELL", 63, 73], ["null elements", "DNA", 31, 44], ["non-", "OBSERVATION_MODIFIER", 27, 31], ["null elements", "OBSERVATION", 31, 44], ["each progenitor", "OBSERVATION", 58, 73]]], ["Each row indicated how many nodes from the next generation are linked to a certain node.", [["nodes", "ANATOMY", 28, 33], ["node", "ANATOMY", 83, 87], ["nodes", "MULTI-TISSUE_STRUCTURE", 28, 33], ["node", "MULTI-TISSUE_STRUCTURE", 83, 87], ["many nodes", "PROBLEM", 23, 33], ["many", "OBSERVATION_MODIFIER", 23, 27], ["nodes", "OBSERVATION", 28, 33], ["node", "OBSERVATION", 83, 87]]], ["The vertical axis represents the nodes as ancestors and the horizontal axis as offspring.", [["nodes", "ANATOMY", 33, 38], ["the nodes", "PROBLEM", 29, 38], ["vertical axis", "OBSERVATION", 4, 17], ["nodes", "OBSERVATION", 33, 38], ["horizontal axis", "OBSERVATION_MODIFIER", 60, 75]]], ["The case of a binary tree is represented at the left of Figure 6 .", [["binary tree", "OBSERVATION", 14, 25], ["left", "ANATOMY_MODIFIER", 48, 52]]], ["Let us compare it with what happens when we have an inbreeding tree, such as the one obtained in Figure 3 , which we show at the right of 6.", [["right", "ANATOMY_MODIFIER", 129, 134]]], ["In the first case, no inbreeding is reflected by the yellow line (which has slope 2), where none of the nodes share a progenitor.", [["nodes", "ANATOMY", 104, 109], ["progenitor", "ANATOMY", 118, 128], ["nodes", "MULTI-TISSUE_STRUCTURE", 104, 109], ["progenitor", "CELL", 118, 128], ["inbreeding", "PROBLEM", 22, 32], ["the yellow line", "PROBLEM", 49, 64], ["no", "UNCERTAINTY", 19, 21], ["inbreeding", "OBSERVATION", 22, 32], ["yellow line", "OBSERVATION", 53, 64], ["nodes", "OBSERVATION", 104, 109]]], ["In the second case, it is interesting to observe that the yellow points separate from the slope corresponding to the di-graph, creating a unique distribution pattern.", [["the yellow points", "PROBLEM", 54, 71], ["yellow", "OBSERVATION", 58, 64]]], ["Adjacency matrix could be used as a useful measure of the degree of inbreeding with respect to the full binary tree.Graph properties of the TreeThe adjacency matrix (lower panel of Figure 6 ) acts as a fingerprint of each of our tree realizations.", [["matrix", "CELLULAR_COMPONENT", 10, 16], ["Adjacency matrix", "PROBLEM", 0, 16], ["inbreeding", "PROBLEM", 68, 78], ["degree", "OBSERVATION_MODIFIER", 58, 64], ["inbreeding", "OBSERVATION", 68, 78], ["binary tree", "OBSERVATION", 104, 115], ["Tree", "ANATOMY_MODIFIER", 140, 144], ["adjacency", "OBSERVATION_MODIFIER", 148, 157], ["matrix", "OBSERVATION_MODIFIER", 158, 164], ["tree realizations", "OBSERVATION", 229, 246]]], ["For each graph, the plot of the adjacency matrix is unique.", [["matrix", "CELLULAR_COMPONENT", 42, 48], ["each graph", "TEST", 4, 14], ["adjacency matrix", "OBSERVATION", 32, 48]]], ["To illustrate this point, Figure 7 shows the adjacency matrices corresponding to the trees presented in Figure 5 .", [["the adjacency matrices", "PROBLEM", 41, 63]]], ["Each of them is different, and so are their corresponding graphs.", [["different", "OBSERVATION_MODIFIER", 16, 25]]], ["In all the matrices, the number of ancestors at the beginning of the tree is low.", [["matrices", "OBSERVATION_MODIFIER", 11, 19], ["number", "OBSERVATION_MODIFIER", 25, 31], ["ancestors", "OBSERVATION", 35, 44], ["tree", "ANATOMY_MODIFIER", 69, 73], ["low", "OBSERVATION_MODIFIER", 77, 80]]], ["As a result, a flattening of the curve appears as the number of the generation increases.", [["a flattening of the curve", "PROBLEM", 13, 38], ["flattening", "OBSERVATION_MODIFIER", 15, 25], ["increases", "OBSERVATION_MODIFIER", 79, 88]]], ["The red rectangles indicate yellow points that must necessarily belong to the same generation.", [["The red rectangles", "TREATMENT", 0, 18], ["yellow points", "PROBLEM", 28, 41], ["yellow points", "OBSERVATION", 28, 41]]], ["The cyan rectangles at the bottom of the graphs indicate the first and second generation from the trees, using the fact that we started from a binary tree.", [["The cyan rectangles", "TREATMENT", 0, 19], ["cyan rectangles", "OBSERVATION", 4, 19], ["bottom", "ANATOMY_MODIFIER", 27, 33]]], ["These show that these graphs also indicate the number of generations from Figure 5 .", [["these graphs", "TEST", 16, 28]]], ["In these plots, the distinctive imprint of each tree can be seen more clearly in the distributions of yellow dots on the dark background.", [["plots", "OBSERVATION_MODIFIER", 9, 14], ["distinctive", "OBSERVATION_MODIFIER", 20, 31], ["tree", "ANATOMY_MODIFIER", 48, 52], ["distributions", "OBSERVATION_MODIFIER", 85, 98], ["yellow dots", "OBSERVATION", 102, 113], ["dark background", "OBSERVATION_MODIFIER", 121, 136]]], ["The red rectangles indicate dots that must be in the same generation.", [["The red rectangles", "TREATMENT", 0, 18]]], ["The cyan rectangles, at the bottom fo the matrices, belong to the first and second generation. each tree: it is simply the number of rectangles.", [["The cyan rectangles", "TREATMENT", 0, 19], ["cyan rectangles", "OBSERVATION", 4, 19], ["bottom", "ANATOMY_MODIFIER", 28, 34]]], ["It can be seen more clearly from these plots that, even though the number of ancestors is the same, the edges in the tree are distributed differently.", [["edges", "OBSERVATION_MODIFIER", 104, 109], ["tree", "ANATOMY_MODIFIER", 117, 121], ["distributed", "OBSERVATION_MODIFIER", 126, 137], ["differently", "OBSERVATION_MODIFIER", 138, 149]]], ["This is reflected in the different distribution of yellow points in the rectangles.Graph properties of the TreeIn order to further explore the information displayed in the adjacency matrices, we compare three cases: one of the trees we have already presented, a 7-generation tree with the same total number of nodes but a different distribution, and a 9-generation tree with the same number of nodes.", [["nodes", "ANATOMY", 310, 315], ["nodes", "ANATOMY", 394, 399], ["nodes", "MULTI-TISSUE_STRUCTURE", 394, 399], ["yellow points in the rectangles", "PROBLEM", 51, 82], ["different", "OBSERVATION_MODIFIER", 25, 34], ["distribution", "OBSERVATION_MODIFIER", 35, 47], ["yellow points", "OBSERVATION", 51, 64], ["rectangles", "OBSERVATION_MODIFIER", 72, 82], ["nodes", "OBSERVATION", 310, 315], ["different", "OBSERVATION_MODIFIER", 322, 331], ["distribution", "OBSERVATION_MODIFIER", 332, 344], ["nodes", "OBSERVATION", 394, 399]]], ["Then, comparing panels (a) and (b) we can see that, for example, the tree associated with the matrix in panel (b) must have more nodes in the last generation.", [["nodes", "ANATOMY", 129, 134], ["matrix", "CELLULAR_COMPONENT", 94, 100], ["the matrix in panel", "TEST", 90, 109], ["more nodes", "PROBLEM", 124, 134], ["more", "OBSERVATION_MODIFIER", 124, 128], ["nodes", "OBSERVATION", 129, 134]]], ["Finally, it is interesting to study other properties of the graph, such as the degree of connectivity of the nodes.", [["nodes", "ANATOMY", 109, 114], ["the graph", "TEST", 56, 65], ["connectivity of the nodes", "PROBLEM", 89, 114], ["nodes", "OBSERVATION", 109, 114]]], ["By studying the distribution of the output degree of the nodes, we can observe that there is inbreeding, as it is shown in Figure 9 .", [["inbreeding", "PROBLEM", 93, 103], ["output", "OBSERVATION_MODIFIER", 36, 42], ["degree", "OBSERVATION_MODIFIER", 43, 49], ["nodes", "OBSERVATION", 57, 62]]], ["Here, we plot a histogram of the number of descendants associated with each node for two cases: on the left, the tree presented in Figure 3 , and on the right, for the 9-generation tree with the same number of nodes shown in Figure 8 .", [["node", "ANATOMY", 76, 80], ["left", "ANATOMY", 103, 107], ["a histogram", "TEST", 14, 25], ["node", "OBSERVATION", 76, 80], ["left", "ANATOMY_MODIFIER", 103, 107], ["tree", "ANATOMY_MODIFIER", 113, 117], ["right", "ANATOMY_MODIFIER", 153, 158], ["nodes", "OBSERVATION", 210, 215]]], ["From the Figure, we can see that in the case of the 7-generation tree, the majority of the nodes have one child, some of them have two, and only a minority have more than 5.", [["nodes", "ANATOMY", 91, 96], ["nodes", "MULTI-TISSUE_STRUCTURE", 91, 96], ["majority", "OBSERVATION_MODIFIER", 75, 83], ["nodes", "OBSERVATION", 91, 96]]], ["For the 9-generation tree, the histogram is flatter and broader.", [["the histogram", "TEST", 27, 40]]], ["This is associated with the fact that since this tree has the same number of nodes than a 7-generation tree, more edges are missing from a full binary tree, and therefore more nodes need to be linked to more than one node from the next generation.Graph properties of the TreeIn this way, we have shown how this algorithm makes it possible to obtain different tree representations and explore the connectivity information in each realization in different manners: either plotting the tree, studying the adjacency matrix or analyzing the connectivity between nodes.ConclusionsIn the present work, we have presented an algorithm with a software implementation to build one possible ancestors' tree with its corresponding graph.", [["node", "ANATOMY", 217, 221], ["nodes", "ANATOMY", 557, 562], ["matrix", "CELLULAR_COMPONENT", 512, 518], ["more nodes", "PROBLEM", 171, 181], ["an algorithm", "TEST", 613, 625], ["nodes", "OBSERVATION", 77, 82], ["edges", "OBSERVATION_MODIFIER", 114, 119], ["nodes", "OBSERVATION", 176, 181], ["node", "OBSERVATION", 217, 221], ["nodes", "OBSERVATION", 557, 562]]], ["We have shown that such a number is really large, which supports the need to use an algorithm to construct and analyze different trees.ConclusionsRegarding the software implementation, this algorithm provides different tools to study the properties of the trees and their degree of inbreeding: it produces the tree itself, the adjacency matrix (which we have shown is a useful tool to visualize and distinguish trees), and a histogram illustrating the degree of connectivity of the nodes.", [["nodes", "ANATOMY", 482, 487], ["matrix", "CELLULAR_COMPONENT", 337, 343], ["an algorithm", "TEST", 81, 93], ["this algorithm", "TEST", 185, 199], ["inbreeding", "PROBLEM", 282, 292], ["a histogram", "TEST", 423, 434], ["connectivity of the nodes", "PROBLEM", 462, 487], ["large", "OBSERVATION_MODIFIER", 43, 48], ["degree", "OBSERVATION_MODIFIER", 272, 278], ["inbreeding", "OBSERVATION", 282, 292], ["tree", "OBSERVATION_MODIFIER", 310, 314], ["adjacency", "OBSERVATION_MODIFIER", 327, 336], ["matrix", "OBSERVATION_MODIFIER", 337, 343], ["degree", "OBSERVATION_MODIFIER", 452, 458], ["nodes", "OBSERVATION", 482, 487]]], ["The code gives the possibility of extending these tools to perform different types of simulations and analysis.", [["simulations and analysis", "TEST", 86, 110]]], ["For example, our next step would be to add attributes to the nodes that could be considered as genes, or maybe diseases, study the propagation of this feature along the tree, and compare it with the degree of inbreeding.ConclusionsConcerning the analytical estimation, similar reasoning can be useful for accounting in other cases where nodes with some attributes are subtracted.ConclusionsIn this way, we have shown how, from a simple ancestor distribution model, we can study the family of corresponding graphs with different edges for the trees.", [["nodes", "MULTI-TISSUE_STRUCTURE", 337, 342], ["the nodes", "PROBLEM", 57, 66], ["diseases", "PROBLEM", 111, 119], ["inbreeding", "PROBLEM", 209, 219], ["the analytical estimation", "TEST", 242, 267], ["nodes", "PROBLEM", 337, 342], ["nodes", "OBSERVATION", 61, 66], ["tree", "ANATOMY_MODIFIER", 169, 173], ["inbreeding", "OBSERVATION", 209, 219], ["nodes", "OBSERVATION", 337, 342]]], ["This situation constitutes an interesting example of how, from a small set of elements or individuals, an enormous diversity of cases can be obtained.", [["enormous", "OBSERVATION_MODIFIER", 106, 114]]], ["In this way, we suggest that even small inbred groups could still give rise to different genetic variability.ConclusionsFinally, the code presented in this work is open source and easily adapted to study other situations relevant to current studies such as opinion spread models, disease propagation, etc. We are thus certain that it will prove to be a useful tool for future studies.", [["small inbred groups", "PROBLEM", 34, 53], ["current studies", "TEST", 233, 248], ["disease propagation", "PROBLEM", 280, 299], ["future studies", "TEST", 369, 383]]]], "2e173208148f2dafcf04f1cd864e95c15f3698ff": [["IntroductionInfectious diseases have tremendous influence on human and animal population sizes.", [["human", "ORGANISM", 61, 66], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 61, 66], ["IntroductionInfectious diseases", "PROBLEM", 0, 31], ["tremendous influence", "PROBLEM", 37, 57], ["tremendous", "OBSERVATION_MODIFIER", 37, 47], ["sizes", "OBSERVATION_MODIFIER", 89, 94]]], ["For example, severe acute respiratory syndrome (SARS) affected China in 2003, myxomatosis caused enormous decreases in the rabbit population in Australia in the 1950s, the Black Death in Europe in the 14th century killed up to a quarter of the human population.", [["acute respiratory syndrome", "DISEASE", 20, 46], ["SARS", "DISEASE", 48, 52], ["myxomatosis", "DISEASE", 78, 89], ["Death", "DISEASE", 178, 183], ["rabbit", "ORGANISM", 123, 129], ["human", "ORGANISM", 244, 249], ["rabbit", "SPECIES", 123, 129], ["human", "SPECIES", 244, 249], ["rabbit", "SPECIES", 123, 129], ["human", "SPECIES", 244, 249], ["severe acute respiratory syndrome", "PROBLEM", 13, 46], ["SARS", "PROBLEM", 48, 52], ["myxomatosis", "PROBLEM", 78, 89], ["enormous decreases", "PROBLEM", 97, 115], ["the rabbit population", "PROBLEM", 119, 140], ["severe", "OBSERVATION_MODIFIER", 13, 19], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["respiratory syndrome", "OBSERVATION", 26, 46], ["enormous", "OBSERVATION_MODIFIER", 97, 105], ["decreases", "OBSERVATION_MODIFIER", 106, 115], ["rabbit population", "OBSERVATION", 123, 140]]], ["Mathematical modelling is of considerable importance in epidemiology because it may provide understanding of the underlying mechanisms which influence the spread of disease and may suggest control strategies.", [["the underlying mechanisms", "PROBLEM", 109, 134], ["disease", "PROBLEM", 165, 172], ["control strategies", "TREATMENT", 189, 207]]], ["In the case where the infectious lose immunity and become susceptible immediately after recovering, an SIS epidemic model is used to describe the dynamics of the population [1] .", [["infectious", "OBSERVATION", 22, 32]]], ["Recent years have also seen wide-scope potential applications of the SIS epidemic model in various scientific fields, such as that of complex networks [2] .IntroductionThe study of the SIS epidemic model mainly concerns global asymptotic stability.", [["the SIS epidemic model", "TREATMENT", 65, 87], ["The study", "TEST", 168, 177], ["global asymptotic stability", "PROBLEM", 220, 247], ["asymptotic stability", "OBSERVATION", 227, 247]]], ["For example, Rass [3] obtained asymptotic stability for a multi-type SIS model, and Iannelli et al. [4] considered an age-structured epidemic model of SIS type and analyzed the global dynamical behavior for the model when the population density converges uniformly to a steady state.", [["Rass", "TEST", 13, 17], ["a multi-type SIS model", "PROBLEM", 56, 78], ["SIS type", "OBSERVATION_MODIFIER", 151, 159], ["density", "OBSERVATION", 237, 244]]], ["Global analysis of discrete-time SI and SIS epidemic models was given in [5] .", [["Global analysis", "TEST", 0, 15], ["SIS epidemic models", "TREATMENT", 40, 59], ["discrete", "OBSERVATION_MODIFIER", 19, 27]]], ["Further, the complex dynamical behavior of the SIS epidemic model is discussed by using bifurcation theory.", [["complex", "OBSERVATION_MODIFIER", 13, 20], ["dynamical", "OBSERVATION_MODIFIER", 21, 30]]], ["For example, Zhang et al. [6] obtained the conditions of backward bifurcation and the existence of bistable endemic equilibria.", [["bistable endemic equilibria", "PROBLEM", 99, 126], ["bistable", "OBSERVATION_MODIFIER", 99, 107], ["endemic equilibria", "OBSERVATION", 108, 126]]], ["Zhang et al. [7] investigated Hopf bifurcation in a delayed SIS epidemic model with stage structure by using the normal form theory and the center manifold argument.IntroductionIn the above cited papers, ordinary differential equations (ODEs) were used to build an SIS epidemic model.", [["Hopf bifurcation", "TREATMENT", 30, 46], ["a delayed SIS epidemic model", "PROBLEM", 50, 78], ["stage structure", "PROBLEM", 84, 99], ["normal", "OBSERVATION", 113, 119]]], ["Impulsive differential equations (IDEs) are suitable for the mathematical simulation of evolutionary processes in which the parameters undergo relatively long periods of smooth variation followed by a short-term rapid change in their values.", [["smooth variation", "PROBLEM", 170, 186], ["a short-term rapid change in their values", "PROBLEM", 199, 240], ["smooth variation", "OBSERVATION", 170, 186], ["short-term", "OBSERVATION_MODIFIER", 201, 211], ["rapid", "OBSERVATION_MODIFIER", 212, 217], ["change", "OBSERVATION", 218, 224]]], ["The study of IDEs mainly concerns the properties of their solutions, such as the existence, uniqueness, stability, boundedness, and periodicity; see [8, 9] .", [["The study", "TEST", 0, 9], ["their solutions", "TREATMENT", 52, 67], ["boundedness", "PROBLEM", 115, 126], ["stability", "OBSERVATION_MODIFIER", 104, 113]]], ["Sufficient conditions for the local and global stability of the susceptible pest-eradication periodic solution are found by means of Floquet theory and comparison methods in [10] .", [["Sufficient conditions", "PROBLEM", 0, 21], ["the susceptible pest", "TREATMENT", 60, 80], ["eradication periodic solution", "TREATMENT", 81, 110]]], ["Nieto and Regan [11] present a new approach via variational methods and critical point theory for obtaining the existence of solutions to impulsive problems.", [["a new approach via variational methods", "TREATMENT", 29, 67], ["impulsive problems", "PROBLEM", 138, 156]]], ["The dynamics of an impulsively controlled three-trophic food chain system with general nonlinear functional responses for the intermediate consumer and the top predator are analyzed using the Floquet theory and comparison techniques in [12] .", [["an impulsively controlled three-trophic food chain system", "TREATMENT", 16, 73]]], ["IDEs are widely used in epidemiology.", [["widely", "OBSERVATION_MODIFIER", 9, 15]]], ["For example, an SIS epidemic model with a pulse vaccination was investigated in [13] and some results are obtained for the global stability of the disease-free periodic solution as well as the existence and stability of the endemic periodic solution are investigated analytically and numerically.IntroductionIn most models of population dynamics, increases in population due to births are assumed to be time independent.", [["an SIS epidemic model", "PROBLEM", 13, 34], ["a pulse vaccination", "TREATMENT", 40, 59], ["the disease", "PROBLEM", 143, 154], ["free periodic solution", "TREATMENT", 155, 177], ["the endemic periodic solution", "TREATMENT", 220, 249], ["disease", "OBSERVATION", 147, 154], ["stability", "OBSERVATION_MODIFIER", 207, 216], ["most models", "OBSERVATION_MODIFIER", 311, 322]]], ["However, many species give birth only during a single period of the year and Caughley [14] termed this growth pattern a birth pulse.", [["a birth pulse", "TEST", 118, 131]]], ["Roberts and Kao [15] proposed a model for the dynamics of a fatal infectious disease and discussed the existence and stability of periodic solutions.", [["infectious disease", "DISEASE", 66, 84], ["a fatal infectious disease", "PROBLEM", 58, 84], ["periodic solutions", "TREATMENT", 130, 148], ["fatal", "OBSERVATION_MODIFIER", 60, 65], ["infectious", "OBSERVATION", 66, 76]]], ["Tang and Chen [16] obtained an exact periodic solution and the threshold conditions for its stability by using the stroboscopic map in a single-species model.", [["an exact periodic solution", "TREATMENT", 28, 54], ["the threshold conditions", "TREATMENT", 59, 83], ["the stroboscopic map", "TEST", 111, 131], ["a single-species model", "TREATMENT", 135, 157]]], ["In this paper, the birth pulse is used to build an SIS epidemic model.IntroductionThe existence and bifurcation of periodic solutions for an epidemic model built from ODEs have been discussed by many authors; see [6, 7] for example.", [["the birth pulse", "TEST", 15, 30], ["bifurcation of periodic solutions", "TREATMENT", 100, 133], ["bifurcation", "OBSERVATION_MODIFIER", 100, 111]]], ["However, little is known about the bifurcation theory of an epidemic model built from IDEs.", [["little", "OBSERVATION_MODIFIER", 9, 15], ["bifurcation", "OBSERVATION_MODIFIER", 35, 46], ["epidemic", "OBSERVATION", 60, 68]]], ["Periodic boundary value problems for non-Lipschitzian impulsive functional differential equations were considered in [17] .", [["Periodic boundary value problems", "PROBLEM", 0, 32], ["non-Lipschitzian impulsive functional differential equations", "PROBLEM", 37, 97], ["boundary", "OBSERVATION_MODIFIER", 9, 17]]], ["Using a projection method, the bifurcation of positive periodic solutions for an impulsively controlled pest management mode was discussed in [18] .", [["a projection method", "TREATMENT", 6, 25], ["positive periodic solutions", "TREATMENT", 46, 73], ["an impulsively controlled pest management", "TREATMENT", 78, 119], ["bifurcation", "OBSERVATION_MODIFIER", 31, 42]]], ["The complex dynamics of a Holling type II prey-predator system with state feedback control was investigated in [19] .", [["a Holling type II prey", "TREATMENT", 24, 46], ["state feedback control", "TREATMENT", 68, 90], ["complex", "OBSERVATION_MODIFIER", 4, 11]]], ["Zhou and Liu [13] discussed the existence of a disease-free periodic solution and an endemic periodic solution by using the explicit solution.", [["a disease", "PROBLEM", 45, 54], ["free periodic solution", "TREATMENT", 55, 77], ["an endemic periodic solution", "TREATMENT", 82, 110], ["the explicit solution", "TREATMENT", 120, 141]]], ["Lakmeche et al. [20] transformed the problem of periodic solution into a fixed-point problem and obtained conditions for the stability of the trivial solution and the existence of a positive period-1 solution.", [["periodic solution", "TREATMENT", 48, 65], ["the trivial solution", "TREATMENT", 138, 158]]], ["Many authors (for example, see [21] ) discussed only the bifurcation of a non-trivial periodic solution of an epidemic model by using the results obtained in [20] .", [["a non-trivial periodic solution", "TREATMENT", 72, 103]]], ["By using the explicit solution, the stroboscopic map is obtained and used to discuss the bifurcation of the periodic solution in [16] .", [["stroboscopic map", "DNA", 36, 52], ["the explicit solution", "TREATMENT", 9, 30], ["the stroboscopic map", "TEST", 32, 52]]], ["However, the explicit solution is not easy to obtain in an epidemic model and the bifurcation of the endemic periodic solution is difficult to discuss.", [["the explicit solution", "TREATMENT", 9, 30], ["the endemic periodic solution", "TREATMENT", 97, 126], ["bifurcation", "OBSERVATION_MODIFIER", 82, 93]]], ["Some authors investigated the complex dynamics of epidemic models, such as period-doubling bifurcation, chaos and crisis etc., by means of numerical simulations; see [22] for example.", [["bifurcation", "OBSERVATION_MODIFIER", 91, 102]]], ["Therefore, theoretically analyzing the bifurcation theory of the SIS model is a challenging task.IntroductionIn this paper, an ordinary differential system is used to build an SIS epidemic model with a birth pulse and a varying population.", [["a birth pulse", "TREATMENT", 200, 213], ["a varying population", "TREATMENT", 218, 238], ["bifurcation", "OBSERVATION_MODIFIER", 39, 50], ["varying", "OBSERVATION_MODIFIER", 220, 227]]], ["To study this epidemic model, we construct discrete maps and present analytical results about the complex dynamical behavior.", [["dynamical behavior", "OBSERVATION", 106, 124]]], ["In the next section, an SIS epidemic model with a birth pulse and a varying population is introduced.", [["a birth pulse", "TREATMENT", 48, 61], ["a varying population", "TREATMENT", 66, 86], ["varying", "OBSERVATION_MODIFIER", 68, 75], ["population", "OBSERVATION", 76, 86]]], ["The conditions for the existence and stability of the periodic infection-free solution are derived in Section 3.", [["infection", "DISEASE", 63, 72], ["the periodic infection", "PROBLEM", 50, 72], ["free solution", "TREATMENT", 73, 86], ["stability", "OBSERVATION_MODIFIER", 37, 46], ["periodic", "OBSERVATION_MODIFIER", 54, 62], ["infection", "OBSERVATION", 63, 72]]], ["In Section 4, the existence and stability of the positive periodic solution are discussed.", [["the positive periodic solution", "TREATMENT", 45, 75], ["stability", "OBSERVATION_MODIFIER", 32, 41]]], ["Bifurcation analysis of the SIS epidemic model is given in detail in Section 5.", [["Bifurcation analysis", "TEST", 0, 20]]], ["The parameter value at which the epidemic periodic solution bifurcates from the infection-free periodic solution is calculated.", [["infection", "DISEASE", 80, 89], ["The parameter value", "TEST", 0, 19], ["the epidemic periodic solution", "TREATMENT", 29, 59], ["the infection", "PROBLEM", 76, 89], ["free periodic solution", "TREATMENT", 90, 112], ["infection", "OBSERVATION", 80, 89]]], ["The conditions of existence for flip bifurcation are derived by using the center manifold theorem and the bifurcation theorem.", [["flip bifurcation", "TREATMENT", 32, 48], ["flip bifurcation", "OBSERVATION", 32, 48], ["bifurcation", "OBSERVATION_MODIFIER", 106, 117]]], ["The numerical results are presented in Section 6, to verify the theoretical analysis, and the conclusion is presented in Section 7, finally.Model descriptionA classical SIS epidemic model was introduced by Kermack and McKendrick [1] .", [["the theoretical analysis", "TEST", 60, 84], ["Model descriptionA classical SIS epidemic model", "TREATMENT", 140, 187]]], ["On the assumption that recovery from the nonfatal infective disease does not confer immunity, one particular case of this classical SIS epidemic model isModel descriptionwhere the overdot denotes differentiation with respect to time, S(t) is the susceptible component of the population, I(t) is the infected component of the population, \u00b5 represents a constant birth rate, \u03b2 is the average number of adequate contacts with susceptibles for an infective individual per unit time, \u03c3 is the natural death rate and \u03b4 is the rate at which infective individuals lose immunity and return to the susceptible class.", [["infective disease", "DISEASE", 50, 67], ["death", "DISEASE", 496, 501], ["the nonfatal infective disease", "PROBLEM", 37, 67], ["infective", "OBSERVATION", 50, 59], ["infected", "OBSERVATION_MODIFIER", 299, 307], ["component", "OBSERVATION_MODIFIER", 308, 317]]], ["The dynamics of system (1) is simple.", [["simple", "OBSERVATION_MODIFIER", 30, 36]]], ["There exists a unique positive equilibriumModel descriptionin (1) for \u03b2\u00b5 > \u03c3 (\u03c3 + \u03b4).", [["\u03c3 + \u03b4", "GENE_OR_GENE_PRODUCT", 78, 83], ["\u03b2\u00b5", "PROTEIN", 70, 72], ["\u03c3", "PROTEIN", 75, 76], ["\u03c3", "PROTEIN", 78, 79], ["\u03b4", "PROTEIN", 82, 83], ["\u03b2\u00b5", "TEST", 70, 72]]], ["Nucci and Leach [23] presented an explicit solution of (1) by means of the Painlev\u00e9 analysis and the Lie theory of transformation groups.Model descriptionIn system (1), \u00b5 represents a constant birth rate, which means that the population is born throughout the year.", [["the Painlev\u00e9 analysis", "TEST", 71, 92], ["a constant birth rate", "PROBLEM", 182, 203]]], ["In most cases, the birth pulse is assumed to be the linear birth pulse N = pN [24] , where N = S +I. Roberts and Kao [15] considered the birth pulseModel descriptionIn paper [16] , B(N) = b exp(N) \u2212 1 and B(N) = p q+N n \u2212 1.", [["the birth pulse", "TEST", 15, 30], ["pN", "TEST", 75, 77], ["paper", "TEST", 168, 173], ["\u2212", "TEST", 197, 198], ["B", "TEST", 205, 206]]], ["In this paper, the birth pulse is taken asModel descriptionis the maximum birth rate, d is the maximum death rate, r is a parameter reflecting the relative importance of density-dependent population regulation through births and deaths.", [["death", "DISEASE", 103, 108], ["deaths", "DISEASE", 229, 235], ["the birth pulse", "TEST", 15, 30], ["the maximum death rate", "TEST", 91, 113], ["density", "OBSERVATION", 170, 177]]], ["If r = 0 all density dependence acts through the death rate, and if r = 1 all density dependence acts through the birth rate.", [["death", "DISEASE", 49, 54], ["the death rate", "TEST", 45, 59], ["the birth rate", "TEST", 110, 124], ["density", "OBSERVATION", 13, 20], ["density", "OBSERVATION", 78, 85]]], ["The newborn population is assumed to be susceptible to disease, that is, S = (b\u2212c(S +I))(S +I) and I = 0.", [["disease", "PROBLEM", 55, 62], ["disease", "OBSERVATION", 55, 62]]], ["Now, on the basis of the impulsive differential equations, we develop system (1) by introducing periodic birth pulses and obtain the following epidemic model with birth pulses:Model descriptionwhere 0 < b < 1, c > 0, the meanings of parameters \u03b2, \u03c3 , and \u03b4 are the same as in model (1), n \u2208 N + , T is the time between two consecutive birth pulses, S(t) = S(t + ) \u2212 S(t), S(t + ) are the quantities of susceptible components of the population after the birth pulse and S(tModel descriptionFor more details about impulsive systems see [8, 9] .Model descriptionThe epidemic model (2) is considered in the region \u2126 = {(S, I)|S \u2265 0, I \u2265 0, S + I < b c exp(\u03c3 T )} in this paper.", [["\u03b2", "GENE_OR_GENE_PRODUCT", 244, 245], ["\u03c3", "GENE_OR_GENE_PRODUCT", 247, 248], ["\u03c3", "PROTEIN", 247, 248], ["\u03b4", "PROTEIN", 255, 256], ["periodic birth pulses", "TEST", 96, 117], ["birth pulses", "TEST", 163, 175], ["Model descriptionwhere", "TEST", 176, 198], ["parameters", "TEST", 233, 243], ["\u03c3", "TEST", 247, 248], ["birth pulses", "TEST", 335, 347], ["S", "TEST", 349, 350], ["S", "TEST", 356, 357], ["the birth pulse", "TEST", 449, 464], ["S", "TEST", 622, 623], ["S", "TEST", 636, 637], ["c exp", "TEST", 646, 651]]], ["On the boundary line l 1 :Model descriptionThe trajectory originating from this initial point remains in region \u2126 for t \u2208 [0, T ).", [["trajectory", "OBSERVATION_MODIFIER", 47, 57]]], ["This trajectory reaches the point (S 1 ,\u012a 1 ) at time T , and next jumps to the point (S 1 , I 1 ) with the effect of the birth pulse, whereS 1Existence and stability of the infection-free periodic solutionIn this section, infectious individuals are entirely absent from the population permanently, i.e.,Existence and stability of the infection-free periodic solutionSuppose the value of S(t) is S k for t = kT ; then the solution for the first equation of system (3) isExistence and stability of the infection-free periodic solutionfor the effect of the impulse.", [["infection", "DISEASE", 174, 183], ["infection", "DISEASE", 335, 344], ["infection", "DISEASE", 501, 510], ["individuals", "ORGANISM", 234, 245], ["the birth pulse", "TEST", 118, 133], ["the infection", "PROBLEM", 170, 183], ["periodic solution", "TREATMENT", 189, 206], ["infectious individuals", "PROBLEM", 223, 245], ["the infection", "PROBLEM", 331, 344], ["free periodic solution", "TREATMENT", 345, 367], ["the solution", "TREATMENT", 418, 430], ["the infection", "PROBLEM", 497, 510], ["infection", "OBSERVATION", 174, 183], ["infectious", "OBSERVATION", 223, 233], ["stability", "OBSERVATION_MODIFIER", 318, 327], ["infection", "OBSERVATION", 335, 344], ["stability", "OBSERVATION_MODIFIER", 484, 493], ["infection", "OBSERVATION", 501, 510]]], ["Thus we obtain the one-dimensional discrete mapExistence and stability of the infection-free periodic solutionFor each fixed point of the map (4) there is an associated periodic solution of system (3), and vice versa.", [["infection", "DISEASE", 78, 87], ["the infection", "PROBLEM", 74, 87], ["free periodic solution", "TREATMENT", 88, 110], ["stability", "OBSERVATION_MODIFIER", 61, 70], ["infection", "OBSERVATION", 78, 87]]], ["The fixed points of map (4) areExistence and stability of the infection-free periodic solutionIn the case of the fixed point S 01 ,Existence and stability of the infection-free periodic solutionIn the case of the fixed point S 02 ,Existence and stability of the infection-free periodic solution, the fixed point S 02 is stable, that is the infection-free periodic solutionExistence and stability of the infection-free periodic solutionof system (2) is stable.Existence and stability of the infection-free periodic solutionThere are three ways in which a fixed point P of a discrete map f : R n \u2192 R n may fail to be hyperbolic, that is, Df (P) has an eigenvalue +1, an eigenvalue \u22121 or a pair of complex eigenvalues \u03bb, \u03bb with |\u03bb| = 1 [25] .", [["infection", "DISEASE", 62, 71], ["infection", "DISEASE", 162, 171], ["infection", "DISEASE", 262, 271], ["infection", "DISEASE", 340, 349], ["infection", "DISEASE", 403, 412], ["infection", "DISEASE", 490, 499], ["Df (P)", "PROTEIN", 636, 642], ["map", "TEST", 20, 23], ["the infection", "PROBLEM", 58, 71], ["periodic solution", "TREATMENT", 77, 94], ["the infection", "PROBLEM", 158, 171], ["periodic solution", "TREATMENT", 177, 194], ["the fixed point S 02", "TREATMENT", 209, 229], ["the infection", "PROBLEM", 258, 271], ["free periodic solution", "TREATMENT", 272, 294], ["the fixed point S 02", "TEST", 296, 316], ["the infection", "PROBLEM", 336, 349], ["free periodic solution", "TREATMENT", 350, 372], ["the infection", "PROBLEM", 399, 412], ["the infection", "PROBLEM", 486, 499], ["free periodic solution", "TREATMENT", 500, 522], ["R n \u2192 R n", "PROBLEM", 590, 599], ["hyperbolic", "PROBLEM", 615, 625], ["an eigenvalue", "TEST", 647, 660], ["fixed", "OBSERVATION_MODIFIER", 4, 9], ["stability", "OBSERVATION_MODIFIER", 45, 54], ["infection", "OBSERVATION", 62, 71], ["stability", "OBSERVATION_MODIFIER", 145, 154], ["infection", "OBSERVATION", 162, 171], ["stability", "OBSERVATION_MODIFIER", 245, 254], ["infection", "OBSERVATION", 262, 271], ["stable", "OBSERVATION_MODIFIER", 320, 326], ["infection", "OBSERVATION", 340, 349], ["stability", "OBSERVATION_MODIFIER", 386, 395], ["infection", "OBSERVATION", 403, 412], ["stable", "OBSERVATION_MODIFIER", 452, 458], ["stability", "OBSERVATION_MODIFIER", 473, 482], ["infection", "OBSERVATION", 490, 499]]], ["The bifurcation associated with the appearance of eigenvalue 1 is called a fold (or tangent) bifurcation.", [["a fold (or tangent) bifurcation", "TREATMENT", 73, 104], ["bifurcation", "OBSERVATION_MODIFIER", 4, 15], ["bifurcation", "ANATOMY_MODIFIER", 93, 104]]], ["This bifurcation is also referred to as a limit point, saddle-node bifurcation, and turning point, among others.", [["saddle-node", "ANATOMY", 55, 66], ["saddle-node bifurcation", "TREATMENT", 55, 78], ["bifurcation", "OBSERVATION_MODIFIER", 5, 16], ["node", "OBSERVATION", 62, 66], ["bifurcation", "OBSERVATION_MODIFIER", 67, 78]]], ["The bifurcation associated with the appearance of eigenvalue \u22121 is called a flip (or period-doubling) bifurcation.Existence and stability of the infection-free periodic solutionFrom the above, the trivial solution of system (2) is stable for T > 1 \u03c3 ln(1 + b) and the infection-free periodic solution (6) of system (2) is stable for 1 \u03c3 lnExistence and stability of the infection-free periodic solution; then a bifurcation occurs at T = 1 \u03c3 ln(1 + b).", [["infection", "DISEASE", 145, 154], ["infection", "DISEASE", 268, 277], ["infection", "DISEASE", 370, 379], ["the infection", "PROBLEM", 141, 154], ["free periodic solution", "TREATMENT", 155, 177], ["T", "TEST", 242, 243], ["the infection", "PROBLEM", 264, 277], ["free periodic solution", "TREATMENT", 278, 300], ["the infection", "PROBLEM", 366, 379], ["free periodic solution", "TREATMENT", 380, 402], ["bifurcation", "OBSERVATION_MODIFIER", 4, 15], ["eigenvalue \u22121", "OBSERVATION", 50, 63], ["bifurcation", "OBSERVATION_MODIFIER", 102, 113], ["stability", "OBSERVATION_MODIFIER", 128, 137], ["infection", "OBSERVATION", 145, 154], ["trivial", "OBSERVATION", 197, 204], ["stable", "OBSERVATION_MODIFIER", 231, 237], ["infection", "OBSERVATION", 268, 277], ["stable", "OBSERVATION_MODIFIER", 322, 328], ["infection", "OBSERVATION", 370, 379]]], ["Moreover, F (S 01 ) = 1 and F (S 02 ) = 1 for T = 1 \u03c3 ln(1 + b); hence this bifurcation is a fold bifurcation.", [["T", "TEST", 46, 47], ["bifurcation", "ANATOMY_MODIFIER", 76, 87], ["fold bifurcation", "OBSERVATION", 93, 109]]], ["Then the following result is obtained.Existence and stability of the infection-free periodic solutionProposition 3.1.", [["infection", "DISEASE", 69, 78], ["the infection", "PROBLEM", 65, 78], ["free periodic solutionProposition", "TREATMENT", 79, 112], ["stability", "OBSERVATION_MODIFIER", 52, 61], ["infection", "OBSERVATION", 69, 78]]], ["A fold bifurcation occurs at T = 1 \u03c3 ln(1 + b) in system (2) .", [["fold", "OBSERVATION_MODIFIER", 2, 6], ["bifurcation", "OBSERVATION_MODIFIER", 7, 18]]], ["The trivial solution of system (2) is stable forExistence and stability of the positive periodic solutionIn this section, we discuss the existence and stability of the positive periodic solution (S(t), I(t)), where S(t) > 0 and I(t) > 0.", [["The trivial solution of system", "TREATMENT", 0, 30], ["the positive periodic solution", "TREATMENT", 75, 105], ["the positive periodic solution", "TREATMENT", 164, 194], ["trivial", "OBSERVATION", 4, 11], ["stable", "OBSERVATION_MODIFIER", 38, 44], ["forExistence", "OBSERVATION", 45, 57], ["stability", "OBSERVATION_MODIFIER", 62, 71]]], ["To obtain the explicit solution of system (2) , letExistence and stability of the positive periodic solutionIt follows from (2)Existence and stability of the positive periodic solutionSet the initial point of system (8)Existence and stability of the positive periodic solutionFrom (9) and (10), we obtain the following discrete map:Existence and stability of the positive periodic solutionFor each fixed point of the map (11) there is an associated periodic solution of system (2), and vice versa.", [["the explicit solution of system", "TREATMENT", 10, 41], ["the positive periodic solution", "TREATMENT", 78, 108], ["the positive periodic solution", "TREATMENT", 154, 184], ["the positive periodic solution", "PROBLEM", 246, 276], ["the positive periodic solution", "TREATMENT", 359, 389], ["the map", "TEST", 413, 420], ["stability", "OBSERVATION_MODIFIER", 141, 150], ["stability", "OBSERVATION_MODIFIER", 233, 242], ["positive", "OBSERVATION_MODIFIER", 250, 258], ["stability", "OBSERVATION_MODIFIER", 346, 355], ["positive", "OBSERVATION_MODIFIER", 363, 371]]], ["For the facts that N(t) = S(t) + I(t) and M(t) = 1 I(t) , the discussion of equilibrium (0, 0) of map (11) is meaningless; we omit it here.", [["the facts", "TEST", 4, 13], ["equilibrium", "TEST", 76, 87], ["map", "TEST", 98, 101]]], ["Now suppose that the positive fixed point of map (11)Existence and stability of the positive periodic solutionFor N 0 > 0 and M 0 > 0, the following conditions are needed:Existence and stability of the positive periodic solutionthat is,Existence and stability of the positive periodic solutionHence there exists a nonlinear periodic solution in system (8) under condition (14) .", [["map", "TEST", 45, 48], ["the positive periodic solution", "TREATMENT", 80, 110], ["the positive periodic solutionthat", "PROBLEM", 198, 232], ["the positive periodic solutionHence", "PROBLEM", 263, 298], ["a nonlinear periodic solution in system", "TREATMENT", 312, 351], ["stability", "OBSERVATION_MODIFIER", 185, 194], ["positive", "OBSERVATION_MODIFIER", 202, 210], ["periodic", "OBSERVATION_MODIFIER", 211, 219], ["stability", "OBSERVATION_MODIFIER", 250, 259]]], ["Now we discuss the stability of this positive periodic solution.", [["this positive periodic solution", "TREATMENT", 32, 63]]], ["The associated characteristic polynomial of the fixed pointExistence and stability of the positive periodic solutionIt is easy to calculate that \u22121 < \u03bb 1 < 1 for 0Existence and stability of the positive periodic solutionand then 0 < \u03bb 2 < 1.Existence and stability of the positive periodic solutionThus, under condition (14) andExistence and stability of the positive periodic solution\u22121 < \u03bb 1 < 1 and 0 < \u03bb 2 < 1, which means that the periodic solution of system (8) is stable.", [["the positive periodic solution", "TREATMENT", 86, 116], ["the positive periodic solutionand", "PROBLEM", 190, 223], ["the positive periodic solution", "TREATMENT", 268, 298], ["the positive periodic solution", "TREATMENT", 355, 385], ["characteristic", "OBSERVATION_MODIFIER", 15, 29], ["polynomial", "OBSERVATION_MODIFIER", 30, 40], ["fixed point", "OBSERVATION", 48, 59], ["stability", "OBSERVATION_MODIFIER", 73, 82], ["stability", "OBSERVATION_MODIFIER", 255, 264], ["positive", "OBSERVATION_MODIFIER", 272, 280], ["stable", "OBSERVATION_MODIFIER", 471, 477]]], ["Thus the following proposition about the existence and stability of an epidemic periodic solution of system (2) is obtained.Existence and stability of the positive periodic solutionSystem (2) has a stable positive periodic solution.Bifurcation of the positive periodic solution near the infection-free periodic solutionIn this subsection, we deal with the problem of the bifurcation of the positive periodic solution of system (2) near the infection-free periodic solution.", [["infection", "DISEASE", 287, 296], ["infection", "DISEASE", 440, 449], ["the positive periodic solutionSystem", "PROBLEM", 151, 187], ["a stable positive periodic solution", "TREATMENT", 196, 231], ["the positive periodic solution", "PROBLEM", 247, 277], ["the infection", "PROBLEM", 283, 296], ["periodic solution", "TREATMENT", 302, 319], ["the positive periodic solution of system", "PROBLEM", 386, 426], ["the infection", "PROBLEM", 436, 449], ["free periodic solution", "TREATMENT", 450, 472], ["stability", "OBSERVATION_MODIFIER", 55, 64], ["stability", "OBSERVATION_MODIFIER", 138, 147], ["positive", "OBSERVATION_MODIFIER", 155, 163], ["periodic", "OBSERVATION_MODIFIER", 164, 172], ["stable", "OBSERVATION_MODIFIER", 198, 204], ["positive", "OBSERVATION", 205, 213], ["positive", "OBSERVATION_MODIFIER", 251, 259], ["periodic", "OBSERVATION_MODIFIER", 260, 268], ["infection", "OBSERVATION", 287, 296], ["bifurcation", "OBSERVATION_MODIFIER", 371, 382], ["positive", "OBSERVATION_MODIFIER", 390, 398], ["infection", "OBSERVATION", 440, 449]]], ["As shown in Section 3, the infection-free periodic solution of system (2) isBifurcation of the positive periodic solution near the infection-free periodic solutionIt follows from (7) and (11) that the positive periodic solution of system (2) isBifurcation of the positive periodic solution near the infection-free periodic solutionnT \u2264 t < (n + 1)T ,Bifurcation of the positive periodic solution near the infection-free periodic solutionwhere M 0 is shown in (12) .Bifurcation of the positive periodic solution near the infection-free periodic solutionLet N(t) = S(t) + I(t); system (2)Bifurcation of the positive periodic solution near the infection-free periodic solutionwhich are satisfied with G 2 (N, 0) \u2261 0, \u03b8 2 (N, 0) \u2261 0, \u03b8 1 = 0 for N = 0 and \u03b8 2 = 0 for I = 0.", [["infection", "DISEASE", 27, 36], ["infection", "DISEASE", 131, 140], ["infection", "DISEASE", 299, 308], ["infection", "DISEASE", 405, 414], ["infection", "DISEASE", 520, 529], ["infection", "DISEASE", 641, 650], ["the infection", "PROBLEM", 23, 36], ["free periodic solution of system", "TREATMENT", 37, 69], ["the positive periodic solution", "PROBLEM", 91, 121], ["the infection", "PROBLEM", 127, 140], ["periodic solution", "TREATMENT", 146, 163], ["the positive periodic solution of system", "PROBLEM", 197, 237], ["the positive periodic solution", "PROBLEM", 259, 289], ["the infection", "PROBLEM", 295, 308], ["the positive periodic solution", "PROBLEM", 365, 395], ["the infection", "PROBLEM", 401, 414], ["the positive periodic solution", "PROBLEM", 480, 510], ["the infection", "PROBLEM", 516, 529], ["the positive periodic solution", "TREATMENT", 601, 631], ["the infection", "PROBLEM", 637, 650], ["G", "TEST", 698, 699], ["\u2261", "TEST", 725, 726], ["\u03b8", "TEST", 730, 731], ["N", "TEST", 742, 743], ["infection", "OBSERVATION", 27, 36], ["infection", "OBSERVATION", 131, 140], ["infection", "OBSERVATION", 299, 308], ["positive", "OBSERVATION_MODIFIER", 369, 377], ["infection", "OBSERVATION", 405, 414], ["positive", "OBSERVATION_MODIFIER", 484, 492], ["infection", "OBSERVATION", 520, 529], ["infection", "OBSERVATION", 641, 650]]], ["Let \u03c8 be the flow associated with (18) ,Bifurcation of the positive periodic solution near the infection-free periodic solutionfollowing notation is given in paper [17] :Bifurcation of the positive periodic solution near the infection-free periodic solutionThe result concerning the bifurcation of the positive periodic solution is the following Lemma: For more details see Ref.", [["infection", "DISEASE", 95, 104], ["infection", "DISEASE", 225, 234], ["Let \u03c8", "GENE_OR_GENE_PRODUCT", 0, 5], ["the positive periodic solution", "PROBLEM", 55, 85], ["the infection", "PROBLEM", 91, 104], ["periodic solutionfollowing notation", "TREATMENT", 110, 145], ["the positive periodic solution", "PROBLEM", 185, 215], ["the infection", "PROBLEM", 221, 234], ["periodic solution", "TREATMENT", 240, 257], ["flow", "OBSERVATION", 13, 17], ["infection", "OBSERVATION", 95, 104], ["infection", "OBSERVATION", 225, 234], ["bifurcation", "OBSERVATION_MODIFIER", 283, 294]]], ["The semi-trivial periodic solution and the positive periodic solutions are given in (16) and (17) ; then the bifurcation of the positive periodic solution does occur in our case.", [["The semi-trivial periodic solution", "TREATMENT", 0, 34], ["the positive periodic solutions", "TREATMENT", 39, 70], ["the positive periodic solution", "PROBLEM", 124, 154], ["bifurcation", "OBSERVATION_MODIFIER", 109, 120], ["positive", "OBSERVATION_MODIFIER", 128, 136]]], ["In what follows, we just calculate the value of the parameter b at which the bifurcation occurs.", [["bifurcation", "ANATOMY_MODIFIER", 77, 88]]], ["In our case,Bifurcation of the positive periodic solution near the infection-free periodic solutionThen we get the following result.Flip bifurcationAs mentioned in Section 3, the bifurcation associated with the appearance of the eigenvalue \u22121 is called a flip (or perioddoubling) bifurcation.", [["infection", "DISEASE", 67, 76], ["eigenvalue \u22121", "DNA", 229, 242], ["the positive periodic solution", "PROBLEM", 27, 57], ["the infection", "PROBLEM", 63, 76], ["periodic solution", "TREATMENT", 82, 99], ["a flip (or perioddoubling) bifurcation", "PROBLEM", 253, 291], ["Bifurcation", "OBSERVATION_MODIFIER", 12, 23], ["positive", "OBSERVATION_MODIFIER", 31, 39], ["infection", "OBSERVATION", 67, 76], ["bifurcation", "OBSERVATION_MODIFIER", 137, 148], ["bifurcation", "ANATOMY_MODIFIER", 179, 190], ["bifurcation", "ANATOMY_MODIFIER", 280, 291]]], ["Hence (N 0 , M 0 , 3 exp(\u03c3 T ) \u2212 1) is a candidate for a flip bifurcation point.", [["a flip bifurcation point", "TREATMENT", 55, 79]]], ["Viewing b as a parameter, we discuss flip bifurcation of system (2) by using the map (11) and the following lemma.Flip bifurcationThen there is a smooth curve of fixed points of f \u00b5 passing through (x 0 , \u00b5 0 ), the stability of which changes at (x 0 , \u00b5 0 ).", [["the map", "TEST", 77, 84], ["bifurcation", "OBSERVATION_MODIFIER", 119, 130], ["smooth", "OBSERVATION_MODIFIER", 146, 152], ["curve", "OBSERVATION_MODIFIER", 153, 158], ["fixed", "OBSERVATION_MODIFIER", 162, 167], ["points", "OBSERVATION_MODIFIER", 168, 174], ["stability", "OBSERVATION_MODIFIER", 216, 225]]], ["There is also a smooth curve \u03b3 passing through (x 0 , \u00b5 0 ) such that \u03b3 \u00a0(x 0 , \u00b5 0 ) is a union of hyperbolic period-2 orbits.Flip bifurcationFor the proof of Lemma 5.2, refer to Ref.", [["smooth", "OBSERVATION_MODIFIER", 16, 22], ["curve", "OBSERVATION_MODIFIER", 23, 28], ["orbits", "ANATOMY", 120, 126], ["bifurcation", "OBSERVATION_MODIFIER", 132, 143]]], ["In (F 2 ) the sign of\u0101 determines the stability and the direction of bifurcation of the orbits of period 2.", [["stability", "OBSERVATION", 38, 47], ["bifurcation", "ANATOMY_MODIFIER", 69, 80], ["orbits", "ANATOMY", 88, 94]]], ["If\u0101 is positive, the orbits are stable; if\u0101 is negative they are unstable.", [["If\u0101", "GENE_OR_GENE_PRODUCT", 0, 3], ["if\u0101", "GENE_OR_GENE_PRODUCT", 40, 43], ["positive", "OBSERVATION", 7, 15], ["orbits", "ANATOMY", 21, 27], ["stable", "OBSERVATION_MODIFIER", 32, 38], ["negative", "OBSERVATION", 47, 55], ["unstable", "OBSERVATION_MODIFIER", 65, 73]]], ["For some > 0, system (2) has a stable 2T -periodic solution for b \u2208 (3 exp(\u03c3 T ) \u2212 1, 3 exp(\u03c3 T ) \u2212 1 + ).Proposition 5.2.", [["exp(\u03c3 T", "TEST", 88, 95], ["\u2212", "TEST", 98, 99], ["stable", "OBSERVATION_MODIFIER", 31, 37]]], ["A flip bifurcation occurs at b = 3 exp(\u03c3 T )\u22121 in systemProof.", [["A flip bifurcation", "TREATMENT", 0, 18], ["flip bifurcation", "OBSERVATION", 2, 18]]], ["A flip bifurcation occurs at b = 3 exp(\u03c3 T )\u22121 in systemis a candidate for a flip bifurcation point.", [["A flip bifurcation", "TREATMENT", 0, 18], ["a flip bifurcation point", "TREATMENT", 75, 99], ["flip bifurcation", "OBSERVATION", 2, 18], ["flip bifurcation", "OBSERVATION", 77, 93]]], ["Map (11) may be rewritten asProposition 5.2.", [["Map", "TEST", 0, 3], ["asProposition", "TEST", 26, 39]]], ["A flip bifurcation occurs at b = 3 exp(\u03c3 T )\u22121 in systemwhereProposition 5.2.", [["A flip bifurcation", "TREATMENT", 0, 18], ["flip bifurcation", "OBSERVATION", 2, 18]]], ["A flip bifurcation occurs at b = 3 exp(\u03c3 T )\u22121 in systemThe map f \u00b5 : R \u2192 R in Lemma 5.2 is one-dimensional while the map (20) is two-dimensional in our case.", [["R \u2192 R", "GENE_OR_GENE_PRODUCT", 70, 75], ["A flip bifurcation", "TREATMENT", 0, 18], ["R \u2192 R in Lemma", "TEST", 70, 84], ["the map", "TEST", 114, 121], ["flip bifurcation", "OBSERVATION", 2, 18], ["R", "ANATOMY_MODIFIER", 74, 75], ["Lemma 5.2", "OBSERVATION", 79, 88]]], ["The center manifold theorem is used here to obtain a one-dimensional map; hence, flip bifurcation is discussed.", [["flip bifurcation", "OBSERVATION", 81, 97]]], ["(12) that the fixed point of map (20) isProposition 5.2.", [["map", "TEST", 29, 32], ["isProposition", "TEST", 38, 51]]], ["A flip bifurcation occurs at b = 3 exp(\u03c3 T )\u22121 in systemLetting u = x \u2212 x 0 , v = y \u2212 y 0 andb = b \u2212 3 exp(\u03c3 T ) + 1, we transform the fixed point (x 0 , y 0 ) of map (20) to the origin; then the map (20) becomesProposition 5.2.", [["A flip bifurcation", "TEST", 0, 18], ["v", "TEST", 78, 79], ["map", "TEST", 163, 166], ["the map", "TEST", 192, 199], ["becomesProposition", "TEST", 205, 223], ["origin", "ANATOMY_MODIFIER", 179, 185]]], ["A flip bifurcation occurs at b = 3 exp(\u03c3 T )\u22121 in systemOn usingProposition 5.2.", [["A flip bifurcation", "TREATMENT", 0, 18], ["flip bifurcation", "OBSERVATION", 2, 18]]], ["A flip bifurcation occurs at b = 3 exp(\u03c3 T )\u22121 in systemwhereProposition 5.2.", [["A flip bifurcation", "TREATMENT", 0, 18], ["flip bifurcation", "OBSERVATION", 2, 18]]], ["A flip bifurcation occurs at b = 3 exp(\u03c3 T )\u22121 in systemIf we letProposition 5.2.", [["A flip bifurcation", "TREATMENT", 0, 18], ["letProposition", "TEST", 62, 76], ["flip bifurcation", "OBSERVATION", 2, 18]]], ["A flip bifurcation occurs at b = 3 exp(\u03c3 T )\u22121 in systemand use the translationProposition 5.2.", [["A flip bifurcation", "TREATMENT", 0, 18], ["flip bifurcation", "OBSERVATION", 2, 18]]], ["A flip bifurcation occurs at b = 3 exp(\u03c3 T )\u22121 in systemwhereProposition 5.2.", [["A flip bifurcation", "TREATMENT", 0, 18], ["flip bifurcation", "OBSERVATION", 2, 18]]], ["A flip bifurcation occurs at b = 3 exp(\u03c3 T )\u22121 in systemNow the center manifold theorem is used to determine the nature of the bifurcation of the fixed point (x,\u1ef9) = (0, 0) at b = 0.", [["A flip bifurcation", "TREATMENT", 0, 18], ["flip bifurcation", "OBSERVATION", 2, 18], ["bifurcation", "ANATOMY_MODIFIER", 127, 138]]], ["A flip bifurcation occurs at b = 3 exp(\u03c3 T )\u22121 in systemIn view of the form of f (x,\u1ef9,b), it is not necessary to calculate h x,b in our case, and the map restricted to the center manifold is given b\u0233Proposition 5.2.", [["A flip bifurcation", "TREATMENT", 0, 18], ["the map", "TEST", 146, 153], ["b\u0233Proposition", "TEST", 197, 210], ["flip bifurcation", "OBSERVATION", 2, 18]]], ["A flip bifurcation occurs at b = 3 exp(\u03c3 T )\u22121 in systemThus \u2202f \u2202bProposition 5.2.", [["A flip bifurcation", "TREATMENT", 0, 18], ["\u2202bProposition", "TEST", 64, 77], ["flip bifurcation", "OBSERVATION", 2, 18]]], ["A flip bifurcation occurs at b = 3 exp(\u03c3 T )\u22121 in systemSince\u0101 > 0 in (F 2 ), then the positive 2T -periodic solution is stable.", [["A flip bifurcation", "TREATMENT", 0, 18], ["systemSince\u0101", "TEST", 50, 62], ["flip bifurcation", "OBSERVATION", 2, 18], ["stable", "OBSERVATION_MODIFIER", 121, 127]]], ["This also means that for some > 0, system (2) has a positive stable 2T -periodic solution for b \u2208 (3 exp(\u03c3 T ) \u2212 1, 3 exp(\u03c3 T ) \u2212 1 + ).", [["stable", "OBSERVATION_MODIFIER", 61, 67]]], ["From Proposition 4.1, system (29) has a stable positive periodic solution (see Fig. 2(a) ).", [["stable", "OBSERVATION_MODIFIER", 40, 46]]], ["It is seen from Fig. 2 (b) that the solution with the initial point (4, 0.96) of system (29) tends to this positive periodic solution with t increasing.Numerical resultsNow set c = 0.5, T = 0.5.", [["this positive periodic solution", "TREATMENT", 102, 133], ["Numerical results", "TEST", 152, 169], ["set c", "TEST", 173, 178], ["T", "TEST", 186, 187]]], ["From (19) and (27), that is, period-adding bifurcation, occurs.", [["bifurcation", "OBSERVATION_MODIFIER", 43, 54]]], ["A period-2 solution bifurcates from the epidemic periodic solution.", [["A period-2 solution bifurcates", "TREATMENT", 0, 30], ["the epidemic periodic solution", "TREATMENT", 36, 66]]], ["It is seen from Fig. 3(a) that the numerical results are in good agreement with the theoretical results and system (29) possesses rich dynamics including different kinds of bifurcation and periodic windows.", [["bifurcation and periodic windows", "TREATMENT", 173, 205], ["bifurcation", "OBSERVATION_MODIFIER", 173, 184], ["periodic windows", "OBSERVATION", 189, 205]]], ["The period-3 solution is stable for b \u2208 (3.448, 3.462) and another flip bifurcation occurs at b = 3.462.Numerical resultsIt is seen from the bifurcation diagram Fig. 3 that there exist periodic solutions.", [["periodic solutions", "TREATMENT", 185, 203], ["stable", "OBSERVATION_MODIFIER", 25, 31], ["bifurcation", "OBSERVATION_MODIFIER", 141, 152], ["diagram Fig", "OBSERVATION", 153, 164]]], ["Fig. 4 shows the 1T -periodic, 2T -periodic, and 3T -periodic solutions in system (29) with b = 2.45, b = 2.492, and b = 3.46, respectively.", [["b", "TEST", 92, 93], ["b", "TEST", 102, 103]]], ["Both theoretical and experimental investigation have revealed that the three main routes to chaos are the route via torus bifurcation, the perioddoubling route, and intermittency.", [["experimental investigation", "TEST", 21, 47]]], ["From Fig. 3(a) , we know that the route to chaos is period-doubling bifurcation in our case.", [["bifurcation", "OBSERVATION_MODIFIER", 68, 79]]], ["Fig. 4(d) shows that chaos does exist in system (29) for b = 3.2.ConclusionThe dynamics of an SIS epidemic model with birth pulses and a varying population was studied in this paper.", [["birth pulses", "TEST", 118, 130], ["a varying population", "PROBLEM", 135, 155]]], ["The existence and stability of the infection-free periodic solution (S(t), 0) and positive periodic It is shown that the trivial solution of the system is stable for T > 1 \u03c3 ln(1+b), the infection-free periodic solution is stable for 1 \u03c3 ln (1+b) 3 < T < 1 \u03c3 ln(1 + b), and the time period between two consecutive births T is important for the population S(t) + I(t).", [["infection", "DISEASE", 35, 44], ["infection", "DISEASE", 187, 196], ["the infection", "PROBLEM", 31, 44], ["T", "TEST", 166, 167], ["the infection", "PROBLEM", 183, 196], ["stability", "OBSERVATION_MODIFIER", 18, 27], ["infection", "OBSERVATION", 35, 44], ["trivial", "OBSERVATION", 121, 128], ["stable", "OBSERVATION_MODIFIER", 155, 161], ["infection", "OBSERVATION", 187, 196], ["stable", "OBSERVATION_MODIFIER", 223, 229]]], ["For avoiding extinction, T should be less than 1 \u03c3 ln(1 + b).", [["extinction", "OBSERVATION", 13, 23]]], ["A positive periodic solution (period 1) bifurcates from this infection-free periodic solution at b = b * (19) through a supercritical bifurcation; a period-2 solution bifurcates from this positive periodic solution (period 1) at b = 3 exp(\u03c3 T ) \u2212 1 through flip bifurcation (period-doubling bifurcations).", [["infection", "DISEASE", 61, 70], ["A positive periodic solution", "TREATMENT", 0, 28], ["this infection", "PROBLEM", 56, 70], ["free periodic solution", "TREATMENT", 71, 93], ["a supercritical bifurcation", "TREATMENT", 118, 145], ["a period-2 solution bifurcates", "TREATMENT", 147, 177], ["this positive periodic solution", "TREATMENT", 183, 214], ["positive", "OBSERVATION_MODIFIER", 2, 10], ["infection", "OBSERVATION", 61, 70], ["supercritical bifurcation", "ANATOMY", 120, 145], ["bifurcation", "ANATOMY_MODIFIER", 262, 273], ["bifurcations", "OBSERVATION_MODIFIER", 291, 303]]], ["The numerical results show that the chaotic solution is generated via a cascade of period-doubling bifurcations.", [["the chaotic solution", "TREATMENT", 32, 52], ["bifurcations", "OBSERVATION_MODIFIER", 99, 111]]]], "PMC7123983": [["IntroductionAllergic diseases are caused by an inappropriate initiation of Type 2 (TH2) immune responses to innocuous environmental antigens that affect the upper airway mucosa (rhinitis), lung (asthma), the gut (food allergy), and the skin (dermatitis) (Julia et al. 2015).", [["upper airway mucosa", "ANATOMY", 157, 176], ["lung", "ANATOMY", 189, 193], ["gut", "ANATOMY", 208, 211], ["skin", "ANATOMY", 236, 240], ["IntroductionAllergic diseases", "DISEASE", 0, 29], ["rhinitis", "DISEASE", 178, 186], ["asthma", "DISEASE", 195, 201], ["food allergy", "DISEASE", 213, 225], ["dermatitis", "DISEASE", 242, 252], ["TH2", "GENE_OR_GENE_PRODUCT", 83, 86], ["upper airway mucosa", "MULTI-TISSUE_STRUCTURE", 157, 176], ["lung", "ORGAN", 189, 193], ["gut", "ORGANISM_SUBDIVISION", 208, 211], ["skin", "ORGAN", 236, 240], ["IntroductionAllergic diseases", "PROBLEM", 0, 29], ["Type 2 (TH2) immune responses", "TREATMENT", 75, 104], ["innocuous environmental antigens", "PROBLEM", 108, 140], ["the upper airway mucosa (rhinitis)", "PROBLEM", 153, 187], ["lung (asthma)", "PROBLEM", 189, 202], ["the gut (food allergy", "PROBLEM", 204, 225], ["the skin (dermatitis", "PROBLEM", 232, 252], ["upper", "ANATOMY_MODIFIER", 157, 162], ["airway mucosa", "ANATOMY", 163, 176], ["rhinitis", "OBSERVATION", 178, 186], ["lung", "ANATOMY", 189, 193], ["asthma", "OBSERVATION", 195, 201], ["gut", "ANATOMY", 208, 211], ["skin", "ANATOMY", 236, 240], ["dermatitis", "OBSERVATION", 242, 252]]], ["Over the last two to three decades, the prevalence of allergic diseases has significantly increased and this has often been explained by a decline in infections during early life.", [["allergic diseases", "DISEASE", 54, 71], ["infections", "DISEASE", 150, 160], ["allergic diseases", "PROBLEM", 54, 71], ["a decline in infections", "PROBLEM", 137, 160], ["allergic diseases", "OBSERVATION", 54, 71], ["significantly", "OBSERVATION_MODIFIER", 76, 89], ["increased", "OBSERVATION_MODIFIER", 90, 99], ["decline", "OBSERVATION_MODIFIER", 139, 146], ["infections", "OBSERVATION", 150, 160]]], ["It is thought that those who have had bacterial and viral infections during childhood are able to direct their maturing immune system (Table 11.1) toward a TH1 type and counterbalance any pro-allergic responses of TH2 cells (Yazdanbakhsh et al. 2002).", [["TH2 cells", "ANATOMY", 214, 223], ["bacterial and viral infections", "DISEASE", 38, 68], ["immune system", "ANATOMICAL_SYSTEM", 120, 133], ["TH1", "GENE_OR_GENE_PRODUCT", 156, 159], ["TH2 cells", "CELL", 214, 223], ["TH2 cells", "CELL_TYPE", 214, 223], ["bacterial and viral infections", "PROBLEM", 38, 68], ["TH2 cells", "PROBLEM", 214, 223], ["viral", "OBSERVATION_MODIFIER", 52, 57], ["infections", "OBSERVATION", 58, 68], ["TH2 cells", "OBSERVATION", 214, 223]]], ["The induction of a robust anti-inflammatory regulatory network by early life exposure to allergens offers a solution to the inverse association of allergen exposure with allergic disorders (Du Toit et al. 2008; Wu et al. 2014).", [["allergic disorders", "DISEASE", 170, 188], ["a robust anti-inflammatory regulatory network", "TREATMENT", 17, 62], ["a solution", "TREATMENT", 106, 116], ["allergic disorders", "PROBLEM", 170, 188]]]]}